NCCN Guidelines Version 1.2017 Panel Members
Central Nervous System Cancers

*Louis Burt Nabors, MD /Chair
University of Alabama at Birmingham
Comprehensive Cancer Center

Jana Portnow, MD /Vice-chair
City of Hope Comprehensive Cancer Center

Mario Ammirati, MD, MBA ¶
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Joachim Baehring, MD ¶
Yale Cancer Center/Smilow Cancer Hospital

Henry Brem, MD ¶
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Nicholas Butowski, MD ¶
UCSF Helen Diller Family Comprehensive Cancer Center

Robert A. Fenstermaker, MD ¶
Roswell Park Cancer Institute

Peter Forsyth, MD ¶
Moffitt Cancer Center

Jona Hattangadi-Gluth, MD §
UC San Diego Moores Cancer Center

Matthias Holdhoff, MD, PhD ¶
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Steven Howard, MD §
University of Wisconsin Carbone Cancer Center

Larry Junck, MD ¶
University of Michigan Comprehensive Cancer Center

Thomas Kaley, MD ¶
Memorial Sloan Kettering Cancer Center

Priya Kumthekar, MD ¶
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Jay S. Loeffler, MD § ¶
Dana-Farber/Brigham and Women’s Cancer Center/Massachusetts General Hospital Cancer Center

Paul L. Moots, MD ¶
Vanderbilt-Ingram Cancer Center

Maciej M. Mrugala, MD, PhD, MPH ¶
Mayo Clinic Cancer Center

Seema Naggal, MD ¶
Stanford Cancer Institute

Manjari Pandey, MD ¶
The University of Tennessee Health Science Center

Ian Parney, MD, PhD ¶
Mayo Clinic Cancer Center

Katherine Peters, MD, PhD ¶
Duke Cancer Institute

Vinay K. Puduvalli, MD ¶
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

John Ragsdale, III, MD ¶
Duke Cancer Institute

Jason Rockhill, MD, PhD ¶
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Lisa Rogers, MD ¶
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Chad Rusthoven, MD ¶
University of Colorado Cancer Center

Nicole Shonka, MD ¶
Fred & Pamela Buffett Cancer Center

Dennis C. Shrieve, MD, PhD ¶
Huntsman Cancer Institute at the University of Utah

Allen K. Sills, Jr., MD ¶
Vanderbilt-Ingram Cancer Center

Lode J. Swinnen, MB, CH ¶
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Christina Tsien ¶
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Stephanie Weiss, MD ¶
Fox Chase Cancer Center

Patrick Yung Wen, MD ¶
Dana-Farber/Brigham and Women’s Cancer Center

Nicole Willmarth, PhD ¥
American Brain Tumor Association

NCCN
Mary Anne Bergman
Anita Engh, PhD

† Medical oncology
‡ Hematology/Hematology oncology
§ Radiotherapy/Radiation oncology
Ψ Neurology/Neuro-oncology
¶ Surgery/Surgical oncology
Þ Internal medicine/Primary care
¥ Patient Advocacy
* Discussion Section Writing Committee
### Meningiomas

Thomas Kaley, MD/Lead
Memorial Sloan Kettering Cancer Center

Henry Brem, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Robert A. Fenstermaker, MD
Roswell Park Cancer Institute

Larry Junck, MD
University of Michigan Comprehensive Cancer Center

Jay S. Loeffler, MD
Dana-Farber/Brigham and Women's Cancer Center/Massachusetts General Hospital Cancer Center

Paul L. Moots, MD
Vanderbilt-Ingram Cancer Center

Allen K. Sills, Jr., MD
Vanderbilt-Ingram Cancer Center

### Metastatic Spine Tumors

Dennis C. Shrieve, MD, PhD
Huntsman Cancer Institute at the University of Utah

Jona Hattangadi-Gluth, MD
UC San Diego Moores Cancer Center

Robert A. Fenstermaker, MD
Roswell Park Cancer Institute

Allen K. Sills, Jr., MD
Vanderbilt-Ingram Cancer Center

### PCNSL Review

Maciej Mrugala, MD, PhD, MPH/Lead
Mayo Clinic Cancer Center

Lode J. Swinnen, MB, ChB
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Thomas Kaley, MD
Memorial Sloan Kettering Cancer Center

Matthias Holdhoff, MD, PhD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

### Adult Medulloblastoma

Maciej Mrugala, MD, PhD, MPH
Mayo Clinic Cancer Center

Jana Portnow, MD
City of Hope Comprehensive Cancer Center

---

**NCCN Guidelines Panel Disclosures**

† Medical oncology  
‡ Hematology/Hematology oncology  
§ Radiotherapy/Radiation oncology  
ψ Neurology/neuro-oncology  
¶ Surgery/Surgical oncology  
¥ Patient advocacy

---

Version 1.2017, 08/18/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
## Principles of Imaging

### Larry Junck, MD
University of Michigan
Comprehensive Cancer Center

### Louis Burt Nabors, MD
University of Alabama at Birmingham
Comprehensive Cancer Center

## Principles of Brain Tumor Management

### Allen K. Sills, Jr., MD
Vanderbilt-Ingram Cancer Center

## Principles of Systemic Therapy

### Louis Burt Nabors, MD/Lead
University of Alabama at Birmingham
Comprehensive Cancer Center

### Matthias Holdhoff, MD PhD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

### Larry Junck, MD
University of Michigan
Comprehensive Cancer Center

### Maciej Mrugala, MD, PhD, MPH
Mayo Clinic Cancer Center

### Jana Portnow, MD
City of Hope
Comprehensive Cancer Center

### Lode J. Swinnen, MB, ChB
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

### Patrick Yung Wen, MD
Dana-Farber/Brigham and Women's Cancer Center

## Principles of Radiation Therapy

### Christina Tsien, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

### Larry Junck, MD
University of Michigan
Comprehensive Cancer Center

### Jay J. Loeffler, MD
Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

### Dennis C. Shrieve, MD, PhD
Huntsman Cancer Institute at the University of Utah

### Allen K. Sills, Jr., MD
Vanderbilt-Ingram Cancer Center

† Medical oncology
‡ Hematology/Hematology oncology
§ Radiotherapy/Radiation oncology
ψ Neurology/neuro-oncology
¶ Surgery/Surgical oncology
¥ Patient advocacy
Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See NCCN Categories of Evidence and Consensus.
Updates in Version 1.2017 of the NCCN Guidelines for Central Nervous System Cancers from Version 1.2016 include:

### General
- Footnotes have been reflowed throughout the guidelines.

### ASTR-1

**Radiologic Presentation**
- Modified: "MRI compatible with a primary brain tumor low-grade glioma"

**Surgery**
- Modified: "Attempted gross total maximal safe resection."

**Adjuvant Treatment**
- "Fractionated external beam RT" is a category 2B designation.

**Follow-up**
- Modified: "Brain MRI every 3–6 mo for 5 y then at least annually."

**Footnotes**
- "e" and "l" were combined and deleted, "Consider testing for deletions in 1p19q if tumor has components of oligodendroglioma for prognostic purposes. Oligodendrogliomas, particularly those that have chromosomal loss of combined 1p19q, have been reported to be sensitive to alkylator chemotherapy. Consider chemotherapy for these patients." (Also for ASTR-2)
- "c" is new to the page, corresponding to "If radiographically the tumor appears to be a high-grade glioma see GLIO-1."
- "y" is new to the page: "See Principles of Brain Tumor Pathology (BRAIN-F)." (Also for ASTR-2)
- "i" modified: "For low-grade gliomas See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C)." (Also for ASTR-2)

### ASTR-2

- On the top and bottom pathways after Unresectable, "Consider biopsy" is new to the page.

**Last column:**
- Top pathway (Prior RT), modified: "Consider Changing chemotherapy regimen"
- Bottom pathway (No prior RT):
  - Deleted: "RT + Chemotherapy"
  - Added: "RT + adjuvant PCV"
  - Added: "RT + adjuvant TMZ"
  - Added: "RT + concurrent and adjuvant TMZ"

**Footnotes**
- "o" modified: "Recurrence on neuroimaging can be confounded by treatment effects. To confirm tumor recurrence and assess for possible transformation of tumor to higher grade, strongly consider tumor tissue sampling (biopsy at minimum) if there is a high index of suspicion of recurrence. Sixty percent or more of astrocytomas and 40%–50% of oligodendrogliomas will eventually undergo transformation to a higher grade. For patients with transformation to high-grade disease (See [GLIO-1])"
  - "p" deleted: "At recurrence, there is a high propensity for these tumors to undergo malignant transformation."
  - New "p" revised: "Additional periodic Brain MRI every 2–3 months while on treatment, then every 6 months indefinitely, to assess disease recurrence/progression (usually every 2–3 mo) to assess disease progression during treatment with chemotherapy (See BRAIN-A)"
  - "q" is new to the page: "RT alone is not encouraged, but may be appropriate for select cases (eg, poor performance status)."

### GLIO-1

**Footnotes**
- "k" is new to the page corresponding to anaplastic oligoastrocytoma: "NOS WHO 2016 has deleted this category, although it may continue to be used for some patients." (Also for GLIO-2 and GLIO-5)

### GLIO-2

- Modified the title: "Anaplastic Gliomas (See GLIO-3/GLIO-4 for GBM)"
- Pathology
  - Moved "Anaplastic oligoastrocytoma": from top pathway to middle pathway
  - Removed label from middle pathway: "1p19q uni- or non-deleted:"  
  - Removed "Anaplastic Oligodendroglioma" from middle pathway
- Adjuvant Treatment
  - Modified top pathway (for anaplastic oligodendroglioma [1p19q codeleted]): "Fractionated external beam RT with concurrent and adjuvant temozolomide chemotherapy"
  - Modified middle pathway (for anaplastic astrocytoma and anaplastic oligoastrocytoma): "Fractionated external beam RT with concurrent and adjuvant temozolomide chemotherapy or Fractionated external beam RT + neoadjuvant or adjuvant PCV or PCV or temozolomide chemotherapy or Fractionated external beam RT (category 1)"

**Follow-up**
- Modified: "Brain MRI 2–6 wks after RT, then every 2–4 mo for 2 3 y then every 6 months indefinitely less frequently" (Also for GLIO-3)

---

Continued on next page

---

Version 1.2017, 08/18/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Updates in Version 1.2017 of the NCCN Guidelines for Central Nervous System Cancers from Version 1.2016 include:

**GLIO-2 (continued)**

**Footnote**
- “o” modified: “Within the first 3 months after completion of RT and concomitant temozolomide, diagnosis of recurrence can be indistinguishable from pseudoprogression on neuroimaging. With pseudoprogression, stabilization or improvement should be expected within 3 mo of the end of radiotherapy.”

(Also for GLIO-3, GLIO-4, GLIO-5)

**GLIO-4**

**Adjuvant Treatment**
- Top pathway (Good performance status, Methylated MGMT promoter): "Hypofractionated brain RT + concurrent and adjuvant temozolomide" is a new treatment option.

**Follow-up**
- Modified: "Brain MRI 2–6 wk after RT, then every 2–4 mo for 2 3 y, then every 6 mo through 5 y post-treatment, then yearly indefinitely less frequently."

**GLIO-5**

**Recurrence**
- “"Unresectable" modified to include,"or resection not recommended/ elected."

**Treatment**
- Upper and lower pathways modified to include the following: “Clinical trials (preferred for eligible patients)"

**Footnotes**
- “w” modified: "The efficacy of standard-of-care treatment for recurrent glioblastoma is suboptimal, so for eligible patients consideration of clinical trials is highly encouraged. Prior treatment with carmustine wafer, reirradiation, or multiple prior systemic therapies may impact enrollment in some adjuvant the majority of clinical trials options."
- “x” modified: "Consider biopsy, MR spectroscopy, MR perfusion, brain PET/CT or brain PET/MRI, or re-image to follow changes that may be due to progression versus radionecrosis to rule out radiation necrosis."

**EPEN-2**

**Adjuvant Treatment**
- Upper pathway (standard risk for recurrence), modified: “Maximal safe gross total resection”

**Footnotes**
- "f" modified: "If not done preoperatively, spine MRI should be delayed by at least 2–3 weeks post surgery to avoid post-surgical artifacts."

**EPEN-3**

**Pathology**
- Modified: “Ependymoma, status post gross total maximal safe resection..”

**Footnotes**
- "f" modified: "If not done preoperatively, spine MRI should be delayed by at least 2–3 weeks performed 24–72 h post surgery. to avoid post-surgical artifacts."
- Previous "f" deleted: "Postoperative brain MRI within 24–72 hours after surgery to determine if spine tumor is drop metastases from brain" (Also for EPEN-4).

**EPEN-4**

**Follow-up**
- "Imaging in the event of emergent signs or symptoms (brain and/or spine MRI)"
- "Imaging of neuroaxis of tumor site (brain or spine MRI) Brain and spine MRI (if initially positive) every 3–4 mo for 1 y, then every 4–6 mo for year 2, then every 6–12 mo indefinitely"

**Clinical Staging**
- Modified: “MRI of brain and spine and CSF analysis”
- Modified upper and lower pathways: "Brain and/or spine MRI"

**Footnote**
- "f" deleted on this page: "Spine MRI should be delayed by at least 2–3 weeks post surgery to avoid post-surgical artifacts."

**AMED-1**

**Title of page modified:** "Adult Medulloblastoma and Supratentorial PNET"

(Also for AMED-2 and AMED-3)

**Clinical Impression**
- "Gross total" replaces "Maximal safe" resection throughout the page.

**AMED-2**

**2nd column, bottom pathway:** "Supratentorial location PNET"

**Adjuvant Treatment**
- Upper pathway (standard risk for recurrence), modified: "Standard-dose craniospinal radiation ± chemotherapy"
- Lower pathway (high risk for recurrence), modified: "Craniospinal radiation with chemotherapy followed by ad post-radiation chemotherapy"

Continued on next page
Updates in Version 1.2017 of the NCCN Guidelines for Central Nervous System Cancers from Version 1.2016 include:

Footnote

- "j" modified: "Bone scan; CT with contrast scans of chest, abdomen, and pelvis or whole body PET/CT; and bone marrow biopsy only if clinically indicated."

Follow-up

- Modified: "Brain MRI: every 3 mo for 2 y; then every 6 mo for 3 y; then at least yearly indefinitely"

Column title: "Treatment for Recurrence or Progression"

Footnotes

- "a" modified: "If patient is HIV positive, consider highly active antiretroviral therapy should be part of their treatment. Antiretrovirals (ARVs) can be administered safely with chemotherapy but consultation with an HIV specialist or pharmacist is important to optimize compatibility. See NCCN Guidelines for Diffuse Large B-Cell Lymphoma, sub-algorithm for AIDS-Related B-Cell Lymphomas." (Also for PCNS-2 and PCNS-3)

- "c" is new to the page: "Includes primary CNS lymphoma of the brain, spine, CSF, and leptomeninges. For lymphoma with primary tumor outside the CNS or involving only the eye, See NCCN Guidelines for Diffuse Large B-Cell Lymphoma."

Evaluation

- 6th bullet modified: "Contrast-enhanced chest/abdominal/pelvis CT or whole body PET/CT scan."

Induction therapy

- Modified: "If CSF positive or spinal MRI positive, and not responding to systemic chemotherapy, consider intra-CSF chemotherapy (category 2B)"
- "If eye exam shows vitreous involvement and patient is not responding to systemic chemotherapy positive, consider RT to globe or intraocular chemotherapy (category 2B)"
- "WBRT if patient is not a candidate for systemic chemotherapy"
- "If eye exam shows vitreous involvement positive, RT to globe"

Consolidation therapy

- "If complete response remission, consider:...."
- New treatment option: "Continue monthly high-dose methotrexate-based regimen for up to 1 y"
- "If residual disease present not complete remission:"

Footnotes

- "i" modified: "Consider less frequent follow-up after 5–10 y."
- "l" is new to the page: "Recommend imaging if cause/symptomatic change at any time."
Updates in Version 1.2017 of the NCCN Guidelines for Central Nervous System Cancers from Version 1.2016 include:

**LTD-1**
- Title of the Page modified: "Limited (1-3) Brain Metastases Metastatic Lesions" (Also for LTD-2, LTD-3, and LTD-4)

*Clinical presentation*
- Modified: "1–3 brain metastases metastatic lesions on MRI"

*Workup*
- Bottom pathway (no known history of cancer):
  - Deleted: "Chest x-ray/CT with contrast"
  - Deleted: "Abdominal/pelvic CT with contrast"
  - Added: "Contrast-enhanced CT chest/abdomen/pelvis"
  - Modified: "Consider whole body PET/CT for 1 unresectable lesion or FDG-PET if 2–3 lesions and no primary found"

**LTD-2**
- Modified middle pathway: "Resectable Surgical resection"
- Modified bottom pathway: "Unresectable or opted not to resect"

*Treatment*
- Middle pathway (surgical resection):
  - "SRS (preferred) or WBRT" replaced "SRS alone or SRS + WBRT"
  - For subsequent imaging, modified: "Brain or spine MRI"
- Bottom pathway (unresectable or opted not to resect):
  - "SRS (preferred) or WBRT" replaced "WBRT and/or SRS"

**Footnotes**
- "i" added: "SRS is preferred when safe, especially for low tumor volume. WBRT is generally not recommended but may be appropriate in some rare clinical circumstances (eg, ventricle is violated, cerebellar lesions, risk of meningeal disease, need for complete CNS control before going on protocol, not good SRS candidate for technical reasons, poor PS, advanced age)."
- "j" added: "SRS + WBRT is generally not recommended but may be appropriate in some rare clinical circumstances. Brown 2016 showed that for tumors <3 cm, SRS + WBRT improved local control compared with SRS alone, but did not significantly improve survival, and was associated with greater cognitive decline and poorer quality of life. (Brown PD et al. JAMA 2016;316:401-409)"

**LTD-3**

*Follow-up*
- Modified: "Brain or spine MRI every 2–3 mo for 1 y then every 4–6 mo indefinitely as clinically indicated."

*Treatment*
- For "previous surgery only": "for large volumes (eg, diameter >3 cm)" was added to WBRT
- For "1–3 lesions," "for large volumes (eg, diameter >3 cm) if not previously administered" was added to WBRT
- For ">3 lesions": "if not previously administered" added to WBRT

*Footnote*
- "^o": "Imaging to evaluate emergent signs/symptoms is appropriate at any time" is new to the page. (Also for MU-2)

**MU-1**
- Title of the page modified: "Multiple (>3) Brain Metastases Metastatic Lesions" (Also for MU-2)

*Clinical presentation*
- Modified: "Multiple (>3) brain metastases metastatic lesions on CT or MRI"

**MU-2**
- Follow-up modified: "Brain MRI every 2–3 mo for 1 y, then every 4–6 mo indefinitely as clinically indicated"

*Treatment*
- Top pathway modified: "Palliative/Best supportive care or Reirradiation"
- Bottom pathway modified: "Surgery or SRS or WBRT (if no prior WBRT) Reirradiation or chemotherapy"

**LEPT-2**
- Treatment:
  - Top pathway (poor risk), modified: "Consider involved field RT fractionated external beam RT to symptomatic painful sites for palliation (including spine and intracranial disease)"
  - Bottom pathway (good risk), modified: "WBRT and/or involved field RT to bulky disease and symptomatic sites (including spine and intracranial disease)"

*Footnotes*
- "h" deleted: "Usually WBRT and/or partial spine field is recommended."
Updates in Version 1.2017 of the NCCN Guidelines for Central Nervous System Cancers from Version 1.2016 include:

LEPT-3
• Top pathway modified: "Normal flow or No clinical evidence of abnormal flow"

Primary Treatment
• Top treatment option modified: "Strongly consider Ommaya reservoir/placing intraventricular catheter intra-CSF chemotherapy and subcutaneous reservoir induction..."

LEPT-4
• Sub-title change: "Postinduction therapy" to "Treatment"
• Modified top pathway (CSF cytology negative): "Continue on current regimen and re-evaluate CSF cytology on a monthly basis induction intra-CSF chemotherapy for 4 mo""Middle pathway (CSF cytology positive, patient clinically stable or improving and no evidence of progression), modified treatment option: "Continue induction intra-CSF chemotherapy for 4 wks"

Footnotes
• "k" deleted: "Induction intra-CSF chemotherapy can start with radiation (concomitant) or high-dose methotrexate for lymphoma or CSI"

SPINE-1
Workup
• Top pathway (asymptomatic), 1st bullet modified: "Systemic imaging (ie, contrast enhanced chest/abdominal/pelvic CT or whole body PET/CT, PET-GT, MRI, bone scan as indicated for metastatic workup)"

Treatment
• Top pathway (asymptomatic), 1st bullet modified: "Observation (periodic spine-MRI) Spine MRI in 6–8 weeks, then every 2–3 months until the nature of the lesion is established"

SPINE-3
Follow-up
• Modified: "Spine MRI/CT 1–3 mo after treatment, then every 3–4 6 mo for 1 y, then as clinically indicated indefinitely."

BRAIN-A
• 1st paragraph modified to include: "Imaging is always recommended to investigate emergent signs or symptoms."

BRAIN-B
• Guiding Principles, 1st bullet modified: "Gross total resection Maximal-tumor removal when appropriate"

BRAIN-C (1 of 3)
High-Grade Gliomas (Grades III/IV)
• First bullet modified: "The GTV is best defined using pre- and postoperative MRI imaging using enhanced T1 and FLAIR/T2. To account for sub-diagnostic tumor infiltration, the GTV is expanded 1–2 cm (CTV) for grade III, and up to 2–3 2–2.5 cm (CTV) for grade IV. A PTV of margin of 3–5 mm is typically added to the CTV to account for daily setup errors and image registration. Daily image guidance is required if smaller..."

BRAIN-C (1 of 3 continued)
PTV margins are used. When edema is included in an initial phase of treatment, fields are usually reduced for the last phase of the treatment (boost)." The boost target volume will typically encompass only the gross residual tumor and the resection cavity. A range of acceptable clinical target volume margins exists. Both strategies appear to produce similar outcomes."
• 2nd bullet modified to include: "If a boost volume is used, the initial phase of the RT plan will receive 46 Gy in 2 Gy fractions or 45–50.4 Gy in 1.8 Gy fractions. The boost plan will typically then receive 14 Gy fractions or 9–14.4 Gy in 1.8 Gy fractions."

Ependymoma
• 2nd bullet, removed "†" next to "Craniospinal"

Primary CNS Lymphoma
• 1st bullet, 3rd sentence modified: "For less than complete response (CR), consider the same WBRT to 30–36 Gy dese followed by a limited field to gross disease to 45 Gy or focal radiation to residual disease only."

Footnotes
• "†" modified: "Considering protons over photons (if available) for craniospinal irradiation in adults is reasonable. To reduce toxicity from craniospinal irradiation in adults, consider the use of intensity-modulated radiotherapy or protons if available."

References
• References 14–17 have been updated and correspond to Primary CNS Lymphoma.

BRAIN-C (2 of 3)
Brain Metastases
• 2nd bullet modified: "SRS: Maximum marginal doses of from 24–15 Gy according to based on tumor volume is recommended (RTOG 90–05)."
• 3rd bullet is new to the page: "SRS generally preferred over WBRT for 1–3 metastases, all <3 cm, with possible exception of patients with poor performance or uncontrolled systemic tumor."

Continued on next page
Updates in Version 1.2017 of the NCCN Guidelines for Central Nervous System Cancers from Version 1.2016 include:

**BRAIN-C (2 of 3) (continued)**

**Metastatic Spine**

- Modified: "Doses to vertebral body metastases will depend on patient’s PS, spine stability, location in relationship to spinal cord, and primary histology, presence of epidural disease, and overall treatment intent (pain relief, long-term local control, or cure). Generally, conventional external beam radiation doses of 8 Gy/1 fx, 20 Gy/5 fx, or 30 Gy/10 fx can be used. It is critical to consider tolerance at the spine and/or nerve root. In selected cases, or recurrences after previous radiation, stereotactic body radiotherapy (SBRT) is appropriate. It is critical to consider tolerance of the spine and/or spinal nerve roots. In patients with uncomplicated spine metastases that are treated primarily for pain relief, 8 Gy in 1 fraction has been shown to provide equivalent pain control to longer fractionation schedules and is more convenient for patients, but may be associated with higher rates of retreatment, which may be a consideration when life expectancy exceeds 6 months. When lower BED regimens are utilized upfront (ie, BED ≤60 Gy2 which includes up to 20 Gy in 5 fractions but does not include 30 Gy in 10 fractions), retreatment with similar BED regimens, such as 20 Gy in 5 fractions or 8 Gy in 1 fraction, can safely be considered as early as 4 weeks from initial treatment for pain relief. In other cases, doses ranging from 15 Gy in 1 fraction to 40 Gy in 20 fractions have been utilized for tumor control, with careful consideration of tolerance of the spinal cord and/or nerve roots. In these instances, it is generally recommended that 6 months or more of time between treatments is required."
- New footnote "†††" "NOS WHO 2016 has deleted this category, although it may continue to be used for some patients."

**BRAIN-D (2 of 6)**

- "Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B surface antigen and core antibody for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add e-antigen. If positive, check viral load and consult with gastroenterologist. NHODG-B, 2 of 3, also has information about HPV testing for patients considering rituximab," is a new footnote corresponding to rituximab.

**BRAIN-D (3 of 6)**

The following systemic therapies were added for the treatment of brain metastases:

- "Ipilimumab + nivolumab (melanoma)"
- "Pembrolizumab (melanoma or non-small cell lung cancer)"
- "Erlotinib, afatinib, gefitinib (EGFR sensitizing mutation-positive non-small cell lung cancer)"
- "Osimertinib (EGFR T790M mutation-positive non-small cell lung cancer)"
- "Crizotinib (ALK rearrangement-positive or ROS1 rearrangement-positive non-small cell lung cancer)"
- "Ceritinib, alectinib (ALK rearrangement-positive non-small cell lung cancer)"

- Two new references corresponding to ipilimumab + nivolumab:

**BRAIN-F (1 of 3)**

**Molecular/Genetic Characterization**

- Last bullet added: "There are no identified targeted agents with demonstrated efficacy in glioblastoma. Assessment of EGFR may lead practitioner to consider EGRF-targeted therapies in some patients."
**RADIOLOGIC PRESENTATION**

- MRI compatible with a low-grade glioma
  - **Maximal safe resection feasible**
    - Attempted gross total resection
    - Attempted subtotal resection or open biopsy or stereotactic biopsy
  - Maximal safe resection not feasible
    - Observation

**CLINICAL IMPRESSION**

- **Low risk**
  - Negative
  - Observe
  - Observation

**SURGERY**

- **Low risk**
  - Attempted gross total resection
  - Attempted subtotal resection or open biopsy or stereotactic biopsy

**ADJUVANT TREATMENT**

- **Low risk**
  - Observe
  - Observation

- **Fractionated external beam RT**
  - Chemotherapy (category 2B)
  - Chemotherapy (category 2B)

**FOLLOW-UP**

- Brain MRI every 3–6 mo for 5 y then at least annually

**All recommendations are category 2A unless otherwise indicated.**

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**See Principles of Brain and Spine Tumor Imaging (BRAIN-A).**

**Consider a multidisciplinary review in treatment planning, especially once pathology is available (See Principles of Brain Tumor Management [BRAIN-E]).**

**If radiographically the tumor appears to be a high-grade glioma see GLIO-1.**

**Surgery is generally recommended, but serial observations are appropriate for selected patients.**

**See Principles of Brain Tumor Surgery (BRAIN-B).**

**See Principles of Brain Tumor Pathology (BRAIN-F).**

**Postoperative brain MRI within 24–72 hours after surgery.**

**Low-risk features: ≤40 y and gross total resection (GTR).**

**High-risk features: >40 y or subtotal resection (STR).**

**Regular follow-up is essential for patients receiving observation alone after resection.**

**If GTR is achieved, consider further observation**

**For low-grade gliomas See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).**

**See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).**

**The results of RTOG 9802 showed that there was a significant improvement in median overall survival in high-risk low-grade glioma patients treated with RT followed by PCV x 6 cycles compared with RT alone after a tissue diagnosis was made. However, this important study did not address whether all of these patients should be treated right away. Observation after diagnosis may be a reasonable option for a high-risk low-grade glioma patient who is neurologically asymptomatic or stable. Close monitoring with brain MRIs is important.**
All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Recurrence**

<table>
<thead>
<tr>
<th>Prior fractionated external beam RT</th>
<th>No prior fractionated external beam RT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recurrent or progressive, low-grade disease</strong></td>
<td><strong>Recurrent or progressive, low-grade disease</strong></td>
</tr>
<tr>
<td>Resectable → Surgery → Brain MRI → Chemotherapy → Progression</td>
<td>Resectable → Surgery → Brain MRI → Chemotherapy → Progression</td>
</tr>
<tr>
<td>Unresectable → Consider biopsy → Chemotherapy → Progression</td>
<td>Unresectable → Consider biopsy → Chemotherapy → Progression</td>
</tr>
</tbody>
</table>

- If GTR is achieved, consider further observation.
- For low-grade gliomas, see Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).
- See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).
- Recurrence on neuroimaging can be confounded by treatment effects. To confirm tumor recurrence and assess for possible transformation of tumor to higher grade, strongly consider tumor tissue sampling (biopsy at minimum) if there is a high index of suspicion of recurrence. Sixty percent or more of astrocytomas and 40%–50% of oligodendrogliomas will eventually undergo transformation to a higher grade. For patients with transformation to high-grade disease, see GLIO-1.
- Brain MRI every 2–3 months while on treatment, then every 6 months indefinitely, to assess disease recurrence/progression during treatment with chemotherapy. (See BRAIN-A).
- RT alone is not encouraged, but may be appropriate for select cases (eg, poor performance status).

---

**ASTR-2**

Version 1.2017, 08/18/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

This pathway includes the classification of mixed anaplastic oligoastrocytoma (AOA), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and other rare anaplastic gliomas.

See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
See Principles of Brain Tumor Surgery (BRAIN-B).
See Principles of Brain Tumor Pathology (BRAIN-F).
Biopsy first if MRI compatible with CNS lymphoma.
Consider a multidisciplinary review in treatment planning, especially once pathology is available (See Principles of Brain Tumor Management [BRAIN-E]).
If frozen section diagnosis supports high-grade glioma.
Treatment with carmustine wafer may impact enrollment in some adjuvant clinical trials.
Postoperative brain MRI within 24–72 hours after surgery.
This pathway also includes gliosarcoma.
NOS WHO 2016 has deleted this category, although it may continue to be used for some patients.
## ANAPLASTIC GLIOMAS
(See GLIO-3/GLIO-4 for GBM)

### PATHOLOGY<sup>d</sup>

<table>
<thead>
<tr>
<th>Anaplastic oligodendroglioma (1p19q codeleted)</th>
<th>ADJUVANT TREATMENT</th>
<th>FOLLOW-UP&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fractionated external beam RT&lt;sup&gt;l&lt;/sup&gt; and neoadjuvant or adjuvant&lt;sup&gt;m&lt;/sup&gt; PCV chemotherapy (category 1)&lt;sup&gt;n&lt;/sup&gt;</td>
<td>Brain MRI 2–6 wks after RT, then every 2–4 mo for 3 y, then every 6 months indefinitely&lt;sup&gt;o&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>or Fractionated external beam RT&lt;sup&gt;l&lt;/sup&gt; with concurrent and adjuvant temozolomide chemotherapy&lt;sup&gt;n&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Anaplastic astrocytoma</td>
<td>Fractionated external beam RT&lt;sup&gt;l&lt;/sup&gt; with concurrent and adjuvant temozolomide chemotherapy&lt;sup&gt;n&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Anaplastic oligoastrocytoma&lt;sup&gt;k&lt;/sup&gt;</td>
<td>or Fractionated external beam RT&lt;sup&gt;l&lt;/sup&gt; + neoadjuvant or adjuvant&lt;sup&gt;m&lt;/sup&gt; PCV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>or Fractionated external beam RT&lt;sup&gt;l&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

| Anaplastic gliomas<sup>a</sup> Poor performance status (KPS <60) | Fractionated external beam RT<sup>l</sup> (hypofractionated [preferred] or standard) | See Recurrence (GLIO-5) |
| | or PCV or temozolomide chemotherapy (category 2B)<sup>n</sup> | |
| | or Palliative/Best supportive care | |

<sup>a</sup>This pathway includes the classification of mixed anaplastic oligoastrocytoma (AOA), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and other rare anaplastic gliomas.

<sup>b</sup>See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

<sup>d</sup>See Principles of Brain Tumor Pathology (BRAIN-F).

<sup>k</sup>NOS WHO 2016 has deleted this category, although it may continue to be used for some patients.

<sup;l</sup>See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

<sup>m</sup>The panel recommends that PCV be administered after RT (as per EORTC 26951) since the intensive PCV regimen given prior to RT (RTOG 9402) was not tolerated as well.

<sup>n</sup>See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

<sup>o</sup>Within the first 3 months after completion of RT and concomitant temozolomide, diagnosis of recurrence can be indistinguishable from pseudoprogression on neuroimaging.

---

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**NCCN Guidelines Version 1.2017**

**Anaplastic Gliomas\(^a\)/Glioblastoma**

### GLIOBLASTOMA PATHOLOGY\(^d\)

#### MGMT\(^p\) PROMOTER STATUS

- **Methylated**
  - Good performance status (KPS ≥60)
  - Standard brain RT\(^l\) + concurrent temozolomide and adjuvant temozolomide + alternating electric field therapy\(^n,r,s,t\)
  - or
  - Standard brain RT\(^l\) + concurrent temozolomide and adjuvant temozolomide (category 1)\(^n,r,s\)

- **Unmethylated or indeterminate**
  - Poor performance status (KPS <60)
  - Standard brain RT\(^l\) + concurrent temozolomide\(^u\) and adjuvant temozolomide\(^u\) + alternating electric field therapy\(^n,r,s,t\)
  - or
  - Standard brain RT\(^l\) + concurrent temozolomide\(^u\) and adjuvant temozolomide (category 1)\(^n,r,s,u\)
  - or
  - Standard brain RT alone\(^l\)

### ADJUVANT TREATMENT

- **Standard or hypofractionated brain RT\(^l\)**
  - or
  - Temozolomide\(^v\)
  - or
  - Palliative/Best supportive care

### FOLLOW-UP\(^b\)

- Brain MRI 2–6 wk after RT, then every 2–4 mo for 3 y, then every 6 mo indefinitely\(^o\)

---

\(^a\)This pathway includes the classification of mixed anaplastic oligoastrocytoma (AOA), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and other rare anaplastic gliomas.

\(^b\)See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

\(^c\)See Principles of Brain Tumor Pathology (BRAIN-F).

\(^d\)This pathway also includes gliosarcoma.

\(^e\)See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

\(^f\)See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

\(^g\)Within the first 3 months after completion of RT and concomitant temozolomide, diagnosis of recurrence can be indistinguishable from pseudoprogression on neuroimaging.

\(^h\)MGMT= \(\beta\)-methylguanine-DNA methyltransferase.

---

**MGMT PROMOTER STATUS**

- Methylated
  - Good performance status (KPS ≥60)
    - Standard brain RT\(^l\) + concurrent temozolomide and adjuvant temozolomide + alternating electric field therapy\(^n,r,s,t\)
    - or
    - Standard brain RT\(^l\) + concurrent temozolomide and adjuvant temozolomide (category 1)\(^n,r,s\)
  - Unmethylated or indeterminate
    - Poor performance status (KPS <60)
      - Standard brain RT\(^l\) + concurrent temozolomide\(^u\) and adjuvant temozolomide\(^u\) + alternating electric field therapy\(^n,r,s,t\)
      - or
      - Standard brain RT\(^l\) + concurrent temozolomide\(^u\) and adjuvant temozolomide (category 1)\(^n,r,s,u\)
      - or
      - Standard brain RT alone\(^l\)

### ADJUVANT TREATMENT

- **Standard or hypofractionated brain RT\(^l\)**
  - or
  - Temozolomide\(^v\)
  - or
  - Palliative/Best supportive care

### FOLLOW-UP\(^b\)

- Brain MRI 2–6 wk after RT, then every 2–4 mo for 3 y, then every 6 mo indefinitely\(^o\)

---

\(^a\)This pathway includes the classification of mixed anaplastic oligoastrocytoma (AOA), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and other rare anaplastic gliomas.

\(^b\)See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

\(^c\)See Principles of Brain Tumor Pathology (BRAIN-F).

\(^d\)This pathway also includes gliosarcoma.

\(^e\)See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

\(^f\)See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

\(^g\)Within the first 3 months after completion of RT and concomitant temozolomide, diagnosis of recurrence can be indistinguishable from pseudoprogression on neuroimaging.

\(^h\)MGMT= \(\beta\)-methylguanine-DNA methyltransferase.

---

**All recommendations are category 2A unless otherwise indicated.**

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2017
Anaplastic Gliomas\textsuperscript{a}/Glioblastoma

### GLIOBLASTOMA PATHOLOGY\textsuperscript{d}

#### MGMT PROMOTER STATUS\textsuperscript{p}

- **Good performance status (KPS $\geq 60$)**
  - Methylated
  - Hypofractionated brain RT\textsuperscript{l}
    - or concurrent and adjuvant temozolomide\textsuperscript{n,r,s}
    - and Temozolomide
  - Hypofractionated brain RT alone\textsuperscript{l} (category 1)
    - or Standard RT\textsuperscript{l} + concurrent temozolomide and adjuvant temozolomide + alternating electric field therapy\textsuperscript{n,r,s,t}
    - or Standard RT\textsuperscript{l} + concurrent temozolomide and adjuvant temozolomide\textsuperscript{n,r,s}
  - Hypofractionated brain RT alone\textsuperscript{l} (category 1)
    - or Standard RT\textsuperscript{l} + concurrent temozolomide\textsuperscript{u} and adjuvant temozolomide\textsuperscript{u} + alternating electric field therapy\textsuperscript{n,r,s,t}
- **Poor performance status (KPS <60)**
  - Unmethylated or indeterminate
  - Hypofractionated brain RT alone\textsuperscript{l} (category 1)
    - or Standard RT\textsuperscript{l} + concurrent temozolomide\textsuperscript{u} and adjuvant temozolomide\textsuperscript{u} + alternating electric field therapy\textsuperscript{n,r,s,u}
  - Hypofractionated brain RT alone\textsuperscript{l}
    - or Temozolomide\textsuperscript{v}
    - or Palliative/Best supportive care
  - Palliative/Best supportive care

### FOLLOW-UP\textsuperscript{b}

- Brain MRI 2–6 wk after RT, then every 2–4 mo for 3 y, then every 6 mo through 5 y post-treatment, then yearly indefinitely\textsuperscript{o}

---

\textsuperscript{a}This pathway includes the classification of mixed anaplastic oligoastrocytoma (AOA), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and other rare anaplastic gliomas.

\textsuperscript{b}See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

\textsuperscript{c}See Principles of Brain Tumor Pathology (BRAIN-F).

\textsuperscript{d}This pathway also includes gliosarcoma.

\textsuperscript{e}See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

\textsuperscript{f}See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

\textsuperscript{g}Within the first 3 months after completion of RT and concomitant temozolomide, diagnosis of recurrence can be indistinguishable from pseudoprogression on neuroimaging.

\textsuperscript{h}MGMT= O\textsuperscript{6}-methylguanine-DNA methyltransferase.

\textsuperscript{i}Combination of agents may lead to increased toxicity or radiographic changes.

\textsuperscript{j}Benefit of treatment with temozolomide for glioblastomas beyond 6 months is unknown.

\textsuperscript{k}The optimal duration of treatment with temozolomide for anaplastic astrocytoma is unknown.

\textsuperscript{l}Alternating electric field therapy is only an option for patients with supratentorial disease.

\textsuperscript{m}Clinical benefit from temozolomide is likely to be lower in patients whose tumors lack MGMT promoter methylation.

\textsuperscript{n}Temozolomide monotherapy is only recommended if tumor is MGMT promoter methylated.

---

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**GLIO-5**

This pathway includes the classification of mixed anaplastic oligoastrocytoma (AOA), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and other rare anaplastic gliomas.

See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

Postoperative brain MRI within 24–72 hours after surgery.

NOS WHO 2016 has deleted this category, although it may continue to be used for some patients.

See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

Within the first 3 months after completion of RT and concomitant temozolomide, diagnosis of recurrence can be indistinguishable from pseudoprogression on neuroimaging.

The efficacy of standard-of-care treatment for recurrent glioblastoma is suboptimal, so for eligible patients consideration of clinical trials is highly encouraged. Prior treatment may impact enrollment in the majority of clinical trial options.

Consider biopsy, MR spectroscopy, MR perfusion, brain PET/CT or brain PET/MRI, or re-image to follow changes that may be due to progression versus radionecrosis.

Anaplastic oligodendrogliomas have been reported to be especially sensitive to chemotherapy. Chemotherapy using temozolomide or nitrosourea-based regimens may be appropriate.

Especially if long interval since prior RT and/or if there was a good response to prior RT.

All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

Consider a multidisciplinary review in treatment planning, especially once pathology is available. See Principles of Brain Tumor Management (BRAIN-E).

If image-confirmed GTR not achieved, consider multidisciplinary review and reresection. See Principles of Brain Tumor Surgery (BRAIN-B).
All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2017
Adult Intracranial and Spinal Ependymoma (Excluding Subependymoma)

SPINAL EPENDYMOMA

PATHOLOGY

Ependymoma, status post gross total resection (Grades I and II)

Anaplastic ependymoma (Grade III), status post gross total resection

POSTOPERATIVE STAGING

Brain MRI and spine MRI; CSF analysis

Brain and spine MRI; CSF analysis

ADJUVANT TREATMENT

Total resection, MRI brain and spine negative, CSF negative

Subtotal resection, MRI brain negative, CSF negative

Total or subtotal resection and evidence of metastasis (brain, spine, or CSF)

Observe

Limited-field fractionated external beam RT

Craniospinal RT

Limited-field fractionated external beam RT

Craniospinal RT

See Follow-up and Recurrence (EPEN-4)

a See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

b See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C)

If not done preoperatively, spine MRI should be performed 24–72 h post surgery.

If lumbar puncture for CSF should be delayed at least 2 weeks after surgery to avoid possible false-positive cytology. Lumbar puncture may be contraindicated (eg, posterior fossa mass).

Consider limited-field fractionated external beam if myxopapillary ependymoma.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**FOLLOW-UP**

<table>
<thead>
<tr>
<th>RECURRENT CLINICAL STAGING</th>
<th>TREATMENT FOR PROGRESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Imaging in the event of emergent signs or symptoms (brain and/or spine MRI)</td>
<td></td>
</tr>
<tr>
<td>• Imaging of neuroaxis of tumor site (brain or spine MRI) every 3–4 mo for 1 y, then every 4–6 mo for year 2, then every 6–12 mo indefinitely</td>
<td></td>
</tr>
<tr>
<td>Spine or brain recurrence</td>
<td>CSF analysis</td>
</tr>
<tr>
<td>Resection with limited-field external beam RT&lt;sup&gt;h,l&lt;/sup&gt; if no prior RT&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Brain and/or spine MRI&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>If unresectable, RT&lt;sup&gt;h,l&lt;/sup&gt; if no prior RT&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Brain and/or spine MRI&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

<sup>h</sup>See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

<sup>l</sup>Consider stereotactic radiosurgery (SRS) if geometrically favorable.

<sup>m</sup>Chemotherapy should be reserved for patients who are refractory to surgery or radiation.

<sup>n</sup>See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### NCCN Guidelines Version 1.2017

**Adult Medulloblastoma**

---

**RADIOLOGIC PRESENTATION**

- Contrast-enhanced MRI compatible with primary brain tumor

**CLINICAL IMPRESSION**

- Gross total resection possible
- Gross total resection not possible

**SURGERY**

- Gross total resection
- Stereotactic biopsy or Open biopsy or Partial resection

---

**Excluding esthesioneuroblastoma.**

**See Principles of Brain and Spine Tumor Imaging (BRAIN-A).**

**Consider a multidisciplinary review in treatment planning, before surgery and once pathology is available (See Principles of Brain Tumor Management [BRAIN-E]).**

**Placement of ventriculoperitoneal (VP) shunt for management of hydrocephalus is acceptable if needed.**

**Strongly recommend referring patient to a brain tumor center to be evaluated for possible further, more complete surgical resection.**

---

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**POSTOPERATIVE STAGING**

<table>
<thead>
<tr>
<th>Standard risk for recurrence: k</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No evidence of metastasis (brain, spine, CSF, extraneural)</td>
</tr>
<tr>
<td>- Small-volume residual disease (contrast volume &lt;1.5 cm²)</td>
</tr>
<tr>
<td>- Classic or desmoplastic histology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>High risk for recurrence: k</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Unresectable tumor or residual tumor &gt;1.5 cm²</td>
</tr>
<tr>
<td>- Disseminated disease within or outside of the neuroaxis</td>
</tr>
<tr>
<td>- Large cell/anaplastic medulloblastoma</td>
</tr>
<tr>
<td>- Supratentorial location a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADJUVANT TREATMENT l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard-dose craniospinal radiation m</td>
</tr>
<tr>
<td>or</td>
</tr>
<tr>
<td>Reduced-dose craniospinal RT m with chemotherapy n followed by post-radiation chemotherapy n,o</td>
</tr>
</tbody>
</table>

| Craniospinal radiation m with chemotherapy followed by post-radiation chemotherapy p,q |

---

**a** Excluding esthesioneuroblastoma.

**b** See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

**c** Postoperative brain MRI within 24–72 hours after surgery.

**d** Spine MRI should be delayed by at least 2–3 weeks post surgery to avoid postsurgical artifacts.

**e** Lumbar puncture should be done after spine MRI. Lumbar puncture for CSF should be delayed at least 2 weeks after surgery to avoid possible false-positive cytology.

**f** Bone scan; CT with contrast of chest, abdomen, and pelvis or whole body PET/CT; and bone marrow biopsy only if clinically indicated.


**h** If only biopsy is possible, consider pre-irradiation chemotherapy followed by an attempt at resection at a center that specializes in the treatment of brain tumors.

---

**m** See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

**n** Omission of vincristine during radiotherapy phase of therapy or dose modification may be required for adults because they do not tolerate this regimen as well. Data supporting vincristine’s use have been found in pediatric trials only. Patients should be closely monitored for neurologic toxicity with periodic exams. (Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24:4202-4208.)

**o** See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

**p** Recommend a platinum-based chemotherapy regimen such as either of the treatment arms used in the Children’s Oncology Group study referenced in footnote o.

**q** Consider collecting stem cells before craniospinal radiation.

---

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
FOLLOW-UP

Brain MRI:
- every 3 mo for 2 y;
- then every 6 mo for 3 y;
- then at least yearly indefinitely
For patients with previous spine disease, concurrent spine imaging as clinically indicated

CLINICAL STAGING

<table>
<thead>
<tr>
<th>Localized brain recurrence</th>
<th>Maximum safe resection</th>
<th>Brain MRI and spine MRI</th>
<th>Recurrent disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain and spine MRI&lt;br&gt;CSF analysis&lt;br&gt;Bone scan&lt;br&gt;Contrast-enhanced CT scans of chest, abdomen, and pelvis&lt;br&gt;Bone marrow biopsy&lt;br&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SURGERY

TREATMENT FOR RECURRENTNESS

<table>
<thead>
<tr>
<th>Chemotherapy and/or Additional radiation, such as stereotactic radiosurgery (SRS), after resection or High-dose chemotherapy with autologous stem cell reinfusion</th>
</tr>
</thead>
</table>

Disseminated disease

<table>
<thead>
<tr>
<th>Chemotherapy or Palliative/Best supportive care, including focal radiation, if indicated</th>
</tr>
</thead>
</table>

aExcluding esthesioneuroblastoma.
bSee Principles of Brain and Spine Tumor Imaging (BRAIN-A).
cPostoperative brain MRI within 24–72 hours after surgery.
dSpine MRI should be delayed by at least 2–3 weeks post surgery to avoid post-surgical artifacts.
eSee Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

If clinically indicated. If patient was treated with radiation only at diagnosis, then a bone scan should be part of restaging imaging at time of recurrence, even if patient is asymptomatic.

If clinically indicated. If patient was treated with radiation only at diagnosis, then a bone scan should be part of restaging imaging at time of recurrence, even if patient is asymptomatic.

If clinically indicated. If patient was treated with radiation only at diagnosis, then a bone scan should be part of restaging imaging at time of recurrence, even if patient is asymptomatic.

If clinically indicated. If patient was treated with radiation only at diagnosis, then a bone scan should be part of restaging imaging at time of recurrence, even if patient is asymptomatic.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2017
Primary CNS Lymphoma

All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

DIAGNOSIS BY TISSUE EVALUATION

Positive diagnosis of primary CNS lymphoma → See Induction Therapy (PCNS-2)

Biopsy of brain lesion with least invasive approach\(^d\)
- Consider CSF sampling (15–20 mL spinal fluid to increase diagnostic yield), if safe, and if it will not delay the diagnostic process or treatment\(^e\)
- Hold initiation of steroids, if possible, prior to diagnostic procedure

Biopsy not diagnostic of primary CNS lymphoma → See Induction Therapy (PCNS-2)

Other CNS tumor → See NCCN Guidelines for Central Nervous System Cancers

\(^a\) If patient is HIV positive, antiretroviral therapy should be part of his/her treatment. Antiretrovirals (ARVs) can be administered safely with chemotherapy but consultation with an HIV specialist or pharmacist is important to optimize compatibility. See NCCN Guidelines for Diffuse Large B-Cell Lymphoma, sub-algorithm for AIDS-Related B-Cell Lymphomas.

\(^b\) See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
\(^c\) Includes primary CNS lymphoma of the brain, spine, CSF, and leptomeninges. For lymphoma with primary tumor outside the CNS or involving only the eye, See NCCN Guidelines for Diffuse Large B-Cell Lymphoma.

\(^d\) If stereotactic biopsy is not available refer to a specialized center.
\(^e\) CSF should be obtained promptly. CSF analysis should include flow cytometry and CSF cytology and may consider gene rearrangements. If there is unequivocal evidence of PCNS lymphoma based on CSF and imaging, then brain biopsy may not be needed. Otherwise brain biopsy is recommended as the primary procedure to obtain diagnosis.
**EXTENT OF DISEASE**

Positive diagnosis of primary CNS lymphoma

- Slit lamp eye exam
- Lumbar puncture if safe
- Spine MRI, if symptomatic or positive CSF
- HIV status
- CBC, Comprehensive chemistry profile
- Contrast-enhanced chest/abdominal/pelvic CT or whole body PET/CT scan
- Bone marrow biopsy (category 2B)
- Consider testicular ultrasound for men >60 y
- Initiate steroids as clinically indicated

Prior steroids

Discontinue steroids and rebiopsy when disease progresses

No prior steroids

Workup for other CNS diagnosis or rebiopsy

**INDUCTION THERAPY**

High-dose methotrexate-based regimen

- If CSF positive or spinal MRI positive, and not responding to systemic chemotherapy, consider intra-CSF chemotherapy (category 2B)
- If eye exam shows vitreous involvement and patient is not responding to systemic chemotherapy, consider RT to globe or intraocular chemotherapy (category 2B)

OR

WBRT if patient is not a candidate for systemic chemotherapy

- If eye exam shows vitreous involvement, RT to globe
- If CSF positive or spinal MRI positive, consider intra-CSF chemotherapy m + focal spinal RT

**CONsolidation Therapy**

If complete response consider:

- High-dose chemotherapy with stem cell rescue
- High-dose cytarabine ± etoposide
- Low-dose WBRT
- Continue monthly high-dose methotrexate-based regimen for up to 1 y

If residual disease present:

- WBRT
- Consider high-dose cytarabine ± etoposide
- Best supportive care

**Evaluation**

If complete response consider:

- High-dose chemotherapy with stem cell rescue
- High-dose cytarabine ± etoposide
- Low-dose WBRT
- Continue monthly high-dose methotrexate-based regimen for up to 1 y

If residual disease present:

- WBRT
- Consider high-dose cytarabine ± etoposide
- Best supportive care

**Discussion**

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### NCCN Guidelines Version 1.2017

**Primary CNS Lymphoma**

### FOLLOW-UP

#### RELAPSED OR REFRACTORY PRIMARY CNS LYMPHOMA

- **Prior WBRT**
  - **Brain MRI**:
    - every 3 mo until 2 y,
    - every 6 mo until 5 y,
    - then annually indefinitely
  - For patients with previous spine disease, concurrent spine imaging and CSF sampling as clinically indicated
  - For patients with prior ocular involvement, concurrent ophthalmologic follow-up as clinically indicated

- **Prior high-dose methotrexate-based regimen without prior RT**
  - Previous response with long duration (≥12 mo)
  - No response or short duration (<12 mo)

- **Prior high-dose chemotherapy with stem cell rescue**
  - Previous response with long duration (≥12 mo)
  - No response or short duration (<12 mo)

### TREATMENT

- **Consider chemotherapy (systemic and/or intra-CSF)**
  - or
  - Consider high-dose therapy with stem cell rescue (category 2B)
  - or
  - Consider focal irradiation
  - or
  - Palliative/Best supportive care

- **Re-treat with high-dose methotrexate**
  - or
  - Other systemic chemotherapy
  - or
  - Consider high-dose therapy with stem cell rescue (category 2B)
  - or
  - Palliative/Best supportive care

- **Consider second high-dose chemotherapy with stem cell rescue**
  - or
  - Other systemic chemotherapy
  - or
  - Best supportive care

- **WBRT or involved field RT ± chemotherapy**
  - or
  - Palliative/Best supportive care

### FOLLOW-UP

- **Brain MRI**:
  - every 3 mo until 2 y,
  - every 6 mo until 5 y,
  - then annually indefinitely

- For patients with previous spine disease, concurrent spine imaging and CSF sampling as clinically indicated

- For patients with prior ocular involvement, concurrent ophthalmologic follow-up as clinically indicated

### Discussion

- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

*aIf patient is HIV positive, antiretroviral therapy should be part of his/her treatment. Antiretrovirals (ARVs) can be administered safely with chemotherapy but consultation with an HIV specialist or pharmacist is important to optimize compatibility. See NCCN Guidelines for B-Cell Lymphomas, sub-algorithm for AIDS-Related B-Cell Lymphomas.*

*bSee Principles of Brain and Spine Tumor Imaging (BRAIN-A).*

*mSee Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).*

*pSee Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).*

*If the recurrent disease goes into complete remission with reinduction chemotherapy.*

*The risk of neurotoxicity should be considered before administrating high-dose therapy to a patient with prior WBRT.*

---


**PCNS-3**
NCCN Guidelines Version 1.2017
Primary Spinal Cord Tumors

RADIOLOGIC PRESENTATION

- Intradural intramedullary
  - MRI well-defined/circumscribed
  - Asymptomatic
    - Observation or Maximum safe resection
    - Spine MRI
  - Symptomatic
    - Maximum safe resection
- Intradural extramedullary
  - MRI poorly defined/infiltrative
  - Asymptomatic
    - Observation or Biopsy
  - Symptomatic
    - Biopsy

CLINICAL PRESENTATION

- Asymptomatic
- Symptomatic

SURGERY

- Observation or Maximum safe resection
- Spine MRI
- Observation or Biopsy
- Biopsy

See Follow-up (PSCT-4)
See Pathology (PSCT-2)
See PSCT-3
See Follow-up (PSCT-4)
See Pathology (PSCT-2)

See Pathology (PSCT-2)

---

**a** See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
**b** Consider a multidisciplinary review in treatment planning, before surgery and once pathology is available (See Principles of Brain Tumor Management [BRAIN-E]).
**c** See Principles of Brain Tumor Surgery (BRAIN-B).

All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
# NCCN Guidelines Version 1.2017

## Primary Spinal Cord Tumors

<table>
<thead>
<tr>
<th>Radiologic Presentation</th>
<th>Pathology</th>
<th>Clinical Presentation</th>
<th>Adjuvant Treatment</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intradural Intramedullary tumor</td>
<td>MRI well-defined/circumscribed</td>
<td>Ependymoma&lt;br&gt;See Adult Intracranial and Spinal&lt;br&gt;Ependymoma (EPEN-1) and (EPEN-3)</td>
<td>Image-verified complete resection</td>
<td>Observation</td>
</tr>
<tr>
<td>Intradural Intramedullary tumor</td>
<td>MRI poorly defined/infiltrative</td>
<td>Infiltrative glioma&lt;br&gt;See Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma (ASTR-1) and Anaplastic Gliomas/Glioblastoma (GLIO-1)</td>
<td>Partial resection or biopsy</td>
<td>Asymptomatic&lt;br&gt; Observation</td>
</tr>
<tr>
<td>Intradural Intramedullary tumor</td>
<td>MRI poorly defined/infiltrative</td>
<td>Low-grade glioma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intradural Intramedullary tumor</td>
<td>MRI poorly defined/infiltrative</td>
<td>Anaplastic glioma&lt;br&gt;Glioblastoma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>d</sup>See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

---

All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

Primary Spinal Cord Tumors

RADIOLOGIC PRESENTATION

Intradural extramedullary

Solitary

Multiple
Consider:
- Neurofibromatosis (Type I and Type II)
- Schwannomatosis
- Leptomeningeal metastases (See LEPT-1)

or

Asymptomatic

Symptomatic

CLINICAL PRESENTATION

SURGERY

PATHOLOGY

FOLLOW-UP

Maximum safe resection

Spine MRI

- Meningioma (See MENI-1)

Other subtypes:
- Peripheral nerve sheath tumor
- Myxopapillary ependymoma

Follow-up (See PSCT-4)

aSee Principles of Brain and Spine Tumor Imaging (BRAIN-A).

bSee Principles of Brain Tumor Surgery (BRAIN-B).

cSee Principles of Brain and Spine Tumor Surgery (BRAIN-B).

dSpine MRI should be delayed by at least 2–3 weeks post surgery to avoid post-surgical artifacts.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

### NCCN Guidelines Version 1.2017
#### Primary Spinal Cord Tumors

<table>
<thead>
<tr>
<th>Patients managed by:</th>
<th>FOLLOW-UP&lt;sup&gt;a&lt;/sup&gt;</th>
<th>RECURRENCE</th>
<th>TREATMENT FOR RECURRENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation or Max. safe resection for intradural intramedullary tumor or intradural extramedullary tumor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-grade tumors (I-II)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spine MRI every 3–6 mo until 5 y, then at least annually indefinitely</td>
<td>New/worsening symptoms or radiographic progression</td>
<td>Re-resection or RT&lt;sup&gt;d&lt;/sup&gt; or re-irradiation (include stereotactic radiotherapy), if surgery not possible or Chemotherapy&lt;sup&gt;f&lt;/sup&gt; if further surgery or RT not possible</td>
<td></td>
</tr>
<tr>
<td>High-grade tumors (III-IV)</td>
<td>Spine MRI 2–6 wk after treatment, then every 2–4 mo until 2–3 y, then every 3–6 mo until 5 y, then every 6–12 mo indefinitely</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
<sup>d</sup>See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).
<sup>f</sup>See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D) for options according to disease histology.

*All recommendations are category 2A unless otherwise indicated.*

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Meningiomas

**PRESENTATION**

<table>
<thead>
<tr>
<th>Radiographic diagnosis by brain MRI:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Dural-based mass</td>
</tr>
<tr>
<td>• Homogeneously contrast-enhancing</td>
</tr>
<tr>
<td>• Dural tail</td>
</tr>
<tr>
<td>• CSF cleft</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Meningioma by radiographic criteria or Possible meningioma:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Consider biopsy/resection</td>
</tr>
<tr>
<td>• Consider octreotide scan if diagnostic doubt exists</td>
</tr>
</tbody>
</table>

**TREATMENT**

Observe (preferred for small tumors)

Surgery (if accessible) ± RT depending on consideration of factors in footnote "b". In general, postoperative management depends on grade and extent of resection as follows:

- Grade III: RT
- Grade II with incomplete resection: RT
- Grade II with complete resection: consider RT
- Grade I: observation or RT

Surgery (if accessible) ± RT depending on consideration of factors in footnote "b". In general, postoperative management depends on grade and extent of resection as follows:

- Grade III: RT
- Grade II with incomplete resection: RT
- Grade I/II with complete resection: consider RT or RT

**Follow-up**

(See MENI-2)

- Grade I/II with complete resection: consider RT or RT

**Asymptomatic**

**Symptomatic**

---

*a* Multidisciplinary input for treatment planning if feasible.

*b* Treatment selection should be based on assessment of a variety of inter-related factors, including patient features (eg, age, performance score, comorbidities, treatment preferences), tumor features (eg, size, grade, growth rate, location [proximity to critical structures], potential for causing neurologic consequences if untreated, presence and severity of symptoms), and treatment-related factors (eg, potential for neurologic consequences from surgery/RT, likelihood of complete resection and/or complete irradiation with SRS, treatability of tumor if it progresses, available surgical or radiation oncology expertise and resources). The decision to administer RT after surgery also depends on the extent resection achieved. Multidisciplinary input for treatment planning is recommended.

*d* See Principles of Brain and Spine Tumor Imaging (BRAIN-A).

*e* WHO Grade I = Benign meningioma, WHO Grade II = Atypical meningioma, WHO Grade III = Malignant (anaplastic) meningioma.

*f* RT can be either external-beam or stereotactic radiosurgery (SRS).

*g* See Principles of Brain Tumor Radiation Therapy (BRAIN-C).

*h* For asymptomatic meningiomas, observation is preferred for small tumors, with a suggested cutoff of ≤3 cm. Active treatment with surgery and/or RT is recommended in cases with one or more tumor- and/or treatment-related risk factors, such as proximity to the optic nerve.

---

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**NCCN Guidelines Version 1.2017**

**Meningiomas**

**FOLLOW-UP**

**RECURRENT/PROGRESSION**

**TREATMENT**

<table>
<thead>
<tr>
<th>WHO Grade I and II(^\text{e, j}) or unresected meningiomas: Brain MRI(^\text{c, d}) at 3, 6, and 12 mo, then every 6–12 mo for 5 y, then every 1–3 y indefinitely(^\text{l})</th>
<th>Recurrent or progressive disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery if accessible</td>
<td>Brain MRI(^\text{c, d})</td>
</tr>
<tr>
<td>Not surgically accessible RT possible</td>
<td>RT(^\text{g})</td>
</tr>
<tr>
<td>Not surgically accessible RT not possible</td>
<td></td>
</tr>
<tr>
<td>Treatment not clinically indicated</td>
<td></td>
</tr>
</tbody>
</table>

\(^{c}\)Postoperative brain MRI 24–72 hours after surgery.

\(^{d}\)See *Principles of Brain and Spine Tumor Imaging (BRAIN-A)*.

\(^{e}\)WHO Grade I = Benign meningioma, WHO Grade II = Atypical meningioma, WHO Grade III = Malignant (anaplastic) meningioma.

\(^{g}\)See *Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C)*.

\(^{l}\)Consider less frequent follow-up after 5–10 y.

\(^{j}\)More frequent imaging may be required for WHO Grade 3 meningiomas, and for meningiomas of any grade that are treated for recurrence or with chemotherapy.

\(^{k}\)See *Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D)*.

\(^{i}\)Recommend imaging if cause/symptomatic change at any time.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2017
Limited (1–3) Brain Metastases

**CLINICAL PRESENTATION**

<table>
<thead>
<tr>
<th>Known history of cancer</th>
<th>If concern exists regarding diagnosis of CNS lesions</th>
<th>Stereotactic or open biopsy/resection or Subtotal resection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known history of cancer</td>
<td>If concern exists regarding diagnosis of CNS lesions</td>
<td>Stereotactic or open biopsy/resection or Subtotal resection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No known history of cancer</th>
<th>• Contrast-enhanced CT chest/abdomen/pelvis • Consider whole body PET/CT • Other tests as indicated</th>
<th>Suspected tumor found outside CNS that can be biopsied or resected</th>
</tr>
</thead>
<tbody>
<tr>
<td>No known history of cancer</td>
<td>• Contrast-enhanced CT chest/abdomen/pelvis • Consider whole body PET/CT • Other tests as indicated</td>
<td>Suspected tumor found outside CNS that can be biopsied or resected</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No other readily accessible tumor for biopsy</th>
<th>Biopsy or resection of tumor outside CNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>No other readily accessible tumor for biopsy</td>
<td>Biopsy or resection of tumor outside CNS</td>
</tr>
</tbody>
</table>

See Clinical Presentation and Primary Treatment (LTD-2)

---

aSee Principles of Brain and Spine Tumor Imaging (BRAIN-A).
bConsider a multidisciplinary review in treatment planning, especially once pathology is available (See Principles of Brain Tumor Management [BRAIN-E]).

All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

NCCN Guidelines Version 1.2017
Limited (1–3) Brain Metastases

**CLINICAL PRESENTATION**

Disseminated systemic disease with poor systemic treatment options

Newly diagnosed or stable systemic disease or Reasonable systemic treatment options exist

**TREATMENT**

Consider best supportive/palliative care or WBRT

Surgical resection

Unresectable or opted not to resect

SRS (preferred) or WBRT

Brain MRI

See Follow-up and Recurrence (LTD-3)

---

**DISCUSSION**

All options listed above should be considered experimental and investigational. The best management of metastatic brain tumor patients is in the context of a clinical trial. Local institutional expertise should be considered when discussing treatment options. Patients should be informed of their treatment options and the implications of each choice. All patients with metastatic brain tumors should be referred for consultation with a neuro-oncologist or radiation oncologist. The role of the radiation oncologist in the management of brain metastases is to deliver the optimal dose of radiation with the least toxicity to the patient. Each patient's treatment plan will be individualized based on patient characteristics, physician's expertise, institutional capabilities, and institutional policies.

- **All options listed above should be considered experimental and investigational.**
- The best management of metastatic brain tumor patients is in the context of a clinical trial.
- Local institutional expertise should be considered when discussing treatment options.
- Patients should be informed of their treatment options and the implications of each choice.
- All patients with metastatic brain tumors should be referred for consultation with a neuro-oncologist or radiation oncologist.
- The role of the radiation oncologist in the management of brain metastases is to deliver the optimal dose of radiation with the least toxicity to the patient. Each patient's treatment plan will be individualized based on patient characteristics, physician's expertise, institutional capabilities, and institutional policies.

---

**REFERENCES**

- See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
- Consider surgery to relieve mass effect.
- For secondary CNS lymphoma treatment may include systemic treatment, whole-brain or focal RT, or combination.
- The decision to resect a tumor may depend on the need to establish histologic diagnosis, the size of the lesion, its location, and institutional expertise. For example, smaller (<2 cm), deep, asymptomatic lesions may be considered for treatment with SRS versus larger (>2 cm), symptomatic lesions that may be more appropriate for surgery. (Ewend MG, Morris DE, Carey LA, Ladha AM, Brem S: Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J Natl Compr Cancer Netw 2008; 6:505-513.)
- See Principles of Brain Tumor Surgery (BRAIN-B).
- See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).
- If an active agent exists (eg, cytotoxic, targeted, or immune modulating), trial of systemic therapy with good CNS penetration may be considered in select patients (eg, patients with small asymptomatic brain metastases who have not had prior systemic therapy).
- SRS is preferred when safe, especially for low tumor volume. WBRT is generally not recommended but may be appropriate in some rare clinical circumstances (eg, ventricle is violated, cerebellar lesions, risk of meningeal disease, need for complete CNS control before going on protocol, not good SRS candidate for technical reasons, poor PS, advanced age).
- SRS + WBRT is generally not recommended but may be appropriate in some rare clinical circumstances. Brown 2016 showed that for tumors <3 cm, SRS + WBRT improved local control compared with SRS alone, but did not significantly improve survival, and was associated with greater cognitive decline and poorer quality of life. (Brown PD et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 2016;316:401-409).
NCCN Guidelines Version 1.2017
Limited (1–3) Brain Metastases

FOLLOW-UP

RECURRENCE

TREATMENT

Previous surgery only

Recurrent disease; local site

Brain MRIa every 2–3k mo for 1 y then every 4–6 mo indefinitelyo

1–3 lesions

Previous WBRT or Prior SRS

Surgery or Single-dose or fractionated stereotactic RTg

or WBRTg for large volumes (eg, diameter >3 cm)

or Consider chemotherapym

>3 lesions

Recurrent disease; distant brain ± local recurrence

Surgery or Single-dose or fractionated stereotactic RTg

or WBRTg for large volumes (eg, diameter >3 cm) if not previously administered

or Consider chemotherapym

Recurrent disease; local site

Surgery or Single-dose (category 2B) or fractionated stereotactic RTg,n

Brain MRIa

If relapses, see LTD-4

mSee Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

nIf patient had previous SRS with a good response >6 mo, then reconsider SRS if imaging supports active tumor and not necrosis.

oImaging to evaluate emergent signs/symptoms is appropriate at any time.

Surgery or Single-dose or fractionated stereotactic RTg

or WBRTg if not previously administered

or Consider chemotherapym

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

All recommendations are category 2A unless otherwise indicated.

See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

MRI every 2 months (instead of 3 mo) for those patients treated with SRS alone.

After stereotactic radiosurgery, recurrence on radiograph can be confounded by treatment effects; consider tumor tissue sampling if there is a high index of suspicion of recurrence.
RECURRENCE | TREATMENT

Systemic disease progression, with limited systemic treatment options and poor PS

- **No prior WBRT**
  - Palliative/Best supportive care or WBRT

- **Prior WBRT**
  - Palliative/Best supportive care or Reirradiation, if prior positive response to RT

---

*See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).*

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
FOLLOW-UP

Brain MRI every 2–3 mo for 1 y, then every 4–6 mo indefinitely

Recurrent disease

Stable systemic disease or reasonable systemic treatment options

Systemic disease progression, with limited systemic treatment options

Palliative/Best supportive care

Surgery or SRS or WBRT (if no prior WBRT) or Chemotherapy

Brain MRI

---

See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).
See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).
After stereotactic radiosurgery, recurrence on radiograph can be confounded by treatment effects; consider tumor tissue sampling if there is a high index of suspicion of recurrence.
Imaging to evaluate emergent signs/symptoms is appropriate at any time.

All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Signs and symptoms suggestive of leptomeningeal disease

- Physical exam with careful neurologic evaluation
- Brain and spine MRI if patient is a candidate for active treatment
- CSF exam

Diagnosis

- CSF positive for tumor cells or Positive radiologic findings with supportive clinical findings or Signs and symptoms with suggestive CSF in a patient known to have a malignancy

Risk Status

Poor risk:
- KPS <60
- Multiple, serious, major neurologic deficits
- Extensive systemic disease with few treatment options
- Bulky CNS disease
- Encephalopathy

See Treatment (LEPT-2)

Good risk:
- KPS ≥60
- No major neurologic deficits
- Minimal systemic disease
- Reasonable systemic treatment options, if needed

See Treatment (LEPT-2)

Notes:

- Consider a multidisciplinary review in treatment planning, especially once pathology is available (See Principles of Brain Tumor Management [BRAIN-E]).
- See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
- Caution is indicated in patients who are anticoagulated, thrombocytopenic, or who have a bulky intra-cranial mass.
- With all malignancies, send for a cell count, differential (including hematopathology review), glucose, and protein. For solid malignancies, CSF analysis utilizes cytology. For hematologic malignancies, use flow cytometry.
- Suggestive CSF includes high WBC, low glucose, and high protein. If CSF is not positive for tumor cells, a second lumbar puncture is sometimes helpful. This is a volume-dependent test and ideally ≥10 mL should be sent for cytologic analysis.
- Patients with exceptionally chemosensitive tumors (eg, small cell lung cancer, lymphoma) may be treated.

All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### NCCN Guidelines Version 1.2017
#### Leptomeningeal Metastases

**RISK STATUS**

<table>
<thead>
<tr>
<th>Poor risk:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• KPS &lt;60</td>
</tr>
<tr>
<td>• Multiple, serious, major neurologic deficits</td>
</tr>
<tr>
<td>• Extensive systemic disease with few treatment options</td>
</tr>
<tr>
<td>• Bulky CNS disease</td>
</tr>
<tr>
<td>• Encephalopathy</td>
</tr>
</tbody>
</table>

**TREATMENT**

- **Palliative/Best supportive care**
  - Consider involved field RT to symptomatic painful sites for palliation (including spine and intracranial disease)

<table>
<thead>
<tr>
<th>Good risk:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• KPS ≥60</td>
</tr>
<tr>
<td>• No major neurologic deficits</td>
</tr>
<tr>
<td>• Minimal systemic disease</td>
</tr>
<tr>
<td>• Reasonable systemic treatment options, if needed</td>
</tr>
</tbody>
</table>

- **WBRT and/or involved field RT**
  - to bulky disease and symptomatic sites (including spine and intracranial disease)
  - See CSF flow scan (LEPT-3)

---

**Notes:**

- Patients with exceptionally chemosensitive tumors (e.g., small cell lung cancer, lymphoma) may be treated.
- See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
NCCN Guidelines Version 1.2017
Leptomeningeal Metastases

TREATMENT

CSF cytology negative

Continue on current regimen and re-evaluate CSF cytology on a monthly basis

Maintenance intrathecal chemotherapy\(^1\) and Monitor CSF cytology every month

CSF cytology positive

Patient clinically stable or improving and there is no evidence of clinical or radiologic progression of leptomeningeal disease

Continue intra-CSF chemotherapy\(^1\) for 4 wks or Consider switching intra-CSF drugs and treat for 4 wks before re-testing CSF

Negative cytology or persistent positive cytology, but patient is clinically stable

Cytology continually positive and evidence of clinical or radiologic progression of leptomeningeal disease

Evidence of clinical or radiologic progression of leptomeningeal disease

Consider switching intra-CSF drug

RT\(^9\) to symptom sites or Systemic chemotherapy\(^1\) or Palliative/Best supportive care

Negative cytology or persistent positive cytology, but patient is clinically stable

Evidence of clinical or radiologic progression of leptomeningeal disease

Consider switching intra-CSF drug

RT\(^9\) to symptom sites or Systemic chemotherapy\(^1\) or Palliative/Best supportive care

Maintenance intrathecal chemotherapy\(^1\) and Monitor CSF cytology every month

All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

\(^9\)See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).
\(^1\)See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).
NCCN Guidelines Version 1.2017
Metastatic Spine Tumors

**PRESENTATION**

Patient diagnosed with cancer or patient with newly discovered abnormality suspicious for spine metastasis

**WORKUP**

- Systemic imaging (ie, contrast-enhanced chest/abdominal/pelvic CT or whole body PET/CT, bone scan as indicated for metastatic workup)
- Biopsy\(^a\) if it alters management

**TREATMENT**

- Observation
- Spine MRI\(^d\) in 6–8 weeks, then every 2–3 months until the nature of the lesion is established
- Surgery/focal RT or chemotherapy\(^e\) are options for patients with asymptomatic epidural disease

\(^a\)Biopsy if remote history of cancer.
\(^b\)If the patient is unable to have an MRI, then a CT myelogram is recommended.
\(^c\)15%–20% of patients have additional lesions. Highly recommend complete spine imaging.
\(^d\)See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
\(^e\)See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).
\(^f\)Includes cauda equina syndrome.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
## NCCN Guidelines Version 1.2017
### Metastatic Spine Tumors

#### PRESENTATION

<table>
<thead>
<tr>
<th>No tumor</th>
<th>Evaluate for other causes of pain and/or neurologic symptoms(^i)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal cord compression(^f)</td>
<td>Steroids(^g)</td>
</tr>
</tbody>
</table>

#### TREATMENT

<table>
<thead>
<tr>
<th>Fracture or spinal instability(^h)</th>
<th>Surgical stabilization or Vertebral augmentation(^o)</th>
<th>Followed by RT(^n)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>No fracture or spinal instability</th>
<th>RT(^n) (preferred) or Chemotherapy(^e) if chemosensitive tumor or Surgery(^i,m) (selective cases) followed by RT</th>
<th>Consider surgery(^m) or SRS(^n) if:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Deterioration during RT</td>
<td>• Intractable pain</td>
</tr>
<tr>
<td></td>
<td>• Tumor progression</td>
<td></td>
</tr>
</tbody>
</table>

#### ADJUVANT TREATMENT

- See Follow-up (SPINE-3)

---

\(^e\)See Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D).

\(^f\)Includes cauda equina syndrome.

\(^g\)The recommended minimum dose of steroids is 4 mg of dexamethasone every 6 hours, although dose of steroids may vary (10–100 mg). A randomized trial supported the use of high-dose steroids (Sorensen PS, et al. Eur J Cancer 1994;30A:22-27).

\(^h\)Spinal instability is grossly defined as the presence of significant kyphosis or subluxation (deformity), or of significantly retropulsed bone fragment.

\(^i\)Regarding surgery, note the following:
- Category 1 evidence supports the role of surgery in patients with a solitary epidural spinal cord compression by a tumor not known to be radiosensitive and who are willing to undergo surgery. (Patchell RA, et al. Lancet 2005;366(9486):643-648)
- For surgery, patients with hematologic tumors (ie, lymphoma, myeloma, leukemia) should be excluded, life expectancy should be ≥3 mo, and the patient should not be paraplegic for >24 h.
- Surgery is especially indicated if the patient has any of the following: spinal instability, no history of cancer, rapid neurologic deterioration during RT, previous RT to site, and single-site spinal cord compression.

\(^m\)See Principles of Brain Tumor Surgery (BRAIN-B).

\(^n\)Recommends stereotactic radiosurgery if oligometastases and radioresistant. See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

\(^o\)Vertebral augmentation: vertebroplasty, kyphoplasty.

---

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2017
Metastatic Spine Tumors

FOLLOW-UP | PRESENTATION (Symptom- or MRI-based) | TREATMENT FOR RECURRENT OR PROGRESSIVE DISEASE

Spine MRI/CT\(^d\)
1–3 mo after treatment, then every 3–4 mo for 1 y, then as clinically indicated indefinitely

Progressive disease or Recurrent disease

If previously treated with:
RT or Surgery and RT
Consider surgery\(^j,m\) or SRS\(^n,p\)
Consider re-irradiation if recurrent

If previously treated with:
Chemotherapy
Consider RT\(^n\)

\(^d\)See Principles of Brain and Spine Tumor Imaging (BRAIN-A).
\(^j\)Postoperative brain MRI within 24–72 hours. (See BRAIN-A).
\(^m\)See Principles of Brain Tumor Surgery (BRAIN-B).
\(^n\) Recommend stereotactic radiosurgery if oligometastases and radioresistant. See Principles of Brain and Spinal Cord Tumor Radiation Therapy (BRAIN-C).

All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
This is a list of imaging modalities available and used in neuro-oncology primarily to make treatment decisions. The most common use for MR spectroscopy, MR perfusion, and PET scanning is to differentiate radiation necrosis from active tumor, as this might obviate the need for surgery or the discontinuation of an effective therapy. Imaging is always recommended to investigate emergent signs or symptoms.

- **MRI** of the brain and spine (with and without contrast):
  - **Gold standard**
  - **Provides a “static” picture of tumors**
  - **Benefits**: Provides a reasonably good delineation of tumors. Higher grade tumors and brain leptomeningeal metastasis usually enhance. Lower grade tumors usually do not enhance.
  - **Limitations**: Sensitive to movement, metallic objects cause artifact, patients with implantable devices cannot have an MRI, claustrophobia may be an issue, or renal insufficiency

  Postoperative brain MRI should be performed within 24–72 hours for gliomas and other brain tumors to determine extent of resection.

  Postoperative spine MRI should be delayed by at least 2–3 weeks to avoid post-surgical artifacts.

- **CT** of the brain and spine (with and without contrast):
  - Should be used in patients who cannot have an MRI
  - **Benefits**: Claustrophobia or implantable devices are not an issue, can be done faster than an MRI
  - **Limitations**: Lacks resolution of MRI, especially in posterior fossa, or renal insufficiency

- **MR spectroscopy**: Assess metabolites within tumors and normal tissue
  - May be useful in differentiating tumor from radiation necrosis; may be helpful in grading tumors or assessing response.
  - **Area most abnormal would be the best place to target for a biopsy**
  - **Limitations**: Tumors near vessels, air spaces, or bone. Extra time in MRI and others as noted under MRI

- **MR perfusion**: Measures cerebral blood volume in tumors
  - May be useful in differentiating grade of tumor or tumor versus radiation necrosis. Area of highest perfusion would be the best place to biopsy.
  - **Limitations**: Tumors near vessels, air spaces, bone, small-volume lesions, or tumors in the spinal cord. Extra time in MRI and others as noted under MRI

- **Brain PET scanning**: Assess metabolism within tumor and normal tissue by using radio-labeled tracers
  - May be useful in differentiating tumor from radiation necrosis but has some limitations; may also correlate with tumor grade or provide the optimal area for biopsy
  - **Limitations**: Accuracy of interpretations, availability of equipment and isotopes

1The imaging modalities listed may not be available at every institution.

PRINCIPLES OF BRAIN TUMOR SURGERY

GUIDING PRINCIPLES
- Gross total resection when appropriate
- Minimal surgical morbidity
- Accurate diagnosis

FACTORS
- Age
- Performance status (PS)
- Feasibility of decreasing the mass effect with surgery
- Resectability, including number of lesions, location of lesions, time since last surgery (recurrent patients)
- New versus recurrent tumor
- Suspected pathology – benign vs. malignant, possibility of other non-cancer diagnoses, projected natural history

OPTIONS
- Gross total resection where feasible
- Stereotactic biopsy
- Open biopsy/debulking followed by planned observation or adjuvant therapy
- Chemotherapy implants, when indicated (See footnote h on GLIO-1)

TISSUE
- Sufficient tissue to pathologist for neuropathology evaluation and molecular correlates
- Frozen section analysis when possible to help with intraoperative decision making
- Review by experienced neuropathologist

- Postoperative brain MRI should be performed within 24–72 hours for gliomas and other brain tumors to determine the extent of resection. Postoperative spine MRI should be delayed by at least 2–3 weeks to avoid post-surgical artifacts.
- The extent of resection should be judged on the postoperative study and used as a baseline to assess further therapeutic efficacy or tumor progression.

All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF BRAIN AND SPINAL CORD TUMOR RADIATION THERAPY

Low-Grade Gliomas (Grades I/II)
• Tumor volumes are best defined using pre- and postoperative imaging, usually fluid-attenuated inversion recovery (FLAIR) and/or T2 signal abnormality on MRI for gross tumor volume (GTV). Clinical target volume (CTV) (GTV plus 1–2 cm margin) should receive 45–54 Gy in 1.8–2.0 Gy fractions.\(^1,2,3\)
• SRS has not been established to have a role in the management of low-grade gliomas. Phase I trials using SRS do not support its role as initial treatment.

High-Grade Gliomas (Grades III/IV)
• The GTV is best defined using pre- and postoperative MRI imaging using enhanced T1 and FLAIR/T2. To account for sub-diagnostic tumor infiltration, the GTV is expanded 1–2 cm (CTV) for grade III, and up to 2–2.5 cm (CTV) for grade IV. A PTV of margin of 3–5 mm is typically added to the CTV to account for daily setup errors and image registration. Daily image guidance is required if smaller PTV margins are used. When edema is included in an initial phase of treatment, fields are usually reduced for the last phase of the treatment (boost). The boost target volume will typically encompass only the gross residual tumor and the resection cavity. A range of acceptable clinical target volume margins exists. Both strategies appear to produce similar outcomes.\(^4\)
• The recommended dose is 60 Gy in 2.0 Gy fractions or 59.4 Gy in 1.8 Gy fractions. A slightly lower dose, such as 55.8–59.4 Gy in 1.8 Gy or 57 Gy in 1.9 Gy fractions, can be applied when the tumor volume is very large (gliomatosis) or for Grade III astrocytoma. If a boost volume is used, the initial phase of the RT plan will receive 46 Gy in 2 Gy fractions or 45–50.4 Gy in 1.8 Gy fractions. The boost plan will typically then receive 14 Gy in 2 Gy fractions or 9–14.4 Gy in 1.8 Gy fractions.\(^4\)
• In poorly performing patients or the elderly a hypofractionated accelerated course is reasonable with the goal of completing the treatment in 2–4 weeks. Typical fractionation schedules are 34 Gy/10 fx, 40.05 Gy/15 fx, or 50 Gy/20 fx.\(^5,6\) Alternatively, a shorter fractionation schedule of 25 Gy/5 fx may be considered for elderly and/or frail patients with smaller tumors for whom a longer course of treatment would not be tolerable.\(^7\)

Ependymoma
• Limited Fields: Intracranial tumor volumes are best defined using pre- and postoperative imaging, usually enhanced T1 and FLAIR/T2. Anatomic areas that are touched by preoperative tumor volume plus postoperative signal abnormality on MRI for GTV, CTV (GTV plus 1–2 cm margin) should receive 54–59.4 Gy in 1.8–2.0 Gy fractions.
• Craniospinal: Whole brain and spine (to bottom of thecal sac) receive 36 Gy in 1.8 Gy fractions, followed by limited field to spine lesions to 45 Gy. (Gross metastatic lesions below the conus could receive higher doses of 54–60 Gy).\(^5,8\) Primary intracranial site should receive total dose of 54–59.4 Gy in 1.8–2.0 Gy fractions. Consider boosting any gross intracranial metastatic sites to a higher dose while respecting normal tissue tolerances.
• For spine ependymomas, see section on primary spinal cord tumors (BRAIN-C 2 of 3).\(^10,11\)

Adult Medulloblastoma
• Standard risk for recurrence:
  ▶ Conventional dose: 30–36 Gy CSI\(^12,\)† and boosting the primary brain site to 54–55.8 Gy with or without adjuvant chemotherapy
  ▶ Reduced dose: May consider reduced dose radiation with adjuvant chemotherapy: 23.4 Gy CSI\(^\)\(^12,13,\)†† and boosting the primary brain site to 54–55.8 Gy\(^1\)
• High risk for recurrence: 36 Gy CSI\(^\)\(^3,\)† with boosting primary brain site to 54–55.8 Gy with adjuvant chemotherapy.

Primary CNS Lymphoma
• WBRT may be withheld in the primary setting in patients treated with chemotherapy. When used, low-dose WBRT should be limited to 23.4 Gy 1.8 Gy fractions following a CR to chemotherapy.\(^14\) For less than complete response (CR), consider WBRT to 30–36 Gy followed by a limited field to gross disease to 45 Gy or focal radiation to residual disease only.\(^15–18\)
• For patients who are not candidates for chemo: WBRT doses of 24–36 Gy followed by a boost to gross disease for a total dose of 45 Gy.

\(^\)†To reduce toxicity from craniospinal irradiation in adults, consider the use of intensity-modulated radiotherapy or protons if available.
\(^\)††Regimen supported by data from pediatric trials only.

Continued
PRINCIPLES OF BRAIN AND SPINAL CORD TUMOR RADIATION THERAPY

Primary Spinal Cord Tumors:
• Doses of 45–54 Gy are recommended using fractions of 1.8 Gy. In tumors below the conus medularis higher doses up to 60 Gy can be delivered.

Meningiomas
• WHO grade I meningiomas may be treated by fractionated conformal radiotherapy with doses of 45–54 Gy.
  ‣ Stereotactic or image-guided therapy is recommended when using tight margins or when close to critical structures. Conformal radiation therapy (eg, 3D-CRT, IMRT, VMAT) is recommended to spare critical structures and uninvolved tissue.
  ‣ WHO grade I meningiomas may also be treated with SRS doses of 12–16 Gy in a single fraction when appropriate.
• For WHO grade II meningiomas undergoing radiation, treatment should be directed to gross tumor (if present) and surgical bed + a margin (1–2 cm) to a dose of 54–60 Gy in 1.8–2.0 Gy fractions. Consider limiting margin expansion into the brain parenchyma if there is no evidence of brain invasion.
• WHO grade III meningiomas should be treated as malignant tumors with treatment directed to gross tumor (if present) and surgical bed + a margin (2–3 cm) receiving 59.4–60 Gy in 1.8–2.0 Gy fractions.

Brain Metastases
• Whole brain radiotherapy (WBRT): Doses vary between 20 and 40 Gy delivered in 5–20 fractions. The standard regimens include 30 Gy in 10 fractions or 37.5 Gy in 15 fractions. Nevertheless 20 Gy in 5 fractions is a good option in poor performers.19
  ‣ SRS: Maximum marginal doses from 24–15 Gy based on tumor volume is recommended.20-23
  ‣ SRS generally preferred over WBRT for 1–3 metastases, all <3 cm, with possible exception of patients with poor performance or uncontrolled systemic tumor.

Leptomeningeal Metastases
• Volumes and dose depend on primary source and sites requiring palliation.

Metastatic Spine
• Doses to vertebral body metastases will depend on patient's PS, spine stability, location in relationship to spinal cord, primary histology, presence of epidural disease, and overall treatment intent (pain relief, long-term local control, or cure). Generally, conventional external beam radiation doses of 8 Gy/1 fx, 20 Gy/5 fx, or 30 Gy/10 fx can be used. It is critical to consider tolerance at the spine and/or nerve root. In selected cases, or recurrences after previous radiation, stereotactic body radiotherapy (SBRT) is appropriate. It is critical to consider tolerance of the spine and/or spinal nerve roots. In patients with uncomplicated spine metastases that are treated primarily for pain relief, 8 Gy in 1 fraction has been shown to provide equivalent pain control to longer fractionation schedules and is more convenient for patients, but may be associated with higher rates of retreatment, which may be a consideration when life expectancy exceeds 6 months. When lower BED regimens are utilized upfront (ie, BED ≤60 Gy2 which includes up to 20 Gy in 5 fractions but does not include 30 Gy in 10 fractions), retreatment with similar BED regimens, such as 20 Gy in 5 fractions or 8 Gy in 1 fraction, can safely be considered as early as 4 weeks from initial treatment for pain relief. In other cases, doses ranging from 15 Gy in 1 fraction to 40 Gy in 20 fractions have been utilized for tumor control, with careful consideration of tolerance of the spinal cord and/or nerve roots. In these instances, it is generally recommended that 6 months or more of time between treatments is required.

All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References on next page
PRINCIPLES OF BRAIN AND SPINAL CORD TUMOR RADIATION THERAPY
(References)


All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF BRAIN AND SPINAL CORD TUMOR SYSTEMIC THERAPY

Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma (excluding pilocytic astrocytoma)

- Adjuvant Treatment: For low-risk patients:
  - Combination PCV (lomustine + procarbazine + vincristine)\(^1\) (category 1)
  - Temozolomide\(^2-4\)

- Adjuvant Treatment: For high-risk patients:
  - RT + adjuvant PCV (category 1)
  - RT + adjuvant temozolomide\(^2-4\) (category 2B)
  - RT + concurrent and adjuvant temozolomide (category 2B)

- Recurrence or Progressive, Low-grade Disease:\(^*\)
  - Temozolomide\(^* ,3-5\)
  - Lomustine or carmustine
  - Combination PCV\(^6\)
  - Platinum-based regimens\(^7-9\)

Anaplastic Gliomas

- Adjuvant Treatment:
  - Temozolomide or PCV with deferred RT\(^10-12\)
  - Concurrent (with RT) temozolomide\(^13\) 75 mg/m\(^2\) daily

- Recurrence Therapy:\(^\phi\)
  - Temozolomide\(^4,5,14,15\)
  - Lomustine or carmustine\(^16\)
  - Combination PCV
  - Bevacizumab\(^†,17-19\)
  - Bevacizumab + chemotherapy\(^††\) (irinotecan,\(^20,21\) carmustine/lomustine,\(^22\) temozolomide, carboplatin [category 2B for carboplatin]\(^23,24\))
  - Irinotecan\(^25,26\)
  - Cyclophosphamide (category 2B)\(^27,28\)
  - Platinum-based regimens\(^α\)
  - Etoposide\(^29\)

- Adjuvant Treatment:
  - RT and PCV for 1p19q co-deleted (category 1)\(^30\)

Glioblastoma

- Adjuvant Treatment:
  - Concurrent (with RT) temozolomide\(^13\) 75 mg/m\(^2\) daily
  - Post RT temozolomide\(^13\) 150–200 mg/m\(^2\) 5/28 schedule
  - Temozolomide\(^13,31\) 150–200 mg/m\(^2\) 5/28 schedule

- Recurrence Therapy:\(^\phi\)
  - Bevacizumab\(^†,32-35\)
  - Bevacizumab + chemotherapy\(^††\)
    - (irinotecan,\(^33-35\) carmustine/lomustine,\(^22\) temozolomide, carboplatin [category 2B for carboplatin]\(^23,24\))
  - Temozolomide\(^5,13,36\)
  - Lomustine or carmustine\(^16\)
  - Combination PCV
  - Cyclophosphamide (category 2B)\(^27\)
  - Platinum-based regimens\(^α\)

Anaplastic Oligoastrocytoma\(^†††/Anaplastic Oligodendroglioma

- Adjuvant Treatment
  - Bevacizumab\(^†,32-35\)
  - Bevacizumab + chemotherapy\(^††\)

- Recurrence Therapy:\(^ϕ\)
  - Bevacizumab\(^†,32-35\)
  - Bevacizumab + chemotherapy\(^††\)

- Temozolomide\(^5,13,36\)
- Lomustine or carmustine\(^16\)
- Combination PCV
- Cyclophosphamide (category 2B)\(^27\)
- Platinum-based regimens\(^α\)

Adult Intracranial and Spinal Ependymoma (excluding subependymoma)

- Recurrence
  - Platinum-based regimens:\(^α\) Single agent or combination\(^37\)
  - Etoposide
  - Lomustine or carmustine\(^37\)
  - Bevacizumab\(^†\)
  - Temozolomide\(^38\)

\(^*\)Oligodendrogliomas, particularly those that have chromosomal loss of combined 1p19q, have been reported to be sensitive to alkylator chemotherapy. Consider chemotherapy for these patients.

\(^†\)For patients not previously treated.

\(^††\)NOS WHO 2016 has deleted this category, although it may continue to be used for some patients.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF BRAIN AND SPINAL CORD TUMOR SYSTEMIC THERAPY

Adult Medulloblastoma

• Adjuvant Treatment
  ▶ Weekly vincristine during craniospinal radiation therapy followed by either of the following regimens:
    ◦ Cisplatin, cyclophosphamide, and vincristine
    ◦ Cisplatin, lomustine, and vincristine
  ◦ Recurrence Therapy
    ▶ No prior chemotherapy
      ◦ High-dose cyclophosphamide ± etoposide
      ◦ Carboplatin, etoposide, and cyclophosphamide
      ◦ Cisplatin, etoposide, and cyclophosphamide
      ◦ Consider high-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a CR with conventional doses of chemotherapy or have no residual disease after re-resection
  ▶ Prior chemotherapy
    ◦ High-dose cyclophosphamide ± etoposide
    ◦ Oral etoposide
    ◦ Temozolomide
    ◦ Consider high-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a CR with conventional doses of chemotherapy or have no residual disease after re-resection

Primary CNS Lymphoma

• Therapy
  ▶ High-dose methotrexate 3.5 g/m² combined with the following plus RT:
    ◦ Vincristine, procarbazine, cytarabine ± rituximab
    ◦ Cytarabine
    ◦ Ifosfamide ± RT
  ▶ High-dose methotrexate 8 g/m² combined with the following plus deferred RT:
    ◦ Rituximab
    ◦ Rituximab and temozolomide
  ▶ Consider urgent glucarpidase (carboxypeptidase G2) for prolonged methotrexate clearance due to methotrexate-induced renal toxicity
• Consolidation Therapy
  ▶ High-dose chemotherapy with stem cell rescue
  ▶ High-dose cytarabine ± etoposide
• Recurrence or Progressive Disease
  ▶ Retreat with high-dose methotrexate
  ▶ Temozolomide
  ▶ Rituximab ± temozolomide
  ▶ Topotecan
  ▶ Consider high-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a CR with conventional doses of chemotherapy
  ▶ High-dose cytarabine
  ▶ Dexamethasone, high-dose cytarabine, cisplatin
  ▶ Pemetrexed

Meningiomas

• Interferon alfa (category 2B)
• Somatostatin analogue, if octreotide scan positive
• Sunitinib (category 2B)

Continued

<sup>φ</sup>Omission of vincristine during radiotherapy phase of therapy or dose modification may be required for adults because they do not tolerate this regimen as well. Data supporting vincristine’s use have been found in pediatric trials only. Patients should be closely monitored for neurologic toxicity with periodic exams.

<sup>λ</sup>Other combinations with methotrexate may be used.

<sup>Ω</sup>Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B surface antigen and core antibody for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add e-antigen. If positive, check viral load and consult with gastroenterologist. See NCCN Guidelines for B-Cell Lymphomas (NHODG-B, 2 of 3) also has information about HPV testing for patients considering rituximab.

All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF BRAIN AND SPINAL CORD TUMOR SYSTEMIC THERAPY

Brain Metastases
- Recurrent Disease‡
  - Treatment as per the regimens of the primary tumor
  - Carmustine wafer
  - Temozolomide 5/28 schedule
  - High-dose methotrexate (breast and lymphoma)
  - Capecitabine ± lapatinib, cisplatin, etoposide (breast)
  - Topotecan (small cell lung)
  - Ipilimumab (melanoma)
  - Ipilimumab + nivolumab (melanoma)
  - Pembrolizumab (melanoma or non-small cell lung cancer)
  - BRAF inhibitors (melanoma)
    - Dabrafenib
    - Vemurafenib
  - Erlotinib, afatinib, gefitinib (EGFR sensitizing mutation-positive non-small cell lung cancer)
  - Osimertinib (EGFR T790M mutation-positive non-small cell lung cancer)
  - Crizotinib (ALK rearrangement-positive or ROS1 rearrangement-positive non-small cell lung cancer)
  - Ceritinib, alectinib (ALK rearrangement-positive non-small cell lung cancer)

Leptomeningeal Metastases
- Treatment
  - Organ-specific systemic chemotherapy; emphasizing drugs with good CNS penetration
  - Intra-CSF chemotherapy
    - Liposomal cytarabine (lymphoma/leukemias)
    - Methotrexate (lymphoma/leukemias, breast)
    - Cytarabine (lymphoma/leukemias)
    - Thiotepa
    - Rituximab (lymphoma)
    - Topotecan
    - Etoposide
    - Interferon alfa (category 2B)
    - Trastuzumab (breast)
    - High-dose methotrexate for lymphoma and breast
    - Weekly pulse erlotinib for EGFR exon 19 deletion or exon 21 L858R mutation (non-small cell lung cancer) (category 2B)

Metastatic Spine Tumors
- Use regimen for disease-specific site

‡Use agents active against primary tumor.

All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References on next page
PRINCIPLES OF BRAIN AND SPINAL CORD TUMOR SYSTEMIC THERAPY

References


All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2017
Central Nervous System Cancers

PRINCIPLES OF BRAIN AND SPINAL CORD TUMOR SYSTEMIC THERAPY

References


All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.


PRINCIPLES OF BRAIN TUMOR MANAGEMENT (1 of 3)

General
Patients diagnosed with a tumor involving the brain, spinal cord, and related support structures should be referred to practitioners who are experienced in the diagnosis and management of these lesions. The patient may (and should) be presented with options for care, which may include procedures or treatments best done by other specialists. The care options should then be discussed with the patient and their chosen supports in a manner that is understandable and culturally and educationally sensitive.

Multidisciplinary Care
• During the course of their treatment, most patients will be seen by physicians from more than one specialty. Where possible, use of a local brain tumor board, or multidisciplinary clinic, facilitates these interactions and allows for input from each of the major neuro-oncology disciplines, as well as allied services (eg, physical/occupational therapy, social work, psychology, nursing) when available, in formulating a plan of care for the patient. When not possible in a single clinic or institution, close and regular communication between the various disciplines involved becomes essential.
• As treatment proceeds, it is important that the patient and family understand the role of each team member. One practitioner should be identified early on as the main point of contact for follow-up care questions. This individual can facilitate referral to the appropriate specialist.
• Offering patients the option of participation in a clinical trial is strongly encouraged. Practitioners should discuss any local, regional, and national options for which the patient may be eligible and the advantages and disadvantages of participation. Centers treating neuro-oncology patients are encouraged to participate in large collaborative trials in order to have local options to offer patients.
• As the patient’s treatment unfolds, their quality of life is the highest priority and should guide clinical decisions. While responses on imaging are benchmarks of successive therapy, other indicators of success such as overall well-being, function in day-to-day activities, social and family interactions, nutrition, pain control, long-term consequences of treatment, and psychological issues must be considered.
• Patients should be informed of the possibility of pseudoprogression, its approximate incidence, and potential investigations that may be needed in the event that pseudoprogression is suspected. Close follow-up imaging, MR spectroscopy, PET/CT imaging, and repeat surgery may be necessary if clinically indicated.

1Depending on local referral patterns and available expertise, this physician may be a neurosurgeon, neurologist, medical oncologist, or radiation oncologist.
PRINCIPLES OF BRAIN TUMOR MANAGEMENT (2 of 3)

Medical Management

1. Corticosteroids
   - Steroid therapy should be carefully monitored. If a patient is asymptomatic, steroids may be unnecessary. Careful questioning for subtle symptoms should be undertaken if edema is extensive on imaging. In general, the lowest dose of steroids should be used for the shortest time possible.\(^2\) Downward titration of the dose should be attempted whenever possible. Patients with extensive mass effect should receive steroids for at least 24 h before radiation therapy. Patients with a high risk of GI side effects (perioperative patients, prior history of ulcers/GI bleed, receiving NSAIDS or anticoagulation) should receive H\(_2\) blockers or proton pump inhibitors. Care should be taken to watch for development of steroid side effects.\(^3\)

2. Antiepileptic Drugs (AEDs)
   - Seizures are frequent in patients with primary or metastatic brain tumors. Despite this, studies have shown that the use of older, “traditional” AEDs, including phenytoin, phenobarbital, and valproic acid as prophylaxis against seizures in patients who have never had a seizure or who are undergoing neurosurgical procedures, is ineffective and is not recommended. Newer agents (ie, levetiracetam, topiramate, lamotrigine, pregabaline) have not yet been systematically studied. Seizure prophylaxis is not recommended as routine in asymptomatic patients but is reasonable to consider perioperatively.
   - Many AEDs have significant effects on the cytochrome P450 system, and may have effects on the metabolism of numerous chemotherapeutic agents such as irinotecan, gefitinib, erlotinib, and temsirolimus among others. Where possible, such enzyme-inducing AEDs (EIAEDs) should be avoided (ie, phenytoin, phenobarbital, carbamazepine), and non-EIAEDs should be used instead (ie, levetiracetam, topiramate, valproic acid). Patients should be closely monitored for any adverse effects of the AEDs or chemotherapeutic agents.

3. Endocrine Disorders
   - Endocrinopathies are common with brain tumor patients. This may be affected by concomitant steroid use as well as by radiotherapy, surgery, and certain medical therapies. Patients who present with a declining sense of well-being or quality of life should be evaluated not only for abnormalities related to their hypothalamic pituitary and adrenal axis, but also with regard to thyroid and gonad function.

4. Fatigue (Also see the NCCN Guidelines for Cancer-Related Fatigue)
   - Fatigue is commonly experienced by brain tumor patients. This symptom can be severe, persistent, emotionally overwhelming, and not related to the degree or duration of physical activity. Screening should be initiated to identify any underlying medical sources of this symptom, after which patients can be taught energy conservation and organizational skills to help manage this effect. Supervised, moderate exercise may be of assistance for those in otherwise good general medical condition. More data are needed on the use of CNS stimulants and these agents are not routinely recommended.

\(^2\)An exception to this rule is in the case of suspected CNS lymphoma. Steroids should be avoided where possible (see PCNS-1) prior to biopsy to allow best chance of diagnosis.

\(^3\)Refractory hyperglycemia, skin changes, visual changes, fluid retention, and myopathy. If any of these changes occur, it is imperative to evaluate potential palliative treatments for them and also to evaluate the current dose of steroids to see if it can be reduced in an attempt to mitigate these side effects.
Medical Management—continued

5. Psychiatric Disorders (Also see the NCCN Guidelines for Distress Management including NCCN Distress Tool [DIS-A])
   • Depression is common in brain tumor patients. These symptoms are greater than simple sadness or anxiety associated with the diagnosis of a tumor. The vegetative symptoms associated with depression or severe anxiety may become very disabling for the patient and distressing for the family. These symptoms will respond to psychotropic medications as they do in non-tumor patients. If less severe, strong support from behavioral health allies and other qualified counselors is also extremely beneficial. Physicians, and other members of their health care teams, should be sensitive to these symptoms and inquire about them in follow-up visits in order to determine if the patient may be a candidate for psychological or psychiatric treatment. Communication between members of the patient's health care team regarding the patient's response to treatment is important.
   • AEDs, anxiolytics, some chemotherapy agents, antiemetics, and other agents used directly in cancer therapy may affect mental status, alertness, and mood. Alterations in thought processes should trigger an investigation for any reversible causes, including endocrine disorders, infection, side effects of medication, or tumor progression.

6. Venous Thromboembolism (VTE)
   • See the NCCN Guidelines for Venous Thromboembolic Disease.

Allied Services

• Physical therapy, occupational therapy, and speech therapy may be helpful for many patients with CNS tumors, either benign or malignant. Surgical intervention is not a prerequisite for referral, and these therapies should not be withheld from patients because of the uncertain course of certain malignant tumors. Many patients with aggressive, malignant primary brain tumors or CNS metastases can benefit from inpatient rehabilitation.
• Practitioners are encouraged to serve as a resource for referrals to social service, tumor support, and educational agencies for their patients. Institutional or community resources that can assist patients and families in dealing with financial, insurance, and legal issues are important.
• Practitioners should be familiar with their state laws concerning seizures and driving so that they can advise patients and families appropriately.
• Practitioners should become familiar with palliative and hospice care resources that are available in their community in order to help educate patients and families that involvement of these services does not indicate a state of hopelessness, no further treatment, or abandonment.
PRINCIPLES OF BRAIN TUMOR PATHOLOGY (1 OF 3)

**Standard Histology**

- Histologic subgrouping of CNS neoplasms provides valuable prognostic information, as is encompassed in the WHO classification of gliomas.¹

- Inter-observer differences in histologic diagnosis and grading are a recognized issue.

- Even so, the traditional histologic distinction of CNS neoplasms into primary neuroectodermal neoplasms (eg, glial, neuronal, embryonal) from other primary CNS neoplasms (eg, lymphoma, germ cell, meningeal), metastatic neoplasms, and non-neoplastic conditions mimicking tumors, remains fundamental to any pathologic assessment.

**Molecular/Genetic Characterization**

- The development of sophisticated genetic and molecular characterization of CNS neoplasms has shown that histologically similar neoplasms can be characterized more accurately for prognosis and in some instances for response to different therapies.²⁻⁶

- Molecular characterization of primary brain tumors/gliomas has had a substantial impact on stratification and eligibility in clinical trials for CNS neoplasms over the last 10 years, and is increasingly becoming a common part of standard neuro-oncology management.

- Molecular/genetic characterization should not be used in lieu of standard histologic assessment, but serves as a complementary approach to provide additional diagnostic and prognostic information that may aid in treatment selection.

- There are no identified targeted agents with demonstrated efficacy in glioblastoma. Assessment of EGFR may lead practitioner to consider EGRF-targeted therapies in some patients.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
The following molecular markers are often used by neuropathologists to facilitate characterization of gliomas and/or by neuro-oncologists to guide treatment decisions:

**Codeletion of 1p and 19q**
- **Description:** This codeletion represents an unbalanced translocation (1;19)(q10;p10).
- **Detection:** The codeletion of 1p and 19q is detectable by FISH or PCR.
- **Diagnostic value:** It is strongly associated with oligodendroglial histology and helps confirm the oligodendroglial character of tumors with equivocal or mixed histologic features.\(^7\)
- **Prognostic value:** The codeletion confers a favorable prognosis and is predictive of response to alkylating chemotherapy and combination therapy with radiation and alkylating chemotherapy.\(^8,9\)

**Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2) Mutation**
- **Description:** IDH1 and IDH2 are metabolic enzymes. Specific mutations of these enzymes are linked to the formation of D-2-hydroxyglutarate, an oncometabolite that causes epigenetic modifications.
- **Detection:** The most common IDH1 mutation (R132) is detectable by immunohistochemistry. Additional IDH1 as well as IDH2 mutations are detectable by PCR or pyrosequencing.
- **Diagnostic value:** Very common in grade II and III gliomas. Much less common in glioblastoma, but can help identify a glioblastoma as being a secondary glioblastoma (one that transformed from a lower grade glioma and generally does not behave as aggressively as a primary [de novo] glioblastoma).\(^10,11\)
- **Prognostic value:**
  - IDH mutations are commonly associated with codeletion of 1p and 19q, and with MGMT promoter methylation.\(^4\)
  - IDH1 or 2 mutations are associated with a favorable prognosis and are important in stratification for clinical trials.\(^12\)
  - In grade II or III gliomas, wild-type IDH1 or 2 is associated with increased risk of aggressive disease.\(^4\)
  - IDH1 or 2 mutations are associated with a survival benefit for patients treated with radiation or alkylator chemotherapy, but not for untreated patients.\(^13,14\)

**MGMT Promoter Methylation**
- **Description:** MGMT (O6-methylguanine-DNA methyltransferase) is a DNA repair enzyme that reverses the DNA damage caused by alkylating agents, resulting in tumor resistance to temozolomide and nitrosourea-based chemotherapy. Methylation of the MGMT promoter silences MGMT, making the tumor more sensitive to treatment with alkylating agents.\(^15\)
- **Detection:** Methylation of the MGMT promoter is detectable by methylation-specific PCR\(^16\) or pyrosequencing.\(^17\)
- **Prognostic value:**
  - MGMT promoter methylation is strongly associated with IDH status and genome-wide epigenetic changes (G-CIMP phenotype).\(^4\)
  - MGMT promoter methylation confers a survival advantage in glioblastoma and is used for risk stratification in clinical trials.\(^18\)
  - MGMT promoter methylation is particularly useful in treatment decisions for elderly patients with high-grade gliomas (grades III-IV).\(^19,20\)
  - Patients with glioblastoma that are not MGMT promoter methylated derive less benefit from treatment with temozolomide compared to those whose tumors are methylated.\(^18\)

References on BRAIN-F (3 of 3)
PRINCIPLES OF BRAIN TUMOR PATHOLOGY (3 OF 3)

REFERENCES


Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 08/27/14

NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

**Overview** .......................................................... MS-2
  Principles of Management ......................................... MS-2
  Treatment Principles ............................................... MS-2
  Tumor Types ................................................................ MS-3

**Low-Grade Infiltrative Astrocytomas and Oligodendrogliomas** .......... MS-3
  Treatment Overview .................................................. MS-4
  NCCN Recommendations ........................................... MS-6

**Anaplastic Gliomas and Glioblastomas** ........................................ MS-6
  Treatment Overview .................................................. MS-7
  NCCN Recommendations ........................................... MS-11

**Intracranial and Spinal Ependymomas** ............................................ MS-12
  Treatment Overview .................................................. MS-12
  NCCN Recommendations ........................................... MS-13

**Medulloblastoma and Supratentorial PNET** .................................... MS-14
  Treatment Overview .................................................. MS-14
  NCCN Recommendations ........................................... MS-15

**Primary CNS Lymphomas** ........................................................ MS-16
  Treatment Overview .................................................. MS-16
  NCCN Recommendations ........................................... MS-18

**Primary Spinal Cord Tumors** ..................................................... MS-20
  Treatment Overview .................................................. MS-20
  NCCN Recommendations ........................................... MS-21

**Meningiomas** ............................................................... MS-21
  Imaging ........................................................................ MS-22
  Treatment Overview .................................................. MS-22
  NCCN Recommendations ........................................... MS-23

**Brain Metastases** .............................................................. MS-24
  Treatment Overview .................................................. MS-24
  NCCN Recommendations ........................................... MS-27

**Leptomeningeal Metastases** ..................................................... MS-29
  Treatment Overview .................................................. MS-29
  NCCN Recommendations ........................................... MS-30

**Metastatic Spinal Tumors** .................................................... MS-31
  Treatment Overview .................................................. MS-32
  NCCN Recommendations ........................................... MS-34

**References** .................................................................... MS-37
Overview
In the year 2014, an estimated 23,380 people in the United States will be diagnosed with primary malignant brain and other central nervous system (CNS) neoplasms. These tumors will be responsible for approximately 14,320 deaths. The incidence of primary brain tumors has been increasing over the last 30 years, especially in elderly persons. Metastatic disease to the CNS occurs much more frequently, with an estimated incidence about 10 times that of primary brain tumors. It is estimated that between 20% and 40% of patients with systemic cancer will develop brain metastases.

Principles of Management
Primary and metastatic brain tumors are a heterogeneous group of neoplasms with varied outcomes and management strategies. Primary brain tumors range from pilocytic astrocytomas, which are very uncommon, noninvasive, and surgically curable, to glioblastoma multiforme, the most common intraparenchymal brain tumor in adults, which is highly invasive and virtually incurable. Likewise, patients with metastatic brain disease may have rapidly progressive systemic disease or no systemic cancer at all. These patients may have one or dozens of brain metastases, and they may have a malignancy that is highly responsive or, alternatively, highly resistant to radiation therapy (RT) or chemotherapy. Because of this marked heterogeneity, the prognostic features and treatment options for brain tumors must be carefully reviewed on an individual basis and sensitively communicated to each patient. In addition, CNS tumors are associated with a range of symptoms and complications such as edema, seizures, endocrinopathy, fatigue, psychiatric disorders, and venous thromboembolism that can seriously impact patients’ quality of life. The involvement of an interdisciplinary team, including neurosurgeons, RT therapists, oncologists, neurologists, or neuroradiologists, is a key factor in the appropriate management of these patients. For any subtype of malignant brain lesions, the NCCN Panel encourages thorough multidisciplinary review of each patient case once the pathology is available. Further discussion of multidisciplinary care and allied services, as well as guidelines on medical management of various disease complications, can be found in the algorithm section, Principles of Brain Tumor Management.

Treatment Principles
Several important principles guide surgical and RT for adults with brain tumors. Regardless of tumor histology, neurosurgeons generally provide the best outcome for their patients if they remove as much tumor as possible (maximal safe resection), minimize surgical morbidity, and ensure an accurate diagnosis by providing sufficient representative tumor tissue. Decisions regarding aggressiveness of surgery for primary brain lesions are complex and depend on the: 1) age and performance status (PS) of the patient; 2) proximity to “eloquent” areas of the brain; 3) feasibility of decreasing the mass effect with aggressive surgery; 4) resectability of the tumor (including the number and location of lesions); and 5) time since last surgery in patients with recurrent disease.

The surgical options include stereotactic biopsy, open biopsy, subtotal resection (STR), or complete resection (gross total resection: GTR). The pathologic diagnosis is critical and may be difficult to determine accurately without sufficient tumor tissue. Review by an experienced neuropathologist is highly recommended. In addition, a postoperative MRI scan, with and without contrast, should be obtained 24 to 72 hours after surgery to document the extent of disease after surgical intervention.

Radiation oncologists use several different treatment modalities in patients with primary brain tumors, including brachytherapy, fractionated...
stereotactic RT, and stereotactic radiosurgery (SRS). Standard fractionated external beam RT (EBRT) is the most common approach, while hypofractionation is emerging as an option for select patients (ie, elderly and patients with compromised performance). RT for patients with primary brain tumors is administered within a limited field (tumor and surround), while whole brain RT (WBRT) and SRS are used primarily for brain metastases.

Clinicians are advised to consult the algorithm sections, *Principles of Brain Tumor Imaging* and *Principles of Brain Tumor Surgery* for further discussion of these diagnostic and treatment modalities. The dose of RT administered varies depending on the pathology as seen in *Principles of Brain Tumor Radiation Therapy*. Appropriate chemotherapeutic and biologic regimens for each tumor subtype are listed under *Principles of Brain Tumor Systemic Therapy*.

**Tumor Types**

The NCCN Guidelines for CNS Cancers focus on management of adult CNS cancers: anaplastic gliomas and glioblastoma multiforme, low-grade infiltrative astrocytomas, oligodendrogliomas, ependymomas, brain metastases, leptomeningeal metastases, non-AIDS primary CNS lymphomas (PCNSLs), and metastatic spinal tumors. In versions 2010 and 2011, specific guidelines on managing meningiomas, primary spinal cord tumors, and primitive neuroectodermal tumors (PNETs) excluding esthesioneuroblastomas were added. These guidelines are updated annually to include new information or treatment philosophies as they become available. However, because this field evolves continually, practitioners should use all of the available information to determine the best clinical options for their patients.

**Low-Grade Infiltrative Astrocytomas and Oligodendrogliomas**

Diffusely infiltrative low-grade gliomas (ie, astrocytomas, oligodendrogliomas, mixed oligoastrocytomas) are a diverse group of relatively uncommon malignancies classified as grade II under the WHO grading system. Multivariate analysis of two phase III trials conducted by the EORTC revealed that age ≥40 years, astrocytoma histology, largest dimension of tumor ≥6 cm, tumor crossing midline, and presence of neurologic deficit before resection were unfavorable prognostic factors. In a separate validation study of 203 patients treated in a North American Intergroup trial, high-risk patients as defined by EORTC criteria (more than two risk factors) had a median overall survival of 3.9 years compared to 10.8 years in the low-risk group.

Seizure is a common symptom (81%) of low-grade gliomas, and is more frequently associated with oligodendrogliomas. The median duration from onset of symptoms to diagnosis ranges from 6 to 17 months. These tumors typically are non-enhancing, low-attenuation/signal intensity lesions on CT or MRI scans.

Diffuse astrocytomas are poorly circumscribed and invasive, and most gradually evolve into higher-grade astrocytomas. Although these were traditionally considered benign, they can behave aggressively and will undergo anaplastic transformation within 5 years in approximately half of patients. The most common non-infiltrative astrocytomas are pilocytic astrocytomas, which are circumscribed, often surgically resectable, and rarely transform. However, the NCCN algorithm does not encompass pilocytic astrocytomas because these tumors are curable by surgery alone.
Oligodendrogliomas are thought to arise from oligodendrocytes, whereas mixed oligoastrocytomas probably develop from a common glial stem cell. Radiographically, low-grade oligodendrogliomas appear well demarcated, occasionally contain calcifications, and do not enhance with contrast. The typical “fried egg” appearance of these tumors is evident in paraffin but not in frozen sections. Over half of oligodendrogliomas have specific molecular genetic alterations (allelic losses of chromosomes 1p and 19q) that can help distinguish them from other types of gliomas.\(^{11}\) Grade II oligodendrogliomas have a much better 5-year survival rate (70%) than mixed gliomas (56%) and astrocytomas (37%).\(^{12}\)

**Treatment Overview**

**Surgery**

The best management strategy for infiltrative low-grade gliomas has yet to be defined.\(^ {13}\) Surgery remains an important diagnostic and therapeutic modality. The primary surgical goal is to provide adequate tissue for a pathologic diagnosis and grading. Needle biopsies are often performed when lesions are in deep or critical regions of the brain. Biopsy results can be misleading, because gliomas often have varying degrees of cellularity, mitoses, or necrosis from one region to another; thus, small samples can provide a lower histologic grade.

The role of maximal tumor resection in low-grade astrocytomas remains unresolved. Because these tumors are relatively uncommon, published series generally include patients treated for decades, which introduces additional variables. For example, the completeness of surgical excision was based on the surgeon’s report in older studies. This approach is relatively unreliable when compared with assessment by modern postoperative imaging studies. Furthermore, most patients also received RT, and thus the net effect of the surgical procedure on outcome is difficult to evaluate. Most of the available retrospective biomedical literature suggests a survival benefit from aggressive surgical resection,\(^{14-17}\) although there are data that reported no difference.\(^ {18}\) Maximal safe resection may also delay or prevent malignant progression\(^ {19,21}\) and recurrence.\(^ {22}\)

Biological considerations also favor an attempt at a complete excision of an astrocytoma. First, the tumor may contain higher-grade foci, which may not be reflected in a small specimen. Second, complete excision may decrease the risk of future dedifferentiation to a more malignant astrocytoma.\(^ {19}\) Third, a large tumor burden is removed, which also may enhance the effect of RT. As a result of these considerations, the general recommendation for treating an astrocytoma is to first attempt as complete an excision of tumor as possible (based on postsurgical MRI verification) without compromising function. Low-grade oligodendrogliomas are often amenable to total excision due to their location in the frontal lobes and distinct tumor margins. However, for tumors that involve eloquent areas, a total removal may not be feasible and an aggressive approach could result in neurologic deficits.

**Radiation Therapy**

No consensus exists regarding the proper timing of postoperative EBRT in low-grade gliomas. Some oncologists advocate immediate fractionated EBRT, whereas others delay RT until tumor progression is evident. A randomized trial of early versus delayed RT in adult patients was conducted by the EORTC.\(^ {23}\) In this EORTC 22845 trial, patients with low-grade gliomas were randomly assigned to either 54-Gy postoperative RT or no immediate therapy. In an interim analysis, the 5-year disease-free survival was better with immediate postoperative RT (44% vs. 37%; \(P = .02\)). However, overall survival was similar indicating that deferring postoperative therapy can be an option for a selected group of patients. Long-term follow-up of these patients showed that overall survival was not increased in patients who had received early...
RT (7.4 vs. 7.2 years); however, seizures were better controlled in these patients.\textsuperscript{24} Although delaying RT in young, healthy patients without progressive neurologic decline can be controversial, there is a consensus to proceed with immediate postoperative RT in older patients after a less-than-total resection, because their survival is as poor as patients with anaplastic astrocytoma. When RT is deferred, regular follow-up is essential for patients receiving observation alone after resection. There is, however, a consensus that high-risk patients with low-grade gliomas as defined by the EORTC benefit with respect to both progression-free survival and overall survival with early up-front RT.

When RT is given to patients with low-grade gliomas, it is administered with restricted margins. A T2-weighted and/or fluid-attenuated inversion recovery (FLAIR) MRI scan is the best means for evaluating tumor extent, because these tumors enhance weakly or not at all. The clinical target volume is defined by the FLAIR or T2-weighted tumor with a 1 to 2 cm margin. Every attempt should be made to decrease the RT dose outside the target volume. This can be achieved with 3-dimensional planning or intensity-modulated RT (IMRT). The standard RT dose for low-grade astrocytomas is 45 to 54 Gy, delivered in 1.8 to 2.0 Gy fractions. The selection of 45 to 54 Gy as the standard dose range is based on its relative safety when applied to a limited volume of the brain and on the lack of evidence for increased efficacy with higher doses.\textsuperscript{25,26} In a randomized trial conducted by the EORTC in patients with low-grade astrocytomas, no survival difference was observed when 45 Gy was compared with 59.4 Gy.\textsuperscript{27} With a median follow-up of 6 years, the 5-year disease-free survival and overall survival were the same indicating that lower doses of RT are probably as effective as higher doses of RT for low-grade gliomas. Enthusiasm for SRS in low-grade gliomas has waned due to insufficient evidence for therapeutic advantage.\textsuperscript{29}

**Systemic Therapy**
Chemotherapy is not a traditional mainstay of upfront treatment for low-grade gliomas. There are some data that support temozolomide as adjuvant therapy, and it is included as a category 2B recommendation based on non-uniform panel consensus. A phase II trial of temozolomide achieved a 61\% objective response rate in 46 patients.\textsuperscript{30} Alternate protracted dosing schedules have produced response rates of 20\% to 52\%.\textsuperscript{31,32} RTOG conducted a clinical trial (RTOG 9802) that allowed observation alone for favorable patients (age <40 with GTR) and randomly assigned unfavorable patients (age ≥40 following any resection or younger patients who were subtotally resected) to postoperative RT with or without combination PCV (procarbazine, lomustine [CCNU], and vincristine). In a report of early results, PCV improved progression-free survival but not overall survival,\textsuperscript{33} although data suggest that PCV may confer survival benefits in the long term.\textsuperscript{34,35}

In the absence of randomized trial data, a number of regimens are currently considered acceptable for recurrence or progressive disease, including temozolomide,\textsuperscript{31,36} lomustine or carmustine, PCV, and platinum-based therapy.\textsuperscript{37-39} Patients with low-grade oligodendrogliomas, especially those with 1p/19q deletions, may represent favorable candidates for chemotherapy in light of good response rates reported in literature; however, this has never been prospectively determined.\textsuperscript{40-45}
NCCN Guidelines Version 1.2017
Central Nervous System Cancers

NCCN Recommendations

Primary and Adjuvant Treatment

When possible, maximal safe resection is recommended for low-grade infiltrative astrocytomas and oligodendrogliomas, and the actual extent of resection should be documented with a T2-weighted or FLAIR MRI scan within 72 hours after surgery. If the tumor is found to have components of oligodendroglioma, 1p/19q deletion testing should be considered, as it is a favorable prognostic factor. Managing the disease by serial observation alone is appropriate for selected patients. The NCCN Panel also discussed the role of the isocitrate dehydrogenase 1 or 2 (IDH1, IDH2) genes in low-grade gliomas. Mutations in the IDH genes are common in patients and are reported to be a significant marker of positive prognosis.\(^{46}\) However, routine IDH testing as a recommendation is not included in the algorithm at this point because its impact on treatment is still unclear.

The following are considered low-risk features for low-grade gliomas: age <40 years, Karnofsky Performance Status (KPS) \(\geq 70\), minor or no neurologic deficit, oligodendroglioma or mixed oligoastrocytoma, tumor dimension <6 cm, 1p and 19q co-deleted, and IDH1 or 2 mutated. Patients are categorized as having high risk if they have three or more of the following: age \(\geq 40\) years, KPS under 70, tumor larger than or equal to 6 cm, tumor crossing midline, or preoperative neurologic deficit of more than minor degree. Other adverse factors to consider include increased perfusion on imaging and one or no deletion on 1p and 19q, wild-type IDH1 or 2. If GTR is achieved, most low-risk patients may be observed without adjuvant therapy. However, close follow-up is essential as over half of these patients eventually progress.\(^{47}\) Low-grade gliomas can behave aggressively in high-risk patients and adjuvant RT or chemotherapy (category 2B for chemotherapy) is recommended for this group, although select patients may be observed.

Patients who only had a stereotactic biopsy, open biopsy, or subtotal excision should be treated with immediate fractionated EBRT or chemotherapy (category 2B), particularly if their symptoms are uncontrolled or progressive. Because of concerns about the neurotoxicity of RT,\(^{48}\) patients with asymptomatic residual tumors or stable symptoms may also be followed until their disease progresses. Patients should be followed using MRI every 3 to 6 months for 5 years and then at least annually.

Recurrence

At the time of recurrence, surgery is recommended (if resectable) followed by chemotherapy if patients have previously had fractionated EBRT. At progression following chemotherapy, the options are: 1) consider another regimen; 2) consider reirradiation; and 3) palliative/best supportive care. Reirradiation is a good choice if the patient has been progression-free for over 2 years after prior RT, the new lesion is outside the target of previous RT, or the recurrence is small and geometrically favorable. If the patient has not previously received RT, he or she should first undergo surgery if the lesion is resectable. Patients may receive RT or chemotherapy after surgery (category 2B for chemotherapy).

Anaplastic Gliomas and Glioblastomas

Anaplastic astrocytomas (grade III) and glioblastomas (grade IV astrocytomas) are the most common of the primary malignant brain tumors in adults, accounting for 6% and 54% of all gliomas, respectively.\(^{49}\) Glioblastoma is the most lethal brain tumor with only a third of patients surviving for one year and less than 5% living beyond 5 years. The 5-year survival rate for anaplastic astrocytoma is 27%. The most important prognostic factors identified in an analysis of 1578 patients are histologic diagnosis, age, and PS.\(^{50}\)
High-grade astrocytomas diffusely infiltrate surrounding tissues and frequently cross the midline to involve the contralateral brain. Patients with these neoplasms often present with symptoms of increased intracranial pressure, seizures, or focal neurologic findings related to the size and location of the tumor and to associated peritumoral edema. These tumors usually do not have associated hemorrhage or calcification but produce considerable edema and mass effect and enhance after the administration of intravenous contrast (>65% of anaplastic gliomas and 96% of glioblastoma). Tumor cells have been found in the peritumoral edema, which corresponds to the T2-weighted MRI abnormalities. As a result, this volume is frequently used to define RT portals.

It is difficult to assess the results of therapy using CT scans or MRI scans, because the extent and distribution of contrast enhancement, edema, and mass effect are more a function of blood-brain barrier (BBB) integrity than of changes in the size of the tumor. Thus, other factors that exacerbate BBB dysfunction (such as surgery, RT, and tapering of corticosteroids) can mimic tumor progression by increasing contrast enhancement, T2-weighted abnormalities, and mass effect.

Anaplastic oligodendrogliomas are relatively rare; they are characterized by high cellularity, nuclear pleomorphism, frequent mitosis, endothelial proliferation, and necrosis. On histopathologic assessment, these tumors can be confused with glioblastoma multiforme; however, characteristic allelic losses of chromosomes 1p and 19q are present in anaplastic oligodendrogliomas. This distinct histologic subtype has a much better prognosis compared to anaplastic astrocytomas and glioblastomas due to its marked sensitivity to chemotherapy; half of the patients are alive at 5 years.

**Treatment Overview**

**Surgery**

The goals of surgery are to obtain a diagnosis, alleviate symptoms related to increased intracranial pressure or compression, increase survival, and decrease the need for corticosteroids. A prospective study of 565 patients with malignant glioma showed that aggressive surgery is a strong prognostic factor when compared with biopsy alone ($P < .0001$). Retrograde analyses also suggest that GTR lengthens survival and is especially effective in patients with good PS.

Unfortunately, the infiltrative nature of high-grade astrocytomas frequently renders gross total removal difficult. On the other hand, total resection is often possible for oligodendrogliomas, because most occur in the frontal lobes and the tumors are frequently well demarcated.

Unfortunately, nearly all glioblastomas recur. At recurrence, reoperation may improve the outcome for select patients. According to an analysis by Park et al., tumor involvement in specific critical brain areas, poor Karnofsky score, and large tumor volume were associated with unfavorable re-resection outcomes.

**Radiation Therapy**

Fractionated EBRT after surgery is standard adjuvant therapy for patients with high-grade astrocytomas. Use of RT is based on two randomized trials conducted in the 1970s that showed extension in survival. Walker et al. compared postoperative supportive care, carmustine (BCNU), RT, and RT plus BCNU in 303 patients; median survival was 14 weeks, 18.5 weeks, 35 weeks, and 34.5 weeks, respectively. Another trial of 118 patients also found a benefit in median survival with RT following surgery compared to no RT (10.8 vs. 5.2 months).

The typical dose is 60 Gy in 1.8 to 2.0 Gy fractions. Some centers use 55.8 to 59.4 Gy in 1.8 Gy fractions or 57 Gy in 1.9 Gy fractions for grade III astrocytomas or when gliomatosis is present.
of hypofractionated courses of RT has been shown to be efficacious in older patients with glioblastoma.\textsuperscript{61-63} Typical schemes are 34 Gy in 10 fractions, 40.05 Gy in 15 fractions, or 50 Gy in 20 fractions. Studies including a radiosurgery boost or brachytherapy boost to conventional RT did not show a survival benefit.\textsuperscript{64,65}

There is a lack of prospective data for re-irradiating recurrent gliomas. Based on retrospective patient series, repeat RT using modern high-precision techniques such as fractionated stereotactic RT may be a palliative option for select patients with good PS and small recurrent tumors.\textsuperscript{66,67}

**Chemotherapy/Systemic Therapy**

Traditionally, chemotherapy was felt to be of marginal value in the treatment of newly diagnosed patients with high-grade gliomas, but this perception has shifted. In particular, combined chemoradiation has emerged as a new standard of care for patients with 1p/19q co-deleted anaplastic oligodendroglioma or oligoastrocytoma as well as good PS non-elderly glioblastoma.

Most earlier trials studied nitrosourea-based chemotherapy regimens. The Medical Research Council reported results from the largest randomized trial of adjuvant chemotherapy in high-grade gliomas.\textsuperscript{68} In this study, 674 patients were randomly assigned either to RT alone or to RT plus PCV. No survival benefit was seen with the addition of PCV, even in patients with anaplastic astrocytomas. In contrast, 2 meta-analyses reviewed data from randomized trials of high-grade glioma patients, and both found a modest survival benefit when chemotherapy was added to postoperative RT.\textsuperscript{69,70} Specifically, the Glioma Meta-Analysis Trialists Group reviewed 12 studies involving approximately 3000 patients and reported an absolute increase in 1-year survival from 40% to 46% and a 2-month increase in median survival when chemotherapy was added to postoperative RT (HR, 0.85; 95% CI, 0.78–0.91; \( P < .0001 \)).\textsuperscript{69} An earlier analysis by Fine and colleagues on 16 randomized trials also found a 10% and 9% increase in survival at 1 and 2 years, respectively.\textsuperscript{70}

**Implanted Wafers**

Other routes of chemotherapy drug delivery have been evaluated. Local administration of carmustine using a biodegradable polymer (wafer) placed intraoperatively in the surgical cavity has demonstrated a statistically significant improvement in survival for patients with recurrent high-grade gliomas (31 vs. 23 weeks; adjusted HR, 0.67; \( P = .006 \)).\textsuperscript{71} As a result, the U.S. Food and Drug Administration (FDA) approved the carmustine wafer for this indication. A phase III placebo-controlled study in 32 patients with malignant glioma showed a statistically significant prolongation of survival when BCNU polymer was used as initial therapy in combination with RT.\textsuperscript{72} A larger phase III trial in 240 newly diagnosed patients with malignant glioma also found a statistically significant improvement in median survival from 11.6 months in the placebo group to 13.9 months in the BCNU wafer-treated group.\textsuperscript{73} This benefit was maintained 2 and 3 years after implantation.\textsuperscript{74} On the basis of these studies, the FDA extended the approval of BCNU polymer wafers for use in malignant gliomas as initial therapy. Clinicians and patients should be aware that carmustine can potentially interact with other agents resulting in increased toxicity (see below). Implantation of the wafer may, however, preclude future participation of clinical trials of adjuvant therapy.

**Temozolomide**

Temozolomide, an alkylating (methylating) agent, is now the standard of care in conjunction with postoperative RT for younger, good performance patients with glioblastoma. Stupp et al\textsuperscript{75} conducted a phase III, randomized study that assessed the drug in 573 glioblastoma
patients’ age ≤70 years with a WHO PS of 2 or less. Patients received either 1) daily temozolomide administered concomitantly with postoperative RT followed by 6 cycles of adjuvant temozolomide; or 2) RT alone. Side effects for temozolomide include hair loss, nausea, vomiting, headaches, fatigue, and anorexia. Due to the risk of lymphocytopenia and subsequent opportunistic infection, prophylaxis against *Pneumocystis carinii* pneumonia is required when the agent is administered with RT. The chemoradiation arm resulted in a statistically better median survival (14.6 vs. 12.1 months) and 2-year survival (26.5% vs. 10.4%) when compared with RT. Final analysis confirmed the survival advantage at 5 years (10% vs. 2%). However, the study design does not shed light on which is responsible for the improvement: temozolomide administered with RT, following RT, or both. The temozolomide dose used in this trial is 75 mg/m² daily concurrent with RT, then 150 to 200 mg/m² post-irradiation on a 5-day schedule every 28 days. Alternate schedules such as a 21/28 dose-dense regimen or a 50 mg/m² continuous daily schedule have been explored in a phase II trial for newly diagnosed glioblastoma. A comparison of the dose-dense 21/28 and standard 5/28 schedules have been completed with RTOG 0525 and the results demonstrated no improvement with the post-irradiation dose-dense temozolomide arm when compared to the standard temozolomide arm.

Wick et al performed a phase III trial of sequential radiochemotherapy in 318 patients with anaplastic gliomas. The three randomized arms were: 1) RT; 2) PCV; and 3) temozolomide. At progression, patients in arm 1 received PCV or temozolomide, while patients in arms 2 and 3 were irradiated. The three strategies resulted in comparable time-to-progression and survival. Another phase III study conducted by the same group (NOA-08) randomized 412 patients with anaplastic astrocytoma (11%) or glioblastoma (89%) who were older than 65 years and had a good performance score (KPS ≥60) to receive temozolomide alone or RT alone. Temozolomide treatment was non-inferior to RT in terms of survival.

The international Nordic trial randomized 291 patients with glioblastoma and good PS across 3 groups: temozolomide, hypofractionated RT, or standard RT. Patients older than 70 years had better survival with temozolomide or fractionated RT compared to standard RT.

MGMT (O-6-methylguanine-DNA methyltransferase) is a DNA repair enzyme that can cause resistance to DNA-alkylating drugs. Oligodendrogliomas frequently exhibit MGMT hypermethylation and low expression levels, which may explain its enhanced chemosensitivity. In the temozolomide arm of both the Nordic and German trials, patients with MGMT promoter methylation had longer survival than those without (9.7 vs. 6.8 months; HR, 0.56; 95% CI, 0.34–0.93). This difference was not observed in the RT groups.

There are no published data directly comparing the benefit of temozolomide to lomustine or carmustine for postoperative chemoradiation in patients with newly diagnosed anaplastic astrocytomas. This RTOG study (RTOG 9813) was prematurely discontinued due to lack of availability of BCNU.

There have been safety concerns regarding adjuvant use of temozolomide in patients with implanted carmustine wafer. However, temozolomide combined with RT after carmustine wafer placement appeared to be safe in multiple studies. For patients old than 70 years but with good performance, there is some evidence from small monocentric studies suggesting the usefulness of temozolomide in addition to adjuvant RT despite old age. For frail patients, temozolomide may be administered alone. A retrospective review of
patients age 70 years or older with mean Karnofsky score of 70 found no survival difference between those receiving RT alone and those taking monthly temozolomide only.\textsuperscript{87} Given the susceptibility of elderly patients to RT-induced neurotoxicity, especially when the PS is poor, chemotherapy alone appears to be a reasonable option.

Combination Chemoradiation

Improved survival observed in 2 randomized clinical trials established combined PCV chemotherapy and RT as the new standard for treating patients with pure or mixed anaplastic oligodendroglioma harboring the 1p/19q co-deletion. RTOG 9402 randomized 291 patients to PCV followed by immediate RT or RT alone.\textsuperscript{88} No difference was observed between the two arms for the entire cohort. However, an unplanned analysis showed that patients with the co-deletion lived longer than those without, and among patients with co-deleted tumors, median survival was doubled when PCV was added to RT (14.7 vs. 7.3 years; HR, 0.59; 95% CI, 0.37–0.95; \(P = .03\)). This difference was not observed for patients without 1p/19q co-deletion.

Similarly, EORTC 26951 randomly assigned 368 patients with pure or mixed anaplastic oligodendroglioma to RT or RT followed by PCV.\textsuperscript{89} At a median follow-up of 140 months, overall survival was longer in the combination arm than in the RT arm (42.3 vs. 30.6 months; HR, 0.75; 95% CI, 0.60–0.95). Median survival was not reached in patients with co-deleted tumors who received PCV/RT compared to 112 months for those in the RT group. No survival advantage was found with the addition of PCV among patients without the co-deletion.

Systemic Therapy for Recurrence

Unfortunately, currently available chemotherapy does not provide cures. Patients with malignant gliomas eventually recur or progress. In addition to temozolomide\textsuperscript{36,90,91} and nitrosoureas,\textsuperscript{71,92} regimens that are commonly used as second-line chemotherapy include combination PCV,\textsuperscript{93} cyclophosphamide (category 2B recommendation),\textsuperscript{94,95} and platinum-based regimens (category 2B recommendation).\textsuperscript{39} Anaplastic gliomas may also be treated by irinotecan\textsuperscript{96} or etoposide.\textsuperscript{97}

Bevacizumab, an anti-angiogenic agent, received accelerated approval in 2009 for recurrent glioblastoma based on two phase II studies. AVF 3708g randomized 167 patients to bevacizumab with or without irinotecan. MRI-defined objective response was achieved in 28% and 38% of patients, respectively.\textsuperscript{98} Median survival was around 9 months, similar to that of a previous phase II trial.\textsuperscript{99} A published report of the other pivotal study (NCI 06-C-0064E) recorded a median survival of 31 weeks in 48 heavily pretreated patients.\textsuperscript{100} In the case that patients with good PS who have received bevacizumab monotherapy showed signs of radiographic progression, continuation of bevacizumab therapy may prevent rapid neurologic deterioration. Bevacizumab in combination with irinotecan, Carmustine or Lomustine, carboplatin (category 2B) or temozolomide has also been used in anaplastic gliomas.\textsuperscript{101-108} These combinations may be considered for patients who have failed bevacizumab monotherapy. While efficacious, bevacizumab is associated with potentially serious adverse events including hypertension, impaired wound healing, colonic perforation, and thromboembolism.

Alternating Electric Field Therapy

In 2011, the FDA approved a portable medical device that generates low-intensity electric fields termed Tumor Treating Fields (TTF) for the treatment of recurrent glioblastoma. Approval was based on results of a clinical trial that randomized 237 patients to TTF or chemotherapy.\textsuperscript{109} Similar survival was observed in the two arms, and TTF therapy was associated with lower toxicity and improved quality of life. Due to the lack of efficacy, not all panelists recommended the treatment.
NCCN Guidelines Version 1.2017
Central Nervous System Cancers

NCCN Recommendations

Primary Treatment

When a patient presents with a clinical and radiologic picture suggestive of high-grade glioma, neurosurgical input is needed regarding the feasibility of maximal safe tumor resection. Whenever possible, major tumor removal should be performed. One exception is when CNS lymphoma is suspected; a biopsy should be performed first and management should follow the corresponding pathway if the diagnosis is confirmed. If high-grade glioma is supported by intraoperative frozen section diagnosis, BCNU wafer placement is an option (category 2B). The extent of tumor debulking should be documented with a postoperative MRI scan within 72 hours after surgery, with and without contrast. If major tumor removal is deemed too risky, a stereotactic or open biopsy or STR should be performed to establish the diagnosis. Multidisciplinary consultation is encouraged once the pathology is available.

Adjuvant Therapy

After surgical intervention, the choice of adjuvant therapy depends on the tumor pathology, status of the 1p/19q loci, and PS of the patient. For patients with 1p/19q co-deleted anaplastic oligodendroglioma or oligoastrocytoma, fractionated EBRT plus PCV given before or after RT is a category 1 recommendation. The panel recommends adjuvant PCV after RT as per EORTC 26951 over intensive neoadjuvant PCV used by RTOG 9402 due to better tolerance. Fractionated RT plus concurrent temozolomide is an acceptable option, while PCV or temozolomide alone is designated category 2B. In the case of anaplastic astrocytoma, anaplastic oligodendroglioma or oligoastrocytoma without 1p/19q co-deletion, fractionated EBRT remains the standard (category 1). Other choices include fractionated RT plus concurrent temozolomide, and PCV or temozolomide chemotherapy (deferred RT). Patients with a poor performance score (below 60) can be managed by RT (hypofractionation is preferred over standard fractionation), PCV or temozolomide chemotherapy (category 2B), or palliative/best supportive care. The optimal duration of treatment with temozolomide for anaplastic astrocytoma is unknown.

If glioblastoma is diagnosed, the adjuvant options mainly depend on the patient PS. Patients with good PS (KPS ≥60) are further stratified by age. Fractionated RT plus concurrent and adjuvant temozolomide is a category 1 recommendation for patients aged 70 years or younger. The panel noted that although data are focused on 6 cycles of post-irradiation temozolomide, 12 cycles are increasingly common, especially in recent clinical trial designs. Benefit of treatment with temozolomide for glioblastomas beyond 6 months is unknown. Options for those >70 years include fractionated RT plus concurrent and adjuvant temozolomide (category 2A for this group), hypofractionated RT (category 1), or chemotherapy with deferred RT. Patients opting for chemotherapy should receive temozolomide if they had MGMT methylation.

For patients with glioblastoma and with KPS below 60, options include fractionated EBRT, chemotherapy, or palliative/best supportive care. In the absence of data, panelists debated whether chemoradiation is appropriate for elderly patients with poor PS and ultimately agreed not to include this option.

The panel noted that given the complexity of symptoms and handicaps that can arise from malignant gliomas, KPS score is a suboptimal measure of fitness for all patients. Similarly, a patient’s ability to tolerate toxic therapy does not necessarily correlate with chronologic age.110
Follow-up and Recurrence

Patients should be followed closely with serial MRI scans (at 2–6 weeks post-irradiation, then every 2–4 months for 2–3 years, then less frequently) after the completion of RT. Because RT can produce additional BBB dysfunction, corticosteroid requirements may actually increase; therefore, scans may appear worse during the first 3 months after completion of RT even though there is no actual tumor progression. Early MRI scans allow for appropriate titration of corticosteroid doses, depending on the extent of mass effect and brain edema. Later scans are used to identify tumor recurrence. Early detection of recurrence is warranted, because local and systemic treatment options are available for patients with recurrent disease. However, MR spectroscopy, MR perfusion, or PET can be considered to rule out RT-induced necrosis or “pseudoprogression.”

Management of recurrent tumors depends on the extent of disease and patient condition. For local recurrence, repeat resection, with or without wafer placement in the surgical bed, can be performed if possible. Following re-resection, or if the local recurrence is unresectable, poor performance patients should undergo palliative/best supportive care without further active treatment. If PS is favorable, systemic chemotherapy may be administered (especially for anaplastic oligodendrogliomas); re-irradiation is a category 2B option to consider if prior RT achieved a good/durable response. Patients with recurring glioblastoma may also consider alternating electric field therapy (category 3). In the case of diffuse or multiple recurring lesions, the options are: 1) palliative/best supportive care for poor performance patients; 2) systemic chemotherapy; 3) surgery to relieve mass effect; or 4) consider alternating electric field therapy for glioblastomas (category 3).

All patients should receive best supportive care.

Intracranial and Spinal Ependymomas

Ependymomas constitute up to 4% of adult CNS tumors and 10% of pediatric CNS tumors. In adults, ependymomas occur more often in the spinal canal than in the intracranial compartment (two-thirds infratentorial). These tumors can cause hydrocephalus and increased intracranial pressure, mimic brainstem lesions, cause multiple cranial nerve palsies, produce localizing cerebellar deficits, and cause neck stiffness and head tilt if they infiltrate the upper portion of the cervical cord. This section focuses on adult intracranial and spinal grade II differentiated (termed ependymomas) and grade III (termed anaplastic ependymomas) ependymomas. Grade I ependymomas (subependymomas and myxopapillary) are non-infiltrative and can be cured by resection alone.

Treatment Overview

Surgery

There is a paucity of robust studies regarding this uncommon disease, but multiple case series have reported that patients with totally resected tumors tend to have the best survival for both low- and high-grade ependymomas. Supratentorial ependymomas generally have a poorer prognosis than their infratentorial counterparts, because a greater proportion of supratentorial lesions are of high grade and because larger volumes of residual disease tend to be present after surgical resection at this location.

Radiation Therapy

The survival benefits of RT following surgical recovery have been established for anaplastic ependymomas and suboptimally resected tumors, although much of the data are derived from pediatric patients. Rodriguez et al reviewed over 2400 cases of ependymomas in the SEER database and reported the lack of RT to be a poor prognostic
factor in partially resected patients (HR = 1.75; P = .024). The short-term and 10-year survival rate after RT reached over 70% and 50%, respectively. The value of RT is more controversial for differentiated ependymomas, with data demonstrating improved survival mainly for subtotally resected tumors.

In the past, the standard practice was to irradiate the entire craniospinal axis or administer WBRT. However, studies have demonstrated that: 1) local recurrence is the primary pattern of failure; 2) spinal seeding is uncommon in the absence of local failure; 3) the patterns of failure are similar in patients with high-grade tumors who are treated with local fields or craniospinal axis irradiation; and 4) spinal metastases may not be prevented by prophylactic treatment. Prophylactic craniospinal or WBRT does not lead to improvement in survival compared to conformal regional RT with higher doses in modern studies of non-disseminated disease. Typical craniospinal irradiation scheme includes 36 Gy in 1.8 Gy fractions to the whole brain and spine, followed by limited field irradiation to spine lesions to 45 Gy. For intracranial ependymomas, the primary brain site should receive a total of 54 to 59.4 Gy in 1.8 to 2.0 Gy fractions. For spinal ependymomas, patients should receive 45 to 50.4 Gy in 1.8 Gy fractions. Higher doses up to 60 Gy are reasonable for spinal tumors below the conus medullaris. Proton beam craniospinal irradiation may be considered when toxicity is a concern.

SRS has been used as a boost after EBRT or to treat recurrence with some success, although long-term results are still lacking.

**Systemic Therapy**

Research on chemotherapeutic regimens has also centered on pediatric ependymomas, while the role of chemotherapy in the treatment of adult patients remains poorly defined. No study has demonstrated a survival advantage with the addition of chemotherapy to irradiation in newly diagnosed tumors. However, chemotherapy is sometimes considered as an alternative to palliative/best supportive care or RT in the recurrence setting. Possible options include platinum-based regimens (cisplatin or carboplatin), etoposide, lomustine or carmustine, bevacizumab, and temozolomide.

**NCCN Recommendations**

**Primary and Adjuvant Treatment**

Whenever possible, maximal safe resection should be attempted with contrast-enhanced brain image verification within 24 to 72 hours. Spine MRI should be delayed by at least 2 to 3 weeks after surgery to avoid post-surgical artifacts. Due to the established relationship between the extent of resection and outcome, multidisciplinary review and re-resection (if possible) should be considered if MRI shows that initial resection is incomplete. If maximal resection is not feasible at diagnosis due to anatomic or other factors, biopsy (stereotactic or open) or STR should be performed. If feasible, reoperation should be considered to complete resection.

The adjuvant treatment algorithm revolves around the extent of surgical resection, histology, and staging by cranial spinal MRI and cerebrospinal fluid (CSF) cytology. For spinal ependymomas, brain MRI is necessary to determine if these are drop metastases from the brain. CSF dissemination develops in up to 15% of intracranial ependymomas. Lumbar puncture for CSF cytology, delayed at least 2 weeks after surgery, should be performed for anaplastic ependymoma and/or if resection is suboptimal. CSF analysis is also indicated for grade II ependymomas following GTR if spine MRI is negative. However, lumbar puncture may be contraindicated in some cases (for example, posterior fossa mass). Patients who have undergone GTR and have negative findings for MRI and CSF may be observed if the tumor is supratentorial.
or spinal or consider adjuvant limited-field fractionated EBRT if the
tumor is intracranial or myxopapillary. Patients with spinal
eypendymomas that have been totally resected usually do not require
adjuvant RT as the recurrence rate is low. Limited-field fractionated
EBRT is the appropriate postoperative management for patients with
anaplastic ependymoma and/or STR, provided MRI (spine MRI for
intracranial ependymoma and brain MRI for spinal ependymoma) and
CSF findings are both negative. Craniospinal RT is mandatory when
MRI spine or CSF results reveal metastatic disease, regardless of
histology and extent of resection.

Follow-up and Recurrence
Follow-up of ependymoma depends on the extent and location of the
disease. For localized disease, contrast-enhanced brain and spine MRI
(if initially positive) should be done 2 to 3 weeks postoperatively and
then every 3 to 4 months for one year. The interval can then be
extended to every 4 to 6 months in the second year and then every 6 to
12 months, depending on the physician’s concern regarding the extent
of disease, histology, and other relevant factors. If tumor recurrence in
the brain or spine is noted on one of these scans, restaging by brain
and spine MRI as well as CSF analysis is necessary. Resection is
recommended if possible. RT should be administered (after surgery if
performed) if not given originally; SRS may be considered in
geoimetrically favorable cases.

Upon disease progression, several options are available depending on
the histologic type, extent of disease, age of the patient, and PS: 1) RT
(including SRS or reirradiation of previously irradiated sites); 2)
chemotherapy for patients who are refractory to surgery or RT; or 3)
palliative or best supportive care.

Medulloblastoma and Supratentorial PNET
Cranial PNETs are embryonal neoplasms showing varying degrees of
differentiation. They are described by their location as infratentorial
(medulloblastomas) and supratentorial (cerebral neuroblastoma,
pineoblastoma, or esthesioneuroblastoma). The WHO classification
system further divided these tumors into histologic variants.\(^7\) CNS
PNETs are infrequent in children and very rare in adults, with an overall
incidence of 0.26 per 100,000 person-years reported by the Central
Brain Tumor Registry of the United States (CBTRUS).\(^{137}\) Overall, it
represents only 1.8% of all brain tumors, although it is the most
common type among pediatric brain malignancies.

About half of the affected patients will present with elevated intracranial
pressure. Headache, ataxia, and nausea are commonly observed
symptoms.\(^{138}\) All PNETs of the brain are WHO grade IV, as they are
invasive and rapidly growing. They also have the tendency to
disseminate through the CSF. Larger retrospective case series of adult
patients reported a 10-year survival of 48% to 55% with frequent
recurrence beyond 5 years, commonly in the posterior fossa.\(^{139,140}\)

Treatment Overview
Surgery
Evidence in adult patients is meager for this rare disease and there are
no randomized trial data, but there is general consensus that surgical
resection should be the routine initial treatment to establish diagnosis,
relieve symptoms, and maximize local control. Complete resection can
be achieved in half of the patients\(^{138,141,142}\) and is associated with
improved survival.\(^{141,143}\) In addition, surgical placement of a
ventriculoperitoneal shunt can be used to treat hydrocephalus.
**Radiation Therapy**

Adjuvant RT following surgery is the current standard of care, although most studies are based on the pediatric population. The conventional dose is 30 to 36 Gy of craniospinal irradiation and a boost to a total of 54 to 55.8 Gy to the primary brain site. A lower craniospinal dose of 23.4 Gy, combined with chemotherapy, has gained popularity for average-risk patients to lessen side effects while maintaining 54 to 55.8 Gy to the posterior fossa, although one randomized trial found an increased relapse risk with dose reduction. It is reasonable to consider proton beam for craniospinal irradiation where available as it is associated with less toxicity. SRS demonstrated safety and efficacy in a small series of 12 adult patients with residual or recurrent disease.

**Systemic Therapy**

The use of post-irradiation chemotherapy to allow RT dose reduction is becoming increasingly common especially for children, but optimal use of adjuvant chemotherapy is still unclear for adult patients. A phase III study that enrolled more than 400 patients between ages 3 and 21 to receive post-irradiation cisplatin-based chemotherapy regimens recorded an encouraging 86% 5-year survival.

Several regimens are in use in the recurrence setting, most of which include etoposide. Temozolomide has also been used in this setting. High-dose chemotherapy in combination with autologous stem cell transplantation is a feasible strategy for patients who have had good response with lower doses.

**NCCN Recommendations**

**Primary Treatment**

MRI scan is the gold standard in the assessment and diagnosis of PNET. The typical tumor shows enhancement and heterogeneity. Fourth ventricular floor infiltration is a common finding related to worse prognosis. Multidisciplinary consultation before treatment initiation is advised. Maximal safe resection is recommended wherever possible. Contrast-enhanced brain MRI should be performed within 24 to 72 hours following surgery, but spinal MRI should be delayed by 2 to 3 weeks. Because of the propensity of PNET to CSF seeding, CSF sampling after spine imaging via lumbar puncture is also necessary for staging. Medulloblastoma should be staged according to the modified Chang system using information from both imaging and surgery.

**Adjuvant Therapy**

Patients should be stratified according to recurrence risk for planning of adjuvant therapy (reviewed by Brandes et al). The NCCN Panel agrees that patients with large cell or anaplastic medulloblastoma, supratentorial PNET, disease dissemination, unresectable tumors, or residual tumors more than 1.5 cm² postsurgery are at heightened risk. These patients should undergo irradiation of the neuraxis followed by chemotherapy. Collection of stem cells before RT may be considered on the condition that RT is not delayed for potential future autologous stem cell reinfusion at disease progression. For patients at average risk, craniospinal RT alone or craniospinal RT with chemotherapy followed by post-irradiation chemotherapy are both viable options.

**Recurrence and Progression**

There are no robust data supporting an optimal follow-up schedule for PNETs. General guidelines include brain MRI every 3 months for the first 2 years, biannual brain MRI for the next 3 years, then yearly brain scans. If recurrent disease is detected on these scans, CSF sampling is also required. Concurrent spine imaging should be performed as clinically indicated for patients with previous spinal disease. Bone scans, CT scans, and bone marrow biopsies should be conducted as indicated.
Maximal safe resection should be attempted on recurrent brain tumors. High-dose chemotherapy with autologous stem cell rescue may be considered for patients showing no evidence of disease following resection or conventional reinduction chemotherapy. On disease progression, options include chemotherapy alone, RT alone (including SRS), and chemoradiation. Patients with metastases should be managed by chemotherapy or best supportive care such as palliative RT.

Primary CNS Lymphomas

PCNSL accounts for approximately 3% of all primary CNS tumors. It is an aggressive form of non-Hodgkin's lymphoma that develops within the brain, spinal cord, eye, or leptomeninges without evidence of systemic involvement. Its age-adjusted incidence has seen a three-fold increase over the past 20 years from 0.15 to 0.48 per 100,000, in part due to the impact of HIV infections. Non-immunosuppressed patients have a better prognosis than AIDS-related cases, and survival of this group has improved over the years with treatment advances.

Pathologically, PCNSL is an angiocentric neoplasm composed of a dense monoclonal proliferation of lymphocytes, usually diffuse large B-cells. The tumor is infiltrative and typically extends beyond the primary lesion, as shown by CT or MRI scans, into regions of the brain with an intact BBB. The brain parenchyma is involved in more than 90% of all PCNSL patients, and the condition can be multifocal in more than 50% of cases. Leptomeningeal involvement may occur, either localized to adjacent parenchymal sites or in diffuse form (that is, positive cytology) in up to 30% of patients. Ocular involvement may develop independently in 10% to 20% of patients. Patients with PCNSL can present with various symptoms because of the multifocal nature of the disease. In a retrospective review of 248 immunocompetent patients, 43% had mental status changes, 33% showed signs of elevated intracranial pressure, 14% had seizures, and 4% suffered visual symptoms at diagnosis.

Treatment Overview

Steroid Administration
Steroids can rapidly alleviate signs and symptoms of PCNSL and improve PS. However, as these drugs are cytolytic, they can significantly decrease enhancement and size of tumors on CT and MRI scans as well as affect the histologic appearance. In the absence of significant mass effect, it is recommended that steroids be withheld or used judiciously until diagnostic tissue can be obtained if PCNSL is suspected.

Stereotactic Biopsy
In contrast to the principles previously outlined for invasive astrocytomas and other gliomas, the surgical goals for PCNSL are more modest, with the goal of obtaining diagnostic tissue under minimal risk of morbidity. Currently, most authors recommend stereotactic biopsy as the surgical method of choice. This approach stems from the fact that data do not demonstrate a survival advantage for patients who have had a complete resection or extensive STR when compared with those who have had only a stereotactic biopsy. In addition, STR is associated with risk for postoperative neurologic deficits.

Systemic Therapy
Methotrexate is the most effective agent against PCNSL. It is commonly used in combination with other drugs such as vincristine, procarbazine, cytarabine, rituximab, and ifosfamide, but it may also be administered as monotherapy if toxicity tolerance is a concern. High doses of intravenous methotrexate are necessary (3.5 g/m² or higher) to overcome the BBB. Intrathecal methotrexate, when given as
prophylaxis in addition to intravenous methotrexate in primary treatment, confers no clinical advantage and is not recommended, but can be useful where CSF cytology yields positive findings.

Renal dysfunction induced by high-dose methotrexate therapy is a potentially lethal medical emergency due to heightened toxicities resulting from a delay in methotrexate excretion. Early intervention with glucarpidase, a recombinant bacterial enzyme that provides an alternative route for methotrexate clearance, has shown efficacy in rapidly reducing plasma concentrations of methotrexate and preventing severe toxicity.

Chemotherapy is usually followed by consolidation RT as initial treatment to maximize response and improve outcome. Pre-irradiation chemotherapy, as opposed to post-irradiation chemotherapy, has been emphasized for several theoretical reasons. Chemotherapy given before RT may be less neurotoxic than if given after RT. Also, drug delivery to a PCNSL may be increased before RT, when the BBB is maximally disrupted by the tumor. RT results in tumor regression as well as partial repair and closure of the BBB behind the regressing tumor. Finally, pre-irradiation chemotherapy allows one to assess the efficacy of chemotherapy without the confounding variable of RT.

Because patients older than 60 years often suffer from significant and sometimes lethal neurotoxic effects from consolidation RT, a number of phase II trials have adopted the approach of chemotherapy with deferred RT. Complete response to chemotherapy ranged from 42% to 61%, with overall survival between 14 and 55 months. However, a high fraction of patients who have forgone initial RT—typically older or with significant comorbidities—will fail to achieve complete response to chemotherapy and later require WBRT.

Unfortunately, even for patients who initially achieved complete response, half of them will eventually relapse. Re-treatment with high-dose methotrexate may be useful in patients who achieved complete response with prior exposure. Several other regimens, including temozolomide, rituximab, rituximab plus temozolomide, topotecan, high-dose cytarabine, dexamethasone plus high-dose cytarabine and cisplatin, and pemetrexed have also shown activity in the recurrence or progressive disease setting, but none has been established as a standard of care. Several groups have tested high-dose chemotherapy with autologous stem cell transplantation with some success, although evidence of its advantage over conventional treatment is lacking. The panel included this as a category 2B option to consider for progressive or recurrent disease.

There has been discussion among panel members regarding the role of intra-arterial therapy with mannitol disruption of the BBB. A series of 149 patients reported a response rate of 82% and overall survival reaching 3.1 years. However, given the complexity of the procedure and the high level of expertise required for safety, the panel opted not to recommend this technique at the present time.

Radiation Therapy

Historically, WBRT has been the treatment standard to cover the multifocal nature of the disease. The majority of studies demonstrated the limitation of high-dose RT and led to the currently recommended dose of 24 to 36 Gy in 1.8 to 2.0 Gy fractions to the whole brain, without a boost. Although RT alone is useful for initial tumor control, frequent and rapid relapse of the disease led to a short overall survival of 12 to 17 months. This dismal outcome has prompted the addition of pre-irradiation methotrexate-based combination chemotherapy in later studies. This approach yields impressive response rates of up to 94% and improved overall survival ranging from
However, excessive grade 3 and 4 hematologic toxicity (up to 78%) as well as RT-induced delayed neurotoxicity (up to 32%) sometimes leading to deaths are primary concerns, although most of these studies utilized a high RT dose of more than or equal to 40 Gy. Of note, younger patients (age <60) consistently fare better, and there is a higher incidence of late neurotoxic effects in older patients.

Thiel and colleagues\textsuperscript{172} conducted a randomized, phase III, non-inferiority trial of high-dose methotrexate plus ifosfamide with or without WBRT in 318 patients with PCNSL. There was no difference in overall survival (HR, 1.06; 95% CI, 0.80–1.40; \( P = .71 \)), but the primary hypothesis (0.9 non-inferiority margin) was not proven. Patients who received WBRT had a higher rate of neurotoxicity than those who did not (49% vs. 26%).

Although WBRT alone is seldom sufficient as primary treatment and is primarily reserved for patients who cannot tolerate multimodal treatment, it can be effective as second-line therapy following chemotherapy failure, with response rates reaching nearly 75%.\textsuperscript{205}

**NCCN Recommendations**

**Initial Evaluation**

Neuroradiologic evaluation is important in the diagnosis of PCNSL and to evaluate the effectiveness of subsequent therapy. With MRI, the tumor is often isointense or hypointense on T1- and T2-weighted images and enhances frequently.\textsuperscript{206} In addition, restricted diffusion can be seen in the area of the enhancing abnormality on diffusion-weighted imaging sequences. On a CT scan, PCNSL is usually isodense or hyperdense compared to the brain and enhances in most cases. Hallmark features include a periventricular distribution, ring enhancement, multiple lesions, and a smaller amount of edema than might otherwise be expected from a similar-sized metastatic tumor or glioma. If enhanced-contrasted MRI (or contrast CT if MRI is contraindicated) suggests PCNSL, clinicians are advised to hold the use of steroids if possible before diagnosis is established, since the imaging and histologic features of PCNSL can be profoundly affected by these drugs.

A lumbar puncture with evaluation of CSF should be considered, if it can be done safely and without concern for herniation from increased intracranial pressure. The yield for a positive diagnostic test can be increased by the use of molecular markers of monoclonality, such as an immunoglobulin gene rearrangement. If the CSF is negative, consider an ophthalmologic evaluation including a slit-lamp examination to exclude an obvious malignant uveitis. Ocular biopsy should follow suspicious findings. Despite CSF or uveal evaluation, the intracranial lesion often requires a brain biopsy for a definitive diagnosis.\textsuperscript{165} Because the role of maximal surgical resection is limited to alleviating symptoms of raised intracranial pressure or preventing herniation,\textsuperscript{164} stereotactic biopsy is generally preferred to minimize invasiveness. Even with molecular marker testing, however, a biopsy can occasionally be falsely negative, particularly if the patient had been treated previously with steroids. Thus, if a biopsy is nondiagnostic, the panel recommended that the steroids be tapered and that the patient be followed closely, both clinically and radiographically. If and when the lesion recurs, the lesion should be promptly rebiopsied before the initiation of steroids. If, on the other hand, no definitive diagnosis of lymphoma is made from biopsy and the patient has not received steroid therapy, workup for other diagnoses (for example, inflammatory processes) or rebiopsy is recommended.
Staging Workup

Once the diagnosis of PCNSL is established, the patient should undergo a thorough staging workup detailed by The International PCNSL Collaborative Group. This workup involves a complete CNS evaluation including imaging of the entire neuraxis (MRI of the spine with contrast). This should be done before CSF analysis is attempted to avoid post-lumbar puncture artifacts that can be mistaken for leptomeningeal disease on imaging. A slit-lamp eye examination, if not previously performed, should also be done, as well as a lumbar puncture for CSF flow cytometry. In addition, blood work (CBC and chemistry panel) and a CT of the chest, abdomen, and pelvis are required to rule out systemic involvement.

An HIV blood test should also be performed, because both prognosis and treatment of patients with HIV-related PCNSL may be different than that of patients who are otherwise immunocompetent. HIV-positive patients should consider highly active retroviral therapy.

More elaborate tests such as bone marrow biopsy, testicular ultrasound for older men, and body PET scan may be considered (category 2B), although their value in routine workup is still under debate.

Primary Treatment

Treatment should be initiated as soon as possible following confirmation of diagnosis. Given the dramatic effect of steroids on symptom relief, they are commonly administered concurrently with workup. Selection of primary therapy depends on the general health condition and age of the patient. For healthier patients with KPS 40 or higher, a high-dose methotrexate-containing regimen is recommended. In the case of methotrexate induced-renal dysfunction, consider urgent glucarpidase to aid clearance.

Whether one performs WBRT after systemic chemotherapy depends on the responsiveness of the disease to chemotherapy and on the clinical judgment of the medical and radiation oncologists. WBRT may increase neurotoxicity, especially in patients older than 60 years, and may be withheld in the primary setting. If a patient is found to have malignant uveitis, RT to the globe has been the standard recommendation because of poor penetration of systemic chemotherapy into the uveal fluid. However, there are reports of clearance of ocular lymphoma in patients who were treated with systemic high-dose methotrexate. Therefore, with a PCNSL patient who has asymptomatic ocular involvement, a reasonable strategy is to delay RT to the globe in order to see if high-dose methotrexate is effective. Intraocular injection of chemotherapy (category 2B) is also an option. Additionally, if the patient is found to have a malignant pleocytosis in the CSF, direct intrathecal chemotherapy can be considered (category 2B).

Patients with KPS below 40 are too weak to undergo multi-modal treatment. However, these patients are potentially eligible for a change to more aggressive therapy if their PS improves following steroid therapy. If the health condition remains poor, it is recommended that treatment consist of WBRT in order to rapidly induce a response, diminish neurologic morbidity, and optimize quality of life. RT to the globe is advised if ocular involvement is detected. Chemotherapy is also an option; non-methotrexate-based regimens may be used if the patient cannot tolerate methotrexate. If the lumbar puncture or spinal MRI is positive, consider intra-CSF chemotherapy plus focal spinal RT. Best supportive care is another option.

Progressive Disease

For patients who are treated with prior WBRT and ultimately relapse, they may consider further chemotherapy (systemic and/or intrathecal),
reirradiation, or palliative/best supportive care. High-dose therapy with stem cell rescue can also be considered (category 2B).

For patients who were initially treated with high-dose methotrexate-based chemotherapy but did not receive WBRT, the decision about whether to use more chemotherapy or proceed to RT at the time of relapse depends on the duration of response to initial chemotherapy. If a patient had experienced a relatively long-term response of one year or more, then treating either with the same or another regimen is reasonable. However, for patients who either have no response or relapsed within a very short time after systemic therapy, recommendations include WBRT or involved-field RT, with or without chemotherapy. In either case, palliative/best supportive care remains an option, or high-dose chemotherapy with stem cell transplantation may be considered (category 2B).

Primary Spinal Cord Tumors

Spinal tumors are classified according to their anatomic location as extradural, intradural-extramedullary, and intradural-intramedullary. Extradural tumors are primarily due to metastatic disease and are discussed in the section Metastatic Spinal Tumors. This section focuses on intradural primary spinal tumors.

Primary spinal cord tumors are a histologically diverse set of disease that represents 2% to 4% of all primary CNS tumors. The overall incidence is 0.74 per 100,000 person-years with a 10-year survival rate of 64%. Extramedullary lesions, most commonly benign meningiomas, account for 70% to 80% of spinal cord tumors. Astrocytomas (more prevalent in children) and ependymomas (more prevalent in adults) are the most common intramedullary tumors. Clinicians are advised to refer to the corresponding sections in these guidelines for further details regarding these subtypes, as intracranial and spinal lesions are biologically similar.

Individuals with type I neurofibromatosis, type II neurofibromatosis, and von Hippel-Lindau syndrome are predisposed to form, respectively, spinal astrocytomas, spinal peripheral nerve sheath tumors, spinal ependymomas, and intramedullary hemangioblastomas.

Since 70% of primary spinal cord tumors are low-grade and slow-growing, it is common for patients to suffer from pain for months to years before diagnosis. Pain that worsens at night is a classic symptom for intramedullary lesions. Progressive motor weakness occurs in half of the patients, and patients may experience sensory loss with late autonomic dysfunction (incontinence).

Treatment Overview

Observation

Many asymptomatic primary tumors of the spinal cord, especially grade I meningiomas and peripheral nerve sheath tumors, follow an indolent course and can be followed by observation without immediate intervention.

Surgery

Surgery is the preferred treatment when the tumor is symptomatic. For lesions that are radiographically well defined, such as ependymoma, WHO grade I astrocytoma, hemangioblastoma, schwannoma, and WHO grade I meningioma, potentially curative, maximal, safe resection is the goal. En bloc total resection yielded excellent local control rates of more than 90%.

GTR is seldom feasible with grade II or higher astrocytomas because they are infiltrative and poorly circumscribed. In a study of 202 patients...
with intramedullary tumors, over 80% of grade I astrocytomas were completely resected, while total resection was achieved in only 12% of grade II tumors.214 Nevertheless, Benes et al215 conducted a review of 38 studies on spinal astrocytomas and concluded that maximal safe resection should be attempted whenever possible based on reports of survival benefit.

Radiation Therapy
RT is not recommended as primary therapy because of limited response, unknown histology without surgery, and low RT tolerance of the spinal cord. It is also not advisable following GTR, as tumors that can be excised completely have a low local recurrence rate.

A large retrospective analysis including over 1700 patients with primary spinal gliomas found an association between RT and worse cause-specific and overall survival, although there may be a bias that patients who received RT had more adverse factors.216 The role of adjuvant RT following incomplete excision or biopsy remains controversial.215,217,218 One exception is primary spinal myxopapillary ependymoma, for which postoperative RT has been demonstrated to reduce the rate of tumor progression.219,220 On the other hand, EBRT is considered a viable option at disease progression or recurrence. SRS has also shown safety and efficacy in several patient series.221-223

Systemic Therapy
Unfortunately, evidence on efficacious chemotherapeutic agents for primary spinal cord tumors is too scant for specific recommendations. The panel agrees that chemotherapy should be an option where surgery and RT fail, but there is no consensus on the best regimen. Chemotherapy is best given in the setting of a clinical trial.

NCCN Recommendations
MRI imaging is the gold standard for diagnosis of spinal cord lesions. Asymptomatic patients may be observed (especially for suspected low-grade) or resected, while all symptomatic patients should undergo some form of surgery. The surgical plan and outcome is influenced by whether a clear surgical plane is available.224 Whenever possible, maximal safe resection should be attempted. Postoperative adjuvant RT is appropriate if symptoms persist after incomplete resection or biopsy, or for patients with asymptomatic, intramedullary, low-grade glioma. Adjuvant RT may also be considered for patients with myxopapillary ependymoma that has been incompletely resected. Patients should be managed according to the pathology results (see Low-Grade Infiltrative Astrocytomas & Oligodendrogliomas, Anaplastic Gliomas and Glioblastomas, and Intracranial and Spinal Ependymomas). Those diagnosed with hemangioblastoma should consider screening for von Hippel-Lindau syndrome including neuraxis imaging.

All patients should be followed by sequential MRI scans. At progression or recurrence, re-resection is the first choice. If this is not feasible, conventional EBRT or SRS is the next option. Chemotherapy is reserved for cases where both surgery and RT are contraindicated.

Meningiomas
Meningiomas are extra-axial CNS tumors arising from the arachnoid cap cells in the meninges. They are most often discovered in middle-to-late adult life, and have a female predominance. The annual incidence for males and females reported by CBTRUS are 1.8 and 3.4 per 100,000 people, respectively.137 In a review of 319 cases using the WHO grading scale, 92% of meningiomas are grade I (benign), 6% are grade II (atypical), and 2% are grade III (malignant).225 Small tumors are
often asymptomatic, incidental findings.\textsuperscript{226} Seizure is a common presenting symptom occurring in 27\% of patients.\textsuperscript{227}

**Imaging**

Brain imaging with contrast-enhanced CT or MRI is the most common method of diagnosing, monitoring, and evaluating response to treatment (review by Campbell et al\textsuperscript{228}). The CT scan best reveals the chronic effects of slowly growing mass lesions on bone remodeling. Calcification in the tumor (seen in 25\%) and hyperostosis of the surrounding skull are features of an intracranial meningioma that can be easily identified on a non-contrast CT scan. Nonetheless, MR imaging reveals a number of imaging characteristics highly suggestive of meningioma, and in stereotactic RT articles, MR has been used to operationally define pathology. These MR findings include a tumor that is dural-based and isointense with gray matter, demonstrates prominent and homogeneous enhancement (>95\%), has frequent CSF/vascular cleft(s), and often has an enhancing dural tail (60\%). However, approximately 10\% to 15\% of meningiomas have an atypical MRI appearance mimicking metastases or malignant gliomas. In particular, secretory meningiomas may have a significant amount of peritumoral edema. Cerebral angiography is occasionally performed, often for surgical planning, as meningiomas are vascular tumors prone to intraoperative bleeding. In some instances preoperative embolization is helpful for operative hemostasis management. Angiographic findings consistent with a meningioma include a dual vascular supply with dural arteries supplying the central tumor and pial arteries supplying the tumor periphery. A "sunburst effect" may be seen due to enlarged and multiple dural arteries, and a prolonged vascular stain or so-called “blushing” can be seen, which results from intratumoral venous stasis and expanded intratumoral blood volume.

Meningiomas are also known to have high somatostatin receptor density, which allows for the use of octreotide brain scintigraphy to help delineate extent of disease and to pathologically define an extra-axial lesion.\textsuperscript{229-231} Octreotide imaging with radiolabeled indium or, more recently, gallium may be particularly useful in distinguishing residual tumor from postoperative scarring in subtotally resected/recurrent tumors.

**Treatment Overview**

**Observation**

Studies that examined the growth rate of incidental meningiomas in otherwise asymptomatic patients suggested that many asymptomatic meningiomas may be followed safely with serial brain imaging until either the tumor enlarges significantly or becomes symptomatic.\textsuperscript{232,233} These studies confirm the tenet that many meningiomas grow very slowly and that a decision not to operate is justified in selected asymptomatic patients. As the growth rate is unpredictable in any individual, repeat brain imaging is mandatory to monitor an incidental asymptomatic meningioma.

**Surgery**

The treatment of meningiomas is dependent upon both patient-related factors (ie, age, PS, medical comorbidities) and treatment-related factors (ie, reasons for symptoms, resectability, goals of surgery). Most patients diagnosed with surgically accessible symptomatic meningioma undergo surgical resection to relieve neurologic symptoms. Complete surgical resection may be curative and is therefore the treatment of choice. Both the tumor grade and the extent of resection impact the rate of recurrence. In a cohort of 581 patients, 10-year progression-free survival was 75\% following GTR but dropped to 39\% for patients receiving STR.\textsuperscript{234} Short-term recurrences reported for grade I, II, and III meningiomas were 1\% to 16\%, 20\% to 41\%, and 56\% to 63\%, respectively.
The Simpson classification scheme that evaluates meningioma surgery based on extent of resection of the tumor and its dural attachment (grades I to V in decreasing degree of completeness) correlates with local recurrence rates. First proposed in 1957, it is still being widely used by surgeons today.

**Radiation Therapy**

Safe GTR is sometimes not feasible due to tumor location. In this case, STR followed by adjuvant EBRT has been shown to result in long-term survival comparable to GTR (86% vs. 88%, respectively), compared to only 51% with incomplete resection alone. Of 92 patients with grade I tumors, Soyuer and colleagues found that RT following STR reduced progression compared to incomplete resection alone, but has no effect on overall survival.

Because high-grade meningiomas have a significant probability of recurrence even following GTR, postoperative high-dose EBRT (>54 Gy) has become the accepted standard of care for these tumors to improve local control. A review of 74 patients showed that adjuvant RT improves survival in patients with grade III meningioma and in those with grade II disease with brain invasion. The role of post-GTR RT in benign cases remains controversial.

Technical advances have enabled stereotactic administration of RT by linear accelerator (LINAC), Leksell Gamma Knife™, or CyberKnife™ radiosurgery. The use of stereotactic RT (either single fraction or fractionated) in the management of meningiomas continues to evolve. Advocates have suggested this therapy in lieu of EBRT for small (<35 mm), recurrent, or partially resected tumors. In addition, it has been used as primary therapy in surgically inaccessible tumors (ie, base-of-skull meningiomas) or in patients deemed poor surgical candidates because of advanced age or medical comorbidities. A study of about 200 patients compared surgery with SRS as primary treatment for small meningiomas. The SRS arm had similar 7-year progression-free survival compared to GTR and superior survival over incomplete resection. In another study, Kondziolka and colleagues followed a cohort of 972 meningioma patients managed by SRS over 18 years. Half of the patients have undergone previous surgery. SRS provided excellent tumor control (93%) in patients with grade I tumors. For grade II and III meningiomas, tumor control was 50% and 17%, respectively. Another smaller study of 72 patients also reported good 5-year overall and progression-free survival for grade 0 and I meningioma (79% and 95%, respectively). These results suggest that stereotactic RT is effective as primary and second-line treatment for meningiomas smaller than 3.5 cm.

**Systemic Therapy**

Targeted therapies that have shown partial efficacy in refractory meningiomas are somatostatin analogues and alpha interferon.

**NCCN Recommendations**

**Initial Treatment**

Meningiomas are typically diagnosed by CT or MRI imaging. Biopsy or octreotide scan may be considered for confirmation. For treatment planning, multidisciplinary panel consultation is encouraged. Patients are stratified by the presence or absence of symptoms and the tumor size. Most asymptomatic patients with small tumors (<30 mm) are best managed by observation. If neurologic impairment is imminent, surgery (if accessible) or RT (EBRT or SRS) is feasible. Asymptomatic tumors 30 mm or larger should be surgically resected or observed. Symptomatic disease requires active treatment by surgery whenever possible. Non-surgical candidates should undergo RT.
Regardless of tumor size and symptom status, all patients with surgically resected grade III meningioma (even after GTR) should receive adjuvant RT to enhance local control. Postoperative RT should be considered for the following: 1) asymptomatic grade II tumors; 2) large asymptomatic grade I tumors that have been incompletely resected; and 3) large symptomatic grade I or II tumors that have been incompletely resected. SRS may be used in lieu of conventional RT as adjuvant or primary therapy in asymptomatic cases.

Follow-up and Recurrence
In the absence of data, panelists have varying opinions on the best surveillance scheme and clinicians should follow patients based on individual clinical conditions. Generally, malignant or recurrent meningiomas are followed more closely than grade I and II tumors. A typical schedule for low-grade tumors is MRI every 3 months in year 1, then every 6 to 12 months for another 5 years. Less frequent imaging is required beyond 5 to 10 years.

Upon detection of recurrence, the lesion should be resected whenever possible, followed by RT. Non-surgical candidates should receive RT. Chemotherapy is reserved for patients with an unresectable recurrence refractory to RT. Regimen options include somatostatin analogues (for somatostatin receptor-positive tumors only) and interferon alfa (category 2B). Observation is an option if there is no clinical indication for treatment at recurrence.

Brain Metastases
Metastases to the brain are the most common intracranial tumors in adults and may occur up to 10 times more frequently than primary brain tumors. Population-based data reported that about 8% to 10% of cancer patients are affected by symptomatic metastatic tumors in the brain.\(^{250,251}\) A much higher incidence based on autopsy has been reported. As a result of advances in the diagnosis and treatment, many patients improve with proper management and do not die of progression of these metastatic lesions. Primary lung cancers are the most common source, accounting for half of intracranial metastases, although melanoma has been documented to have the highest predilection to spread to the brain. Diagnosis of CNS involvement is becoming more common in patients with breast cancer as therapy for metastatic disease is improving.\(^{252}\)

Nearly 80% of brain metastases occur in the cerebral hemispheres, an additional 15% occur in the cerebellum, and 5% occur in the brainstem.\(^{253}\) These lesions typically follow a pattern of hematogenous spread to the gray-white junction where the relatively narrow caliber of the blood vessels tends to trap tumor emboli. The majority of cases have multiple brain metastases evident on MRI scans. The presenting signs and symptoms of metastatic brain lesions are similar to those of other mass lesions in the brain, such as headache, seizures, and neurologic impairment.

Treatment Overview
Surgery
Advances in surgical technique have rendered upfront resection followed by WBRT the standard of care for solitary brain metastases. A retrospective analysis of 13,685 patients admitted for resection of metastatic brain lesions showed a decline in in-hospital mortality from 4.6% in the period of 1988 through 1990 to 2.3% in the period of 1997 through 2000.\(^{254}\) High-volume hospitals and surgeons produced superior outcomes.

Patchell conducted a study that randomized 95 patients with single intracranial metastases to complete resection alone or surgery plus adjuvant WBRT.\(^{255}\) Postoperative RT was associated with dramatic
reduction in tumor recurrence (18% vs. 70%; \( P < .001 \)) and likelihood of neurologic deaths (14% vs. 44%; \( P = .003 \)). Overall survival, a secondary endpoint, showed no difference between the arms. Comparison of surgery plus WBRT versus WBRT alone is discussed in the WBRT section.

In the case of multiple lesions, the role of surgery is more restricted to obtaining biopsy samples or relieving mass effect due to large symptomatic metastases. However, evidence from retrospective series suggested survival benefits from tumor resection for selected patients of good prognosis with up to three metastatic sites.\(^{256,257}\)

**Stereotactic Radiosurgery**

The advent of SRS offered a minimally invasive option as opposed to surgery. Patients undergoing SRS avoid the risk of surgery-related morbidity. Late side effects such as edema and RT necrosis are uncommon.\(^ {258}\)

Accumulating evidence suggests that low disease volume is a better selection criterion for SRS than a low number of metastatic lesions. A multivariate analysis of 205 patients who received SRS for 4 or more brain metastases demonstrated total treatment volume to be the most significant prognostic factor of survival, while the number of metastases did not reach significance.\(^ {259}\) The same group conducted another analysis that identified a favorable subgroup of patients with a total treatment volume less than 7 cc and less than 7 brain lesions. These patients had significantly prolonged median survival (13 months) than other patients (6 months; \( P < .00005 \)).\(^ {260}\) A cohort study revealed that patients with a total SRS-treated volume of less than 5 cc or 5 to 10 cc survived longer than those with a total treated volume greater than 10 cc.\(^ {261}\) No survival difference was observed between patients with a single metastasis or multiple metastases. Another group analyzed patients divided by their number of brain lesions and found no difference in survival times or local control rates among the groups after SRS treatment.\(^ {262}\) However, patients with more than 15 lesions had a higher risk of developing new lesions and distant disease progression.

Taken together, patients with multiple lesions but a low total volume of disease may be amenable to SRS. Additionally, patients with a favorable histology of the primary tumor (such as breast cancer) or controlled primary tumors can often benefit from SRS regardless of the number of brain metastases present.\(^ {263,264}\) Some brain metastases of radio-resistant primary tumors such as melanoma and renal cell carcinoma have also been shown to achieve good local control with SRS.\(^ {265}\) Other predictors of longer survival with SRS include younger age, good PS, and primary tumor control.\(^ {259,263,264,266}\)

In a randomized Japanese study of 132 patients with 1 to 4 metastatic brain tumors smaller than 3 cm, addition of WBRT to SRS did not prolong median survival compared to SRS alone (7.5 months vs. 8.0 months, respectively).\(^ {267}\) However, 1-year brain recurrence rate was lowered in the WBRT plus SRS arm (47% vs. 76%; \( P < .001 \)). Another small randomized trial of 58 patients with 1 to 3 brain metastases was stopped early due to a significant decline in learning and memory function among the group receiving both SRS and WBRT compared to the SRS group (52% vs. 24%).\(^ {268}\) Analysis showed that SRS plus WBRT was associated with better 1-year recurrence-free survival (73%) than SRS alone (27%). A third trial recruited 359 patients with 1 to 3 metastatic brain lesions who underwent surgery or SRS.\(^ {269}\) They were randomized to either adjuvant WBRT or observation. Compared to the observation arm, intracranial relapse rates and neurologic mortality were lower in the WBRT arm, but overall survival and duration of functional independence were similar. A meta-analysis concluded no overall survival improvement with the addition of WBRT to SRS.\(^ {270}\)
Retrospective comparative studies showed that SRS plus WBRT resulted in equivalent if not better survival compared with surgery and WBRT. SRS also conferred a significant improvement in local control, especially for patients with radiosensitive tumors or solitary brain lesions. A prospective observational study of 1194 patients reported no difference in overall survival between patients with 2 to 4 metastatic brain lesions and those with 5 to 10 lesions treated with SRS alone (HR, 0.97; 95% CI, 0.81–1.18; \( P \) non-inferiority < .0001). SRS alone compared to resection plus WBRT was evaluated in a randomized controlled trial by Muacevic et al. The study was stopped prematurely due to poor accrual. In the final analysis based on 64 patients with solitary brain metastases, radiosurgery alone was less invasive and resulted in equivalent survival and local control, but it was associated with a higher rate of distant relapse.

Several patient series have demonstrated local control rates greater than 70% with SRS in the recurrence setting for patients with good PS and stable disease who have received prior WBRT.

**Whole Brain Radiation Therapy**

Historically, WBRT was the mainstay of treatment for metastatic lesions in the brain. It continues to play multiple roles in the modern era, such as primary intervention where surgery or SRS is not feasible (eg, polymetastatic brain metastases), as adjunctive therapy to prevent recurrence, and as treatment for recurrent disease.

Three randomized trials investigated the effectiveness of WBRT with or without surgery in patients with single brain metastases. In a study of 48 patients, Patchell et al demonstrated that surgery followed by WBRT lengthened overall survival (40 vs. 15 weeks in WBRT arm; \( P < .01 \)) and functional dependence (38 vs. 8 weeks; \( P < .005 \)), as well as decreased recurrence (20% vs. 52%; \( P < .02 \)) compared to RT alone.

Similarly, combined treatment led to longer survival and functional independence in another randomized study by Vecht and colleagues (n=63). The greatest difference was observed in patients with stable disease; median survival was 12 months versus 7 months, and functional independence was 9 months versus 4 months. A third study of 84 patients found no difference in survival between the two strategies; however, patients with extensive systemic disease and lower performance level were included, which likely resulted in poorer outcomes in the surgical arm.

The impact of SRS boost in addition to WBRT was evaluated in two published randomized controlled studies. A multi-institutional trial by RTOG (RTOG 9508) randomly assigned 333 patients with 1 to 3 brain metastases to WBRT plus SRS or WBRT only. Despite the inclusion of larger tumors (3–4 cm) that are not favorable to SRS, the authors found a significant survival benefit in the combined arm (6.5 vs. 4.9 months; \( P = .04 \)) when treating a single metastases; this benefit was not observed in patients with multiple (2 or 3) lesions. A much smaller trial of 27 patients with 2 to 4 lesions found no significant difference in survival, although SRS did extend time to local failure (36 vs. 6 months; \( P = .0005 \)). Overall, no difference in overall survival was reported between the 2 approaches in a meta-analysis of the 2 trials. However, the addition of SRS to WBRT significantly improved local control and PS. SRS plus WBRT also prolonged overall survival of patients with single brain metastasis compared to WBRT alone (6.5 vs. 4.9 months; \( P = .04 \)).

Taken together, WBRT in conjunction with surgery or SRS leads to better clinical outcomes than WBRT alone for good performance patients with solitary metastatic intracranial lesions. However, many patients are not candidates for resection because of the inaccessibility
of the tumor, extensive systemic disease, or other factors. WBRT is the main choice of primary therapy for this patient group.

No randomized data are available in the recurrent setting, but case series reported 31% to 70% of symptom-relieving response to irradiation.288-290

**Systemic Therapy**

Systemic therapy is rarely used as primary therapy for brain metastases. In randomized studies, addition of carboplatin or temozolomide to WBRT did not improve overall survival compared to RT alone,291,292 although there have been reports of increase in progression-free survival or radiologic response with temozolomide.292,293 Many tumors that metastasize to the brain are not very chemosensitive or have been already heavily pretreated with organ-specific effective agents. Poor penetration through the BBB is an additional concern. As such, chemotherapy is usually considered as a last line of therapy for recurrent disease when other options have been exhausted (ie, surgery, SRS, RT). The choice of agent depends on the histology of the primary tumor. Carmustine wafer implantation is a reasonable option at recurrence when resection is considered.294

Among various agents, temozolomide may be useful in some patients with previously untreated brain metastases from metastatic melanoma.295 Temozolomide given on a prolonged schedule in combination with thalidomide has been tested in a phase II study of patients with brain metastases, but the high toxicity and lack of response rendered the regimen inappropriate.296

A study of high-dose methotrexate in patients mostly with breast cancer achieved disease control in 56% of patients.297 Other agents shown to have activity in breast cancer include platinum plus etoposide298,299 and capecitabine with or without lapatinib.300-302

A phase I/II study of topotecan plus WBRT has shown a 72% response rate in 75 patients with brain metastases.303 Unfortunately, a follow-up phase III trial was closed early due to slow accrual.304

Rapid advancements in melanoma have produced effective systemic options for metastatic disease. These immunotherapeutic agents (ipilimumab) and BRAF inhibitors (dabrafenib and vemurafenib) have demonstrated activity in melanoma that has metastasized to the brain.305-307

**NCCN Recommendations**

**Workup**

Patients who present with a single mass or multiple lesions on MRI or CT imaging suggestive of metastatic cancer to the brain, and who do not have a known primary, require a careful systemic workup with chest x-ray or CT, abdominal or pelvic CT, or other tests as indicated. FDG-PET can be considered if there is more than one brain lesion and no primary has yet been found. If no other readily accessible tumor is available for biopsy, a stereotactic or open biopsy resection is indicated to establish a diagnosis. Among patients with a known history of cancer and if there are concerns regarding the diagnosis of CNS lesions, a stereotactic or open biopsy resection or STR is also needed. Because brain metastases are often managed by multiple modalities, the NCCN Panel encourages multidisciplinary consultation prior to treatment for optimal planning.

**Treatment for Limited (1–3) Metastatic Lesions**

For patients with limited systemic disease or for whom reasonable systemic treatment options exist, aggressive management should be
strongly considered. For surgical candidates, high-level evidence supports category 1 recommendations for surgical resection plus postoperative WBRT and for SRS plus WBRT if only one brain lesion is involved. Other options include SRS alone or SRS following resection (category 2B). Macroscopic total removal is the objective of surgery. The choice between open resection and SRS depends on multiple factors such as tumor size and location. The best outcome for SRS is achieved for small, deep lesions at institutions with experienced staff. If the tumor is unresectable, WBRT and/or radiosurgery can be used.

Patients with progressive extracranial disease whose survival is <3 months should consider best supportive care or be treated with WBRT alone, but surgery may be considered for symptom relief. In patients with systemic cancers and druggable targets (eg, epidermal growth factor receptor [EGFR] mutations in non-small cell lung cancer; BRAF mutations in metastatic melanoma), targeted therapy in neurologically asymptomatic patients with brain metastases is considered reasonable before administration of radiotherapy.

Patients should be followed with MRI every 2 to 3 months for 1 year and then as clinically indicated. Closer follow-up every 2 months is particularly helpful for patients treated with SRS alone. Recurrence on radiograph can be confounded by treatment effects of SRS. Consider tumor tissue sampling if there is a high index of suspicion of recurrence. Upon detection of recurrent disease, prior therapy clearly influences the choice of further therapies. Patients with recurrent CNS disease should be assessed for local versus systemic disease, because therapy will differ. For local recurrences, patients who were previously treated with surgery only can receive the following options: 1) surgery, 2) single-dose or fractionated SRS, 3) WBRT, or 4) chemotherapy. However, patients who previously received WBRT probably should not undergo WBRT at recurrence due to concern regarding neurotoxicity. If the patient had previous SRS with a durable response for >6 months, reconsider SRS if imaging supports active tumor and not necrosis. Repeat SRS to a prior location is a category 2B recommendation. The algorithm for distant brain recurrences branches depending on whether patients have either 1 to 3 lesions or more than 3 lesions. In both cases, patients may receive WBRT or consider local/systemic chemotherapy, but patients with 1 to 3 recurrent tumors have the additional options of surgery or SRS.

WBRT should be used (30–45 Gy, given in 1.8–3.0 Gy fractions) depending on the patient’s PS, if this modality was not used for initial therapy. Local or systemic chemotherapy may be considered for select patients, if the multiple lesions cannot be controlled by a combination of surgery and radiosurgery. If systemic CNS disease progression occurs in the setting of limited systemic treatment options and poor PS, palliative or best supportive care is the first option. WBRT may be administered if the patients have not been previously irradiated. For patients who have received prior WBRT, re-irradiation is an option only if they had a positive response to the first course of RT treatment.

**Treatment for Multiple (>3) Metastatic Lesions**

All patients diagnosed with more than three metastatic lesions should be treated with WBRT or SRS as primary therapy. The standard regimens for WBRT are 30 Gy in 10 fractions or 37.5 Gy in 15 fractions. For patients with poor neurologic performance, a more rapid course of RT can be considered (20 Gy, delivered in 5 fractions). SRS may be considered in patients with good PS and low overall tumor volume. Palliative neurosurgery should be considered if a lesion is causing a life-threatening mass effect, hemorrhage, or hydrocephalus.
After WBRT or SRS, patients should have a repeat contrast-enhanced MRI scan every 3 months for 1 year. If a recurrence is found, the algorithm branches depending on whether patients have 1) systemic disease progression with limited systemic treatment options; or 2) stable systemic disease or reasonable systemic treatment options. For patients with systemic disease progression, options include palliative/best supportive care or reirradiation. For patients with stable systemic disease, options include surgery, reirradiation, or chemotherapy.

Leptomeningeal Metastases

Leptomeningeal metastasis or neoplastic meningitis refers to the multifocal seeding of the leptomeninges by malignant cells. It is known as leptomeningeal carcinomatosis or carcinomatous meningitis when these cells originate from a solid tumor. When it is related to a systemic lymphoma, it is called lymphomatous meningitis, and when associated with leukemia, it is termed leukemic meningitis. Leptomeningeal metastasis occurs in approximately 5% of patients with cancer. This disorder is being diagnosed with increasing frequency as patients live longer and as neuroimaging studies improve. Most cases arise from breast and lung cancers; melanoma has the highest rate of leptomeningeal spread.

Tumor cells gain access to the leptomeninges by hematogenous dissemination, lymphatic spread, or direct extension. Once these cells reach the CSF, they are disseminated throughout the neuraxis by the constant flow of CSF. Infiltration of the leptomeninges by any malignancy is a serious complication that results in substantial morbidity and mortality. Cranial nerve palsies, headaches, cerebral disturbances, mental changes, and motor weakness are among the most common presenting symptoms. The median survival of patients diagnosed with this disorder is <3 months with death resulting from progressive neurologic dysfunction, but may be extended by early detection and intervention.

Treatment Overview

The goals of treatment in patients with leptomeningeal metastases are to improve or stabilize the neurologic status of the patient and to prolong survival. Unfortunately, there is a lack of standard treatments due to meager evidence in literature. Because treatment is palliative, aggressive chemotherapy should only be given to patients most likely to benefit (see Patient Stratification).

Radiation Therapy

RT is mainly given for symptom alleviation, CSF flow correction, or for debulking to facilitate chemotherapy.

Surgery

The role of neurosurgery for leptomeningeal metastases is mainly to place an intraventricular catheter and subcutaneous reservoir for drug administration. This is preferred over lumbar punctures because of improved drug delivery, safety, superior pharmacokinetics, lower inter-patient variability, and patient comfort.

Systemic Therapy

Chemotherapy can reach the whole neuraxis and can improve outcome of patients. Intrathecal (intra-CSF) chemotherapy is widely used, although drugs with good CNS penetration, particularly organ-specific targeted therapies, may be administered systemically in high doses. Intrathecal therapy can involve either administration via a lumbar puncture or intraventricular injections via an Ommaya reservoir. However, both intra-CSF therapy and high-dose systemic therapy are
Associated with significant toxicity or complications and are therefore restricted to patients with good PS.

Agents used for intra-CSF therapy are often organ-specific with good penetration capacity. The panel included options deemed appropriate based on moderate benefit: methotrexate for breast cancer, lymphoma, and leukemia; cytarabine and liposomal cytarabine for lymphoma and leukemia; thiotepa, rituximab for lymphoma; topotecan; etoposide; trastuzumab for breast cancer; and interferon alfa. Interferon alfa received a category 2B designation due to concerns of its toxicity and limited evidence of efficacy.

Breast cancers and lymphomas are also particularly responsive to high-dose methotrexate. In addition, weekly pulse erlotinib has been used for metastatic non-small cell lung cancer with EGFR exon 19 or exon 21 deletions (category 2B).

NCCN Recommendations

**Patient Evaluation**

Patients present with signs and symptoms ranging from injury to nerves that traverse the subarachnoid space, direct tumor invasion of the brain or spinal cord, alter the local blood supply, obstruct normal CSF flow pathways leading to increased intracranial pressure, or interfere with normal brain function. Patients should have a physical examination with a careful neurologic evaluation and neuraxis imaging. MRI of the brain and spine should also be performed if intra-CSF chemotherapy is being considered. A definitive diagnosis is most commonly made by lumbar puncture if it is safe for the patient. The CSF protein is typically increased, and there may be a pleocytosis or decreased glucose levels. The CSF cytology is positive approximately 50% of the time with the first lumbar puncture, and 90% of the time after repeated CSF examinations in affected patients. Clinicians should be aware that lumbar punctures may be contraindicated in patients with anticoagulation, thrombocytopenia, or bulky intracranial disease. In these cases, suspicious CSF biochemical results combined with suggestive clinical and/or radiologic features should be taken into consideration. Although a positive CSF cytology in patients with solid tumors is virtually always diagnostic, reactive lymphocytes from infections (for example, herpes zoster infection) can often be mistaken for malignant lymphocytes.

**Patient Stratification**

Once the diagnosis has been established, the patient's overall status should be carefully assessed to determine how aggressively the carcinomatous or lymphomatous meningitis should be treated. Unfortunately, this disease is most common in patients with advanced, treatment-refractory systemic malignancies for whom treatment options are limited. In general, fixed neurologic deficits (such as cranial nerve palsies or paraplegia) do not resolve with therapy, although encephalopathies may improve dramatically. As a result, patients should be stratified into “poor-risk” and “good-risk” groups. The poor-risk group includes patients with KPS below 60; multiple, serious, major neurologic deficits; extensive systemic disease with few treatment options; bulky CNS disease; and neoplastic meningitis related to encephalopathy. The good-risk group includes patients with KPS greater than or equal to 60, no major neurologic deficits, minimal systemic disease, and reasonable systemic treatment options. Many patients fall in between these 2 groups, and clinical judgment will dictate how aggressive their treatment should be.

**Treatment**

Patients in the poor-risk group are usually offered palliative/supportive care measures. Fractionated EBRT to symptomatic sites (eg, to the
whole brain for increased intracranial pressure or to the lumbosacral spine for a developing cauda equina syndrome) can be considered. Good-risk patients should receive fractionated EBRT to symptomatic sites and to areas of bulky disease identified on neuroimaging studies. If an intraventricular catheter was placed, a CSF flow scan should be strongly considered to ensure correct flow of chemotherapy.

For patients with a normal CSF flow scan and otherwise stable disease, surgical implantation of a subcutaneous reservoir and ventricular catheter (SRVC) should be considered for intrathecal chemotherapy administration. Induction intrathecal chemotherapy should be given for 4 to 6 weeks. Alternately, patients with breast cancer or lymphoma may receive high-dose methotrexate or craniospinal RT. Craniospinal RT is also an appropriate option for patients with leukemia. The patient should be reassessed clinically and with a repeat CSF cytology. Because the cytology is much less likely to be positive from the SRVC than from the lumbar subarachnoid space, it is critical that it be sampled from the lumbar spine. Neuraxis imaging can also be considered for sites that were previously positive on a radiograph.

If negative cytology is achieved after induction, continue the induction chemotherapy for another month before switching to maintenance intrathecal chemotherapy. The CSF cytology status should be followed every month. If the patient is clinically stable or improving after induction and there is no clinical or radiologic evidence of progressive leptomeningeal disease, the patient should receive another 4 weeks of “induction” intrathecal chemotherapy or should consider switching intrathecal drugs for 4 weeks. This regimen should be followed by maintenance therapy and monthly cytology if the cytology has converted to negative or is improving (still positive) while the patient is clinically stable.

CSF flow abnormalities are common in patients with neoplastic meningitis and often lead to increased intracranial pressure. Administering chemotherapy into the ventricle of a patient with a ventricular outlet obstruction increases the patient’s risk for leukoencephalopathy. In addition, the agent administered will not reach the lumbar subarachnoid space where the original CSF cytology was positive. CSF flow scans are easily performed in most nuclear medicine departments. Indium-111-DTPA is administered into the SRVC, imaging of the brain and spine is performed immediately after injection, and then imaging is done again at 4 and 24 hours. If significant flow abnormalities are seen, fractionated EBRT can be administered to the sites of obstruction before repeating a CSF flow scan. High-dose methotrexate remains an option for patients with breast cancer or lymphoma, as normal CSF flow is not required to reach cytotoxic concentrations. Patients with breast cancer, leukemia, or lymphoma may receive craniospinal RT as an alternative. If CSF flow normalizes after RT, which occurs most commonly in radiosensitive neoplasms, intrathecal chemotherapy commences. If significant flow abnormalities remain, then the patient should be treated as a poor-risk patient (ie, with supportive measures or RT).

**Progressive Disease**

If the patient’s clinical status is deteriorating from progressive leptomeningeal disease or if the cytology is persistently positive, the clinician has several options: 1) RT to symptom sites, 2) systemic chemotherapy, or 3) palliative or best supportive care.

**Metastatic Spinal Tumors**

Bone metastases are a growing problem among cancer patients due to increasing life expectancy, with the spine being the most frequently affected site. In a report of 832 patients who died of malignancies,
vertebral involvement was found in 36% upon autopsy. Spinal metastases primarily arise from breast, lung, prostate, and renal cancers. Extradural lesions account for about 95% of spinal tumors, mostly in the thoracic region.

Some patients are found to have vertebral involvement as an asymptomatic, incidental finding. However, for most affected patients, pain is the primary presenting symptom preceding neurologic dysfunction. Three types of pain have been classically defined. Local pain due to tumor growth is often described as a constant, deep aching that improves with steroid medications. Mechanical back pain varies with movement and position and is attributed to structural spinal instability. While seldom responsive to steroids, mechanical pain can be alleviated by surgical stabilization. Radicular pain is a sharp or stabbing sensation that occurs when nerve roots are compressed by the tumor. Patients may experience any one or a combination of these types of pain.

Spinal cord compression is the most debilitating complication of spine metastases. It affects 5% to 10% of all patients with cancer, with more than 20,000 cases diagnosed each year in the United States. The majority of patients initially complain of progressive radicular pain. This is followed by neurologic symptoms such as motor weakness and sensory loss, and may even include autonomic bladder dysfunction. If left untreated, neurologic deficits rapidly progress to paralysis. Unfortunately, a study of 319 patients with cord compression revealed significant delay in the report of initial pain (3 months) as well as diagnosis (2 months) that can lead to irreversible spinal cord damage. Therefore, it is paramount that the clinician watches for early suspicious signs and establishes prompt diagnosis by spine MRI. Once diagnosed, spinal cord compression is considered a medical emergency; intervention should be implemented immediately to prevent further neurologic decline.

**Treatment Overview**

Dissemination to the spinal column is largely incurable. Therefore, the goals of treatment are palliation and improvement of quality of life through preservation of neurologic function, pain relief, and stabilization of mechanical structure. One exception is slow-growing cancers (mainly renal cell carcinoma) with solitary spinal metastasis, for which surgery may achieve possible cure.

The type and aggressiveness of the primary tumor often dictates the choice of treatment, as different cancers have varying sensitivities to systemic therapy and RT. In addition, patient characteristics including PS and comorbidities will determine whether they can tolerate surgery and, if so, which surgical technique should be used.

**Surgery**

There is general consensus that a patient should have a life expectancy of at least three months to be a surgical candidate. Paraplegia for over 24 hours is an exclusion criterion due to low chances of improvement when prolonged neurologic deficits exist before surgery. Patients with hematologic malignancies should also be excluded, as they are best managed by RT or chemotherapy. Because estimation of life expectancy can be difficult, several groups have developed prognostic scoring systems to help predict surgical outcomes.

Posterior laminectomy has been widely used in the past but is now obsolete due to frequent complications and lack of benefit. Modern surgical techniques enable surgeons to achieve 360° decompression of the spinal cord, and stabilization can be performed concomitantly, if required. The development of a plethora of spinal implants composed of...
high-quality materials such as titanium greatly improve reconstruction outcome. The surgical approach—anter ior, posterior, or combined/circumferential—is primarily determined by disease anatomy.\textsuperscript{338,339}

Sundaresan and colleagues\textsuperscript{332} reported favorable results using a variety of surgical approaches on 80 patients with solitary spine metastases. Both pain and mobility were improved in the majority of patients. Overall survival reached 30 months, with 18% of patients surviving 5 years or more. The best outcome was observed in patients with kidney and breast cancers.

Surgery followed by adjuvant EBRT has emerged as a highly effective approach in relieving spinal cord compression and restoring function, especially for solid tumors. A meta-analysis including 24 surgery cohort studies and 4 RT studies found that patients are twice as likely to regain ambulatory function after surgery than RT alone.\textsuperscript{340} However, data also revealed significant surgery-related mortality (6.3%) and morbidity (23%). In another review of literature from 1964 to 2005, anterior decompression with stabilization plus RT was associated with superior outcome over RT alone or laminectomy, achieving 75% mean improvement in neurologic function. However, high surgical mortality rate (mean 10%) was also reported.\textsuperscript{341}

To date, only one relevant randomized trial has been reported.\textsuperscript{342} Approximately 100 patients with metastatic spinal compression were randomized to surgery plus postoperative RT or RT alone. Compared to the RT group, significantly more patients in the surgery group regained walking ability (84\% vs. 57\%; $P = .001$) and for a longer period of time (median 122 days vs. 13 days; $P = .003$). The impressive results were obtained with strict eligibility criteria. The study excluded patients with radiosensitive tumors, neurologic deficits for 24 hours, multiple spinal tumors, lesions only compressing spinal roots, and prior RT to the vertebrae. Although studies demonstrated high efficacy of surgery, the formidable complications related to surgery cannot be overlooked. Using the Nationwide Inpatient Sample all-payer database, Patil et al.\textsuperscript{343} reviewed data of over 26,000 patients who had undergone surgery for spinal metastases. The in-hospital mortality and complication rates were 5.6\% and 22\%, respectively. The most common complications were pulmonary (6.7\%) and hemorrhages or hematomas (5.9\%). Clearly, careful individual patient selection based on life expectancy and overall health is warranted.

**Radiation Therapy**

Traditionally, EBRT has been the main form of treatment for spinal metastases. In the modern surgery era, RT alone is often not sufficient in achieving decompression or stabilization (see above), but it is routinely used as adjuvant therapy following surgery as it is difficult to obtain wide negative margins. Given the potential impact of RT on wound healing, most studies posed an interval of one to three weeks between resection and subsequent RT.\textsuperscript{344}

An excellent response to RT alone for spinal compression was reported by Marazano and colleagues.\textsuperscript{345} Three hundred patients were randomized to a short-course (8 Gy x 2 days) or split-course (5 Gy x 3 days; 3 Gy x 5 days) schedule. After RT, 35% of nonambulatory patients regained walking ability, and pain relief was recorded in 57\% of patients with a median survival of 4 months. Efficacy of RT was highly dependent on the histology: 70\% of nonambulatory breast cancer patients recovered mobility compared to only 20\% of hepatocellular carcinoma patients. In general, solid tumors are considered either moderately radiosensitive (eg, breast and prostate cancers) or radioresistant (eg, melanoma; osteosarcomas; cancers of the thyroid, colon, and kidney).\textsuperscript{346} On the other hand, hematologic malignancies...
such as lymphomas and multiple myelomas are highly responsive to RT. Hence, RT alone is routinely utilized as therapy for these cancers, even in the presence of cord compression.

Where there is no compression, fracture, or instability, EBRT is effective in achieving local control as primary treatment. A mean 77% local control rate from seven retrospective studies including 885 patients was found in a systematic review by Gerszten and colleagues. RT is also a mainstay of palliative treatment for patients with poor PS, significant comorbidities, and/or limited life expectancy (<3–4 months). Klimo’s meta-analysis, including 543 patients treated by RT, revealed pain control rates of 54% to 83%. Unlike surgery, RT has no immediate significant treatment-related complications and very few local recurrences. However, it increases surgical complications as it impairs wound healing.

The advent of SRS allowed precise high-dose targeting in one or two fractions while minimizing exposure of the surrounding cord. This is especially important in pre-irradiated patients. The largest prospective study involved a cohort of nearly 400 patients with 500 spinal metastases, 70% of which had previous conventional irradiation. At a median follow-up of 21 months, radiosurgery resulted in long-term pain improvement and tumor control in 85% and 90% of cases, respectively. Other single-institution reports also suggest that SRS is safe and offers more durable response than conventional therapy. An ongoing phase II/III trial (RTOG 0631) is comparing single-dose stereotactic RT of 16 Gy to single-dose EBRT of 8 Gy in patients with 1 to 3 spinal metastases.

Vertebroplasty is a direct injection, while kyphoplasty involves inserting a balloon that provides a cavity for the injection. These vertebral augmentation procedures immediately reinforce and stabilize the column, thereby relieving pain and preventing further fractures. They are suitable in poor surgical candidates with painful fractures, but are relatively contraindicated in the case of spinal cord compression because they do not achieve decompression. Symptomatic complications occur in up to 8% of patients (mostly with vertebroplasty), including embolization of the cement and local metastasis along the needle tract.

**Systemic Therapy**

Corticosteroids remain a routine initial prescription for patients presenting with cord compression, with a number of theoretical benefits including anti-inflammation, reduction in edema, short-term neurologic function improvement, and enhanced blood flow. However, the preference between high-dose (96 mg daily) and low-dose (10–16 mg daily) is still unclear. Chemotherapy has a limited role in metastatic spinal tumors except for chemosensitive tumors such as lymphoma, myeloma, and germ cell tumor. Agents efficacious for the primary tumor are used.

**NCCN Recommendations**

**Workup**

Initial workup depends on the presence or absence of symptoms. Patients with an incidental, asymptomatic, metastatic lesion confirmed by systemic imaging can be observed with MRI. However, biopsy and further treatment of an incidental lesion are indicated if treatment of the patient is altered as a result of treatment of the incidental lesion. In the absence of symptoms, it is not mandatory to obtain a spinal MRI for every incidental metastatic lesion seen on surveillance bone scans. The
alternate category involves severe or new back pain. Increasing intensity, duration, and changes in the character of pain should trigger an evaluation with an MRI study, even in patients with pre-existing degenerative spine conditions. Immediate spinal MRI is warranted in the occurrence of neurologic symptoms including weakness, paresthesias, and bladder or bowel incontinence. Contrast can be used to highlight and further evaluate any focal abnormality. The MRI can be used to image the entire spine or a focal area of interest. If the patient is unable to have an MRI, then a CT myelogram is recommended.

A normal neurologic examination implies that there is no spinal radiculopathy or myelopathy correlating with the patient’s symptoms. In this case, other causes should be considered (e.g., leptomeningeal disease). An abnormal neurologic examination includes motor abnormalities, sphincter abnormalities, and/or sensory deficits attributable to a dysfunction of nerve root(s) and/or the spinal cord. Therefore, detection of radiculopathy, myelopathy, or cauda equina syndrome is indicative of an abnormal examination. However, reflex asymmetry and/or presence of pathologic reflexes, as well as sensory deficits of a stocking/glove distribution are excluded.

**Treatment**

Once metastatic vertebral involvement is diagnosed, treatment is based on whether the patient is suffering from spinal cord compression, fracture, or spinal instability. In the presence of multiple metastatic spinal tumors, the one causing the patient’s main symptoms is addressed first. Additional tumors can be treated at a later point according to the algorithm.

Radiographic spinal cord compression implies deformation of the spinal cord because of epidural tumor, retropulsed bone fragment, or both. It should be noted that epidural tumor may occupy part of the spinal canal with or without partial obliteration of CSF around the spinal cord. Those cases are excluded because there is no cord deformation. For tumors occurring below L1, any canal compression of 50% or more should be considered of equal importance as spinal cord compression. Patients with radiographic cord compression should start on dexamethasone (10–100 mg) to alleviate symptoms. Decompressive surgery (concomitant stabilization if indicated) and adjuvant RT is the preferred treatment (category 1) where there is spinal instability and no surgical contraindication. Primary EBRT alone is appropriate for patients with radiosensitive cancers (hematologic malignancies) and without evidence of spinal instability. Many fractionation schemes are available (15–40 Gy in 1–15 fractions over 1 day–3 weeks); the most common is a total of 30 Gy in 3-Gy daily fractions for 10 days. Tolerance at the spine and/or nerve route must be considered in determining dose. Primary chemotherapy is also an option for chemo-responsive tumors in the absence of clinical myelopathy. In general, a treatment interval of at least 6 months is recommended.

Metastases to the spine without cord compression include the presence of tumor in the vertebral body, pedicle(s), lamina, transverse, or spinous process. It can also include epidural disease without cord deformation. Patients in this category should be assessed for fractures and spinal instability. Because the criteria for spinal destabilization secondary to tumor remain unclear, consultation by a surgeon is recommended. Spinal instability is grossly defined as the presence of significant kyphosis or subluxation (deformity) or of significantly retropulsed bone fragment. Not every pathologic fracture implies unstable structure. The degree of kyphosis or subluxation compatible with instability depends on the location of the tumor in the spine. The cross-sectional area of the vertebral body unaffected by the tumor and the patient’s bone mineral density are additional factors affecting stability. In addition, vertebral...
body involvement is more important than dorsal element involvement with regard to stability. Circumferential disease as well as junctional and contiguous tumor location should be taken into account when assessing spinal stability. If fracture or instability is detected, the patient should undergo surgical stabilization or minimally invasive vertebral augmentation to relieve pain. These procedures should be followed by adjuvant RT to obtain local control.

If no fracture or instability is found, EBRT is the treatment of choice. Stereotactic RT may be appropriate in select cases of limited disease. Other alternatives are chemotherapy for responsive tumors, or surgery plus adjuvant RT in select cases. Patients experiencing intractable pain or rapid neurologic decline during RT should consider surgery or SRS. Neurologic deterioration is apparent when the patient’s neurologic examination is becoming worse on a daily basis and the patient’s ambulatory status is threatened. Intractable pain means either that pain is not controlled with oral analgesics or that the patient cannot tolerate the medication due to side effects.

**Progression and Recurrence**
Follow-up involves MRI or CT imaging within one to three months post-treatment, then every three to six months as indicated. Upon detection of progression or recurrence on imaging scans, management strategy is based on previous treatment. Patients who underwent prior RT or surgery plus adjuvant RT may consider surgery or re-irradiation to the recurred area. Stereotactic RT may be appropriate for select patients. Clinicians should plan 6 months or more between treatments in consideration of tolerance of the spine and its nerve roots. Retreatment dose should be limited to no more than 10 Gy to the surface of the spinal cord. Patients previously treated by chemotherapy can consider RT.
References


60. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the


265. Hanson PW, Elaimy AL, Lamoreaux WT, et al. A concise review of the efficacy of stereotactic radiosurgery in the management of


293. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in...


351. Heimdal K, Hirschberg H, Slettebo H, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients...
